This invention relates to new replication competent adenovirus vectors comprising an internal ribosome entry site which replicate preferentially in target cells. The present invention also relates to cell transduction using adenovirus vectors comprising an internal ribosome entry site.
Diseases involving altered cell proliferation, particularly hyperproliferation, constitute an important health problem. For example, despite numerous advances in medical research, cancer remains the second leading cause of death in the United States. In the industrialized nations, roughly one in five persons will die of cancer. Traditional modes of clinical care, such as surgical resection, radiotherapy and chemotherapy, have a significant failure rate, especially for solid tumors. Neoplasia resulting in benign tumors can usually be completely cured by surgical removal of the tumor mass. If a tumor becomes malignant, as manifested by invasion of surrounding tissue, it becomes much more difficult to eradicate. Once a malignant tumor metastasizes, it is much less likely to be eradicated.
Excluding basal cell carcinoma, there are over one million new cases of cancer per year in the United States alone, and cancer accounts for over one half million deaths per year in this country. In the world as a whole, the five most common cancers are those of lung, stomach, breast, colon/rectum, and uterine cervix, and the total number of new cases per year is over 6 million.
In the United States, transitional cell carcinoma (TCC) accounts for 90 to 95 percent of all tumors of the bladder. Squamous cell carcinoma (SCC) represents 5 to 10 percent, and adenocarcinoma approximately 1 to 2 percent. Squamous cell and adenomatous elements are often found in association with transitional cell tumors, especially with high grade tumors. Bladder cancer is generally divided into superficial and invasive disease. A critical factor is the distinction between those tumors that are confined to the mucosa and those that have penetrated the basem*nt membrane and extended into the lamina propria. The term “superficial bladder tumor” is generally used to represent a tumor that has not invaded the muscularis. Invasive tumors are described as those that have invaded the muscularis propria, the perivesical fibroadipose tissue, or adjacent structures. Carcinoma in situ (CIS) is a high grade and aggressive manifestation of TCC of the bladder that has a highly variable course.
A number of urothelial cell-specific proteins have been described, among which are the uroplakins. Uroplakins (UP), including UPIa and UPIb (27 and 28 kDa, respectively), UPII (15 kDa), and UPIII (47 kDa), are members of a group of integral membrane proteins that are major proteins of urothelial plaques. These plaques cover a large portion of the apical surface of mammalian urothelium and may play a role as a permeability barrier and/or as a physical stabilizer of the urothelial apical surface. Wu et al. (1994)
Melanoma, a malignant neoplasm derived from melanocytes of the skin and other sites, has been increasing in incidence worldwide. The American Joint Committee on Cancer recognizes five different forms of extraocular melanoma occurring in humans: lentigo maligna melanoma; radial spreading; nodular; acral lentiginous; and unclassified. Known melanoma-associated antigens can be classified into three main groups: tumor-associated testis-specific antigens MAGE, BAGE, GAGE, and PRAME; melanocyte differentiation antigens tyrosinase, Melan-A/MART-1 (for Melanoma Antigen Recognized by T cells), gp100, tyrosinase related protein-1(TRP-1), tyrosinase related protein-2 (TRP-2); and mutated or aberrantly expressed antigens MUM-1, cyclin-dependent kinase 4 (CDK4), beta-catenin, gp100-in4, p15, and N-acetylglucosaminyltransferase V. See, for example, Kirkin et al. (1998)
A major, indeed the overwhelming, obstacle to cancer therapy is the problem of selectivity; that is, the ability to inhibit the multiplication of tumor cells without affecting the functions of normal cells. For example, in traditional chemotherapy of prostate cancer, the therapeutic ratio, (i.e., the ratio of tumor cell killing to normal cell killing) is only 1.5:1. Thus, more effective treatment methods and pharmaceutical compositions for therapy and prophylaxis of neoplasia are needed.
Accordingly, the development of more specific, targeted forms of cancer therapy, especially for cancers that are difficult to treat successfully, is of particular interest. In contrast to conventional cancer therapies, which result in relatively non-specific and often serious toxicity, more specific treatment modalities, which inhibit or kill malignant cells selectively while leaving healthy cells intact, are required.
Gene therapy, whereby a gene of interest is introduced into a malignant cell, has been attempted as an approach to treatment of many cancers. See, for example, Boulikas (1997)
A number of viral vectors and non-viral delivery systems (e.g., liposomes), have been developed for gene transfer. Of the viruses proposed for gene transfer, adenoviruses are among the most easily produced and purified. Adenovirus also has the advantage of a high efficiency of transduction (i.e., introduction of the gene of interest into the target cell) and does not require cell proliferation for efficient transduction. In addition, adenovirus can infect a wide variety of cells in vitro and in vivo. For general background references regarding adenovirus and development of adenoviral vector systems, see Graham et al. (1973)
Adenoviruses generally undergo a lytic replication cycle following infection of a host cell. In addition to lysing the infected cell, the replicative process of adenovirus blocks the transport and translation host cell mRNA, thus inhibiting cellular protein synthesis. For a review of adenoviruses and adenovirus replication, see Shenk, T. and Horwitz, M. S.,
When used for gene transfer, adenovirus vectors are often designed to be replication-defective and are thus deliberately engineered to fail to replicate in the target cell. In these vectors, the early adenovirus gene products E1A and/or E1B are often deleted, and the gene to be transduced is commonly inserted into the E1A and/or E1B region of the deleted virus genome. Bett et al. (1994) supra. Such vectors are propagated in packaging cell lines such as the 293 line, which provides E1A and E1B functions in trans. Graham et al. (1987)
In the treatment of cancer by replication-defective adenoviruses, the host immune response limits the duration of repeat doses at two levels. First, the capsid proteins of the adenovirus delivery vehicle itself are immunogenic. Second, viral late genes are frequently expressed in transduced cells, eliciting cellular immunity. Thus, the ability to repeatedly administer cytokines, tumor suppressor genes, ribozymes, suicide genes, or genes which convert a prodrug to an active drug has been limited by the immunogenicity of both the gene transfer vehicle and the viral gene products of the transfer vehicle, coupled with the transient nature of gene expression. Despite these limitations, development of adenoviral vectors for gene therapy has focused almost exclusively on the use of the virus as a vehicle for introducing a gene of interest, not as an effector in itself. In fact, replication of adenovirus vectors has been viewed as an undesirable result, largely due to the host immune response.
More recently, however, the use of adenovirus vectors as effectors has been described. International Patent Application Nos. PCT/US98/04080, PCT/US98/04084, PCT/US98/04133, PCT/US98/04132, PCT/US98/16312, PCT/US95/00845, PCT/US96/10838, PCT/EP98/07380 and U.S. Pat. No. 5,998,205. Adenovirus E1A and E1B genes are disclosed in Rao et al. (1992,
Replication-competent adenovirus vectors, which take advantage of the cytotoxic effects associated with adenovirus replication, have recently been described as agents for effecting selective cell growth inhibition. In such systems, a cell-specific transcriptional regulatory element (TRE) is used to control the expression of a gene essential for viral replication, thus limiting viral replication to cells in which the TRE is functional. See, for example International Patent Application No. PCT/EP99/07380, Henderson et al., U.S. Pat. No. 5,698,443; Hallenbeck et al., PCT/US95/15455 and U.S. Pat. No. 5,998,205; Rodriguez et al. (1997)
PCT publication PCT/US98/04080 discloses replication-competent, target cell-specific adenovirus vectors comprising heterologous TREs, such as those regulating expression of prostate-specific antigen (PSA), probasin (PB), α-fetoprotein (AFP), kallikrien (hKLK2), mucin (MUC1) and carcinoembryonic antigen (CEA). PCT/US98/04084 discloses replication-competent adenovirus vectors comprising an α-fetoprotein (AFP) TRE that replicate specifically in cells expressing AFP, such as hepatoma cells.
Internal ribosome entry sites (IRES) are sequences which initiate translation from an internal initiation codon (usually AUG) within a bi- or multi-cistronic RNA transcript continuing multiple protein coding regions. IRES have been characterized in encephalomyocarditis virus and related picornaviruses. See, for example, Jackson et al. (1995)
Thus, there is a continuing need for improved replication-competent adenovirus vectors in which cell-specific replication can be further enhanced, while minimizing the extent of replication in non-target (i.e., non-cancerous cells).
The disclosure of all patents and publications cited herein are incorporated by reference in their entirety.
The present invention provides improved replication competent adenovirus vectors comprising co-transcribed first and second genes under transcriptional control of a heterologous, target cell-specific transcriptional regulatory element (TRE), wherein the second gene is under translational control of an internal ribosome entry site (IRES). In one embodiment, the first and second genes are co-transcribed as a single mRNA and the second gene has a mutation in or deletion of its endogenous promoter. The present invention further provides host cells and methods using the adenovirus vectors.
In one aspect, the first and/or second genes are adenovirus genes and in another aspect, the first and/or second adenovirus genes are essential for viral replication. An essential gene can be an early viral gene, including for example, E1A; E1B; E2; and/or E4, or a late viral gene. In another aspect an early gene is E3.
In one embodiment, the first gene is an adenovirus gene and the second gene is a therapeutic gene. In another embodiment, both genes are adenovirus genes. In an additional embodiment, the first adenovirus gene is E1A, and the second adenovirus gene is E1B. Optionally, the endogenous promoter for one of the co-transcribed adenovirus gene essential for viral replication, such as for example, E1A, is deleted and/or mutated such that the gene is under sole transcriptional control of a target cell-specific TRE.
In another aspect, the present invention provides adenovirus vectors comprising an adenovirus gene essential for viral replication under control of a target cell-specific TRE, wherein said adenovirus gene has a mutation of or deletion in its endogenous promoter. In one embodiment, the adenovirus gene is essential for viral replication. In another embodiment, the adenovirus gene is E1A wherein the E1A promoter is deleted and wherein the E1A gene is under transcriptional control of a heterologous cell-specific TRE. In another embodiment, the adenovirus gene is E1B wherein the E1B promoter is deleted and wherein the E1B gene is under transcriptional control of a heterologous cell-specific TRE.
In another aspect, the present invention provides adenovirus vectors comprising E1B under control of a target cell-specific TRE, wherein said E1B has a deletion in or mutation of the 19-kDa region of E1B, that encodes a product shown to inhibit apoptosis.
In other embodiments, an enhancer element for the first and/or second adenovirus genes is inactivated. The present invention provides an adenovirus vector comprising E1A wherein an E1A enhancer is inactivated. In yet other embodiments, the present invention provides an adenovirus vector comprising E1A wherein the E1A promoter is inactivated and E1A enhancer I is inactivated. In further embodiments, the present invention provides an adenovirus vector comprising a TRE which has its endogenous silencer element inactivated.
Any TRE which directs cell-specific expression can be used in the disclosed vectors. In one embodiment, TREs include, for example, TREs specific for prostate cancer cells, breast cancer cells, hepatoma cells, melanoma cells, bladder cells and/or colon cancer cells. In another embodiment, the TREs include, probasin (PB) TRE; prostate-specific antigen (PSA) TRE; mucin (MUC1) TRE; α-fetoprotein (AFP) TRE; hKLK2 TRE; tyrosinase TRE; human uroplakin II TRE (hUPII) and carcinoembryonic antigen (CEA) TRE. In other embodiments, the target cell-specific TRE is a cell status-specific TRE. In yet other embodiments, the target cell-specific TRE is a tissue specific TRE.
In additional embodiments, the adenovirus vector comprises at least one additional co-transcribed gene under the control of the cell-specific TRE. In another embodiment, an additional co-transcribed gene is under the translational control of an IRES.
In another aspect of the present invention, adenovirus vectors further comprise a transgene such as, for example, a cytotoxic gene. In one embodiment, the transgene is under the transcriptional control of the same TRE as the first gene and second genes and optionally under the translational control of an internal ribosome entry site. In another embodiment, the transgene is under the transcriptional control of a different TRE that is functional in the same cell as the TRE regulating transcription of the first and second genes and optionally under the translational control of an IRES.
The present invention also provides compositions comprising the replication-competent adenovirus vectors described herein. In one embodiment, the compositions further comprise a pharmaceutically acceptable excipient. The present invention also provides kits comprising the replication-competent adnenovirus vectors described herein.
Host cells comprising the disclosed adenovirus vectors are also provided. Host cells include those used for propagation of a vector and those into which a vector is introduced for therapeutic purposes.
In another aspect, methods are provided for propagating replication-competent adenovirus vectors of the present invention specific for mammalian cells which permit the function of a target cell-specific TRE, said method comprising combining an adenovirus vector(s) described herein with mammalian cells that permit the function of a target cell-specific TRE, such that the adenovirus vector(s) enters the cell, whereby said adenovirus is propagated.
In another aspect, methods are provided for conferring selective cytotoxicity in target cells, comprising contacting the cells with an adenovirus vector(s) described herein, whereby the vector enters the cell.
The invention further provides methods of suppressing tumor cell growth, more particularly a target tumor cell, comprising contacting a tumor cell with an adenovirus vector(s) of the invention such that the adenovirus vector enters the tumor cell and exhibits selective cytotoxicity for the tumor cell.
In another aspect, methods are provided for detecting a cell which allows the function of a target cell-specific TRE, which comprise contacting a cell in a biological sample with an adenovirus vector(s) of the invention, and detecting replication of the adenovirus vector(s), if any.
In another aspect, methods are provided for modifying the genotype of a target cell, comprising contacting the cell with an adenovirus vector as described herein, wherein the adenovirus vector enters the cell.
The present invention provides an adenovirus vector comprising an adenovirus gene, wherein said adenovirus gene is under transcriptional control of a melanocyte-specific TRE. In another embodiment, a melanocyte-specific TRE is human. In another embodiment, a melanocyte-specific TRE comprises a melanocyte-specific promoter and a heterologous enhancer. In other embodiments, a melanocyte-specific TRE comprises a melanocyte-specific promoter. In other embodiments, a melanocyte-specific TRE comprises a melanocyte-specific enhancer and a heterologous promoter. In other embodiments, a melanocyte-specific TRE comprises a melanocyte-specific promoter and a melanocyte-specific enhancer.
In some embodiments, the adenovirus gene under transcriptional control of a melanocyte-specific TRE is an adenovirus gene essential for replication. In some embodiments, the adenoviral gene essential for replication is an early gene. In another embodiment, the early gene is E1A. In another embodiment, the early gene is E1B. In yet another embodiment, both E1A and E1B are under transcriptional control of a melanocyte-specific TRE. In further embodiments, the adenovirus gene essential for replication is E1B, and E1B has a deletion in the 19-kDa region.
In some embodiments, the melanocyte-specific TRE is derived from the 5′ flanking region of a tyrosinase gene. In other embodiments, the melanocyte-specific TRE is derived from the 5′ flanking region of a tyrosinase related protein-1 gene. In other embodiments, the melanocyte-specific TRE is derived from the 5′-flanking region of a tyrosinase related protein-2 gene. In other embodiments, the melanocyte-specific TRE is derived from the 5′ flanking region of a MART-1 gene. In other embodiments, the melanocyte-specific TRE is derived from the 5′-flanking region of a gene which is aberrantly expressed in melanomas.
In other embodiments, the invention provides an adenovirus vector comprising (a) an adenovirus gene under transcriptional control of a melanocyte-specific TRE; and (b) an E3 region. In some of these embodiments the E3 region is under transcriptional control of a melanocyte-specific TRE.
In another aspect, the invention provides a host cell comprising the melanocyte specific adenovirus vector(s) described herein.
In another aspect, the invention provides pharmaceutical compositions comprising a melanocyte specific adenovirus vector(s) described herein.
In another aspect, the invention provides kits which contain a melanocyte adenoviral vector(s) described herein.
In another aspect, methods are provided for conferring selective cytotoxicity in target cells (i.e., cells which permit or induce a melanocyte-specific TRE to function), comprising contacting the cells with an adenovirus vector(s) described herein, whereby the vector enters the cell.
In another aspect, methods are provided for propagating an adenovirus specific for melanocytes, said method comprising combining an melanocyte specific adenovirus vector(s) described herein with melanocytes, whereby said adenovirus is propagated.
The invention further provides methods of suppressing melanoma cell growth, comprising contacting a melanoma cell with a melanocyte specific adenoviral vector of the invention such that the adenoviral vector enters the melanoma cell and exhibits selective cytotoxicity for the melanoma cell.
In another aspect, methods are provided for detecting melanocytes, including melanoma cells, in a biological sample, comprising contacting cells of a biological sample with a melanocyte adenovirus vector(s) described herein, and detecting replication of the adenovirus vector, if any.
We have discovered and constructed improved adenovirus vectors comprising co-transcribed first and second genes under transcriptional control of a heterologous, target cell-specific transcriptional regulatory element (TRE), wherein the second gene is under translational control of an internal ribosome entry site (IRES). In one embodiment, the first and second genes are co-transcribed as a single mRNA and the second gene has a mutation in or deletion of its endogenous promoter. In another embodiment, at least one of the genes is an adenovirus gene and in yet another embodiment, both genes are adenovirus genes, including adenovirus genes that are essential for viral replication. The adenovirus vector may comprise a gene that contributes to cytotoxicity (whether direct and/or indirect), and/or causes cell death. An example of an adenovirus gene that contributes to cytotoxicity includes, but is not limited to, the adenovirus death protein gene.
In some aspects of the present invention, an adenovirus vector comprising co-transcribed first and second genes under transcriptional control of a target cell-specific TRE, wherein the second gene is under translational control of an IRES, exhibits greater specificity for the target cell than an adenovirus vector comprising a target cell-specific TRE operably linked to a gene and lacking an IRES. In some embodiments, specificity is conferred by preferential transcription and/or translation of the first and second genes due to the presence of a target cell specific TRE. In other embodiments, specificity is conferred by preferential replication of the adenovirus vectors in target cells due to the target cell-specific TRE driving transcription of a gene essential for replication.
Also disclosed herein are IRES containing adenovirus vectors comprising an adenovirus gene essential for viral replication wherein said essential gene has a mutation in or deletion of its endogenous promoter. In an embodiment disclosed herein, the adenovirus vectors comprise the adenovirus early gene E1A which has a deletion of its endogenous promoter. In another embodiment disclosed herein, the adenovirus vectors comprise the adenovirus early gene E1B which has a deletion of its endogenous promoter. In other embodiments disclosed herein, the 19-kDa region of E1B is deleted.
In another aspect, the adenovirus vectors disclosed herein comprise an adenovirus gene essential for viral replication wherein said essential gene has a mutation in or deletion of its endogenous enhancer. In one embodiment, the adenovirus vector comprises the adenovirus early gene E1A which has a mutation of or deletion in its endogenous promoter. In one embodiment, the adenovirus vector comprises the adenovirus early gene E1A which has a mutation of or deletion in E1A enhancer 1. In a further embodiment, the adenovirus vector comprises the adenovirus early gene E1A which has a mutation of or deletion in its endogenous promoter and a mutation of or deletion in the E1A enhancer. In an additional embodiment, the adenovirus vector comprises the adenovirus early gene E1A which has a mutation of or deletion in its endogenous promoter and the adenovirus early gene E1B which has a mutation of or deletion in its endogenous promoter. In an additional embodiment, the adenovirus vector comprises the adenovirus early gene E1A, which has a mutation of or deletion in its endogenous promoter and a mutation of or deletion in the E1A enhancer 1, and the adenovirus early gene E1B which has a mutation of or deletion in its endogenous promoter. In other embodiments disclosed herein, the 19-kDa region of E1B is deleted.
The replication-competent adenovirus vectors of the present invention take advantage of what has been heretofore considered an undesirable aspect of adenovirus vectors, namely their replication and possible concomitant immunogenicity. Runaway infection is prevented due to the cell-specific requirements for viral replication. Without wishing to be bound by any particular theory, it is noted that production of adenovirus proteins can serve to activate and/or stimulate the immune system, either generally or specifically, toward target cells producing adenoviral proteins. This type of immune stimulation can be an important consideration in the cancer context, where patients are often moderately to severely immunocompromised.
The adenovirus vectors of the present invention comprising an intergenic IRES element(s) which links the translation of two or more genes, reflects an improvement over vector constructs which use identical control regions to drive expression of two or more desired genes in that any potential for hom*ologous recombination based on the presence of hom*ologous control regions in the vector is removed. As demonstrated herein, adenovirus vectors comprising an IRES are stable and in some embodiments provide better specificity than vectors not containing an IRES. Another advantage of an adenovirus vector comprising an intergenic IRES is that the use of an IRES rather than a second TRE may provide additional space in the vector for an additional gene(s) such as a therapeutic gene.
Thus, the adenovirus vectors comprising a second gene under control of an IRES retain a high level of target cell specificity and remain stable in the target cell. Accordingly, in one aspect of the invention, the viral vectors disclosed herein comprise at least one IRES within a multicistronic transcript, wherein production of the multicistronic transcript is regulated by a heterologous, target cell-specific TRE. For adenovirus vectors comprising a second gene under control of an IRES, it is preferred that the endogenous promoter of a gene under translational control of an IRES be deleted so that the endogenous promoter does not interfere with transcription of the second gene. It is preferred that the second gene be in frame with the IRES if the IRES contains an initiation codon. If an initiation codon, such as ATG, is present in the IRES, it is preferred that the initiation codon of the second gene is removed and that the IRES and the second gene are in frame. Alternatively, if the IRES does not contain an initiation codon or if the initiation codon is removed from the IRES, the initiation codon of the second gene is used. In one embodiment, the adenovirus vectors comprises the adenovirus essential genes, E1A and E1B genes, under the transcriptional control of a heterologous, cell-specific TRE, and an IRES introduced between E1A and E1B. Thus, both E1A and E1B are under common transcriptional control, and translation of E1B coding region is obtained by virtue of the presence of the IRES. In one embodiment, E1A has its endogenous promoter deleted. In another embodiment, E1A has an endogenous enhancer deleted and in yet an additional embodiment, E1A has its endogenous promoter deleted and E1A enhancer I deleted. In another embodiment, E1B has its endogenous promoter deleted. In other embodiments disclosed herein, the 19-kDa region of E1B is deleted.
To provide cytotoxicity to target cells, one or more transgenes having a cytotoxic effect may be present in the vector. Additionally, or alternatively, an adenovirus gene that contributes to cytotoxicity and/or cell death, such as the adenovirus death protein (ADP) gene, can be included in the vector, optionally under the selective transcriptional control of a heterologous TRE and optionally under the translational control of an IRES.
Examples of target cells include neoplastic cells, although any cell for which it is desirable and/or tolerable to sustain a cytotoxic activity can be a target cell. By combining an adenovirus vector(s) comprising a target cell-specific TRE with a mixture of target and non-target cells, in vitro or in vivo, the vector(s) preferentially replicates in the target cells, causing cytotoxic and/or cytolytic effects. Once the target cells are destroyed due to selective cytotoxic and/or cytolytic activity, replication of the vector(s) is significantly reduced, lessening the probability of runaway infection and undesirable bystander effects. In vitro cultures can be retained to continually monitor the mixture (such as, for example, a biopsy or other appropriate biological sample) for the presence of the undesirable target cell, e.g., a cancer cell in which the target cell-specific TRE is functional. The adenovirus vectors of the present invention can also be used in ex vivo procedures wherein desirable biological samples comprising target cells are removed from the animal, subjected to exposure to an adenovirus vector of the present invention comprising a target cell-specific TRE and then replaced within the animal.
General Techniques
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as,
For techniques related to adenovirus, see, inter alia, Felgner and Ringold (1989)
Definitions
As used herein, an “internal ribosome entry site” or “IRES” refers to an element that promotes direct internal ribosome entry to the initiation codon, such as ATG, of a cistron (a protein encoding region), thereby leading to the cap-independent translation of the gene. Jackson R J, Howell M T, Kaminski A (1990)
A “multicistronic transcript” refers to an mRNA molecule which contains more than one protein coding region, or cistron. A mRNA comprising two coding regions is denoted a “bicistronic transcript.” The “5′-proximal” coding region or cistron is the coding region whose translation initiation codon (usually AUG) is closest to the 5′-end of a multicistronic mRNA molecule. A “5′-distal” coding region or cistron is one whose translation initiation codon (usually AUG) is not the closest initiation codon to the 5′ end of the mRNA. The terms “5′-distal” and “downstream” are used synonymously to refer to coding regions that are not adjacent to the 5′ end of a mRNA molecule.
As used herein, “co-transcribed” means that two (or more) coding regions of polynucleotides are under transcriptional control of single transcriptional control element.
A “gene” refers to a coding region of a polynucleotide. A “gene” may or may not include non-coding sequences and/or regulatory elements.
As used herein, a “transcription response element” or “transcriptional regulatory element”, or “TRE” is a polynucleotide sequence, preferably a DNA sequence, which increases transcription of an operably linked polynucleotide sequence in a host cell that allows that TRE to function. A TRE can comprise an enhancer and/or a promoter. A “transcriptional regulatory sequence” is a TRE. A “target cell-specific transcriptional response element” or “target cell-specific TRE” is a polynucleotide sequence, preferably a DNA sequence, which is preferentially functional in a specific type of cell, that is, a target cell. Accordingly, a target cell-specific TRE transcribes an operably linked polynucleotide sequence in a target cell that allows the target cell-specific TRE to function. The term “target cell-specific”, as used herein, is intended to include cell type specificity, tissue specificity, developmental stage specificity, and tumor specificity, as well as specificity for a cancerous state of a given target cell. “Target cell-specific TRE” includes cell type-specific and cell status-specific TRE, as well as “composite” TREs. The term “composite TRE” includes a TRE which comprises both a cell type-specific and a cell status-specific TRE. A target cell-specific TRE can also include a heterologous component, including, for example, an SV40 or a cytomegalovirus (CMV) promoter(s). An example of a target cell specific TRE which is tissue specific is a CMV TRE which contains both promoter(s) and enhancer(s).
As described in more detail herein, a target cell-specific TRE can comprise any number of configurations, including, but not limited to, a target cell-specific promoter; and target cell-specific enhancer; a heterologous promoter and a target cell-specific enhancer; a target cell-specific promoter and a heterologous enhancer; a heterologous promoter and a heterologous enhancer; and multimers of the foregoing. The promoter and enhancer components of a target cell-specific TRE may be in any orientation and/or distance from the coding sequence of interest, as long as the desired target cell-specific transcriptional activity is obtained. Transcriptional activation can be measured in a number of ways known in the art (and described in more detail below), but is generally measured by detection and/or quantitation of mRNA or the protein product of the coding sequence under control of (i.e., operably linked to) the target cell-specific TRE. As discussed herein, a target cell-specific TRE can be of varying lengths, and of varying sequence composition. As used herein, the term “cell status-specific TRE” is preferentially functional, i.e., confers transcriptional activation on an operably linked polynucleotide in a cell which allows a cell status-specific TRE to function, i.e., a cell which exhibits a particular physiological condition, including, but not limited to, an aberrant physiological state. “Cell status” thus refers to a given, or particular, physiological state (or condition) of a cell, which is reversible and/or progressive. The physiological state may be generated internally or externally; for example, it may be a metabolic state (such as in response to conditions of low oxygen), or it may be generated due to heat or ionizing radiation. “Cell status” is distinct from a “cell type”, which relates to a differentiation state of a cell, which under normal conditions is irreversible. Generally (but not necessarily), as discussed herein, a cell status is embodied in an aberrant physiological state, examples of which are given below.
A “functional portion” of a target cell-specific TRE is one which confers target cell-specific transcription on an operably linked gene or coding region, such that the operably linked gene or coding region is preferentially expressed in the target cells.
By “transcriptional activation” or an “increase in transcription,” it is intended that transcription is increased above basal levels in the target cell (i.e., target cell) by at least about 2 fold, preferably at least about 5 fold, preferably at least about 10 fold, more preferably at least about 20 fold, more preferably at least about 50 fold, more preferably at least about 100 fold, more preferably at least about 200 fold, even more preferably at least about 400 fold to about 500 fold, even more preferably at least about 1000 fold. Basal levels are generally the level of activity (if any) in a non-target cell (i.e., a different cell type), or the level of activity (if any) of a reporter construct lacking a target cell-specific TRE as tested in a target cell line.
A “functionally-preserved variant” of a target cell-specific TRE is a target cell-specific TRE which differs from another target cell-specific TRE, but still retains target cell-specific transcription activity, although the degree of activation may be altered (as discussed below). The difference in a target cell-specific TRE can be due to differences in linear sequence, arising from, for example, single base mutation(s), addition(s), deletion(s), and/or modification(s) of the bases. The difference can also arise from changes in the sugar(s), and/or linkage(s) between the bases of a target cell-specific TRE. For example, certain point mutations within sequences of TREs have been shown to decrease transcription factor binding and stimulation of transcription. See Blackwood, et al. (1998)
As used herein, a TRE derived from a specific gene is referred to by the gene from which it was derived and is a polynucleotide sequence which regulates transcription of an operably linked polynucleotide sequence in a host cell that expresses said gene. For example, as used herein, a “human glandular kallikrein transcriptional regulatory element”, or “hKLK2-TRE” is a polynucleotide sequence, preferably a DNA sequence, which increases transcription of an operably linked polynucleotide sequence in a host cell that allows an hKLK2-TRE to function, suoh as a cell (preferably a mammalian cell, even more preferably a human cell) that expresses androgen receptor, such as a prostate cell. An hKLK2-TRE is thus responsive to the binding of androgen receptor and comprises at least a portion of an hKLK2 promoter and/or an hKLK2 enhancer (i.e., the ARE or androgen receptor binding site).
As used herein, a “probasin (PB) transcriptional regulatory element”, or “PB-TRE” is a polynucleotide sequence, preferably a DNA sequence, which selectively increases transcription of an operably-linked polynucleotide sequence in a host cell that allows a PB-TRE to function, such as a cell (preferably a mammalian cell, more preferably a human cell, even more preferably a prostate cell) that expresses androgen receptor. A PB-TRE is thus responsive to the binding of androgen receptor and comprises at least a portion of a PB promoter and/or a PB enhancer (i.e., the ARE or androgen receptor binding site).
As used herein, a “prostate-specific antigen (PSA) transcriptional regulatory element”, or “PSA-TRE”, or “PSE-TRE” is a polynucleotide sequence, preferably a DNA sequence, which selectively increases transcription of an operably linked polynucleotide sequence in a host cell that allows a PSA-TRE to function, such as a cell (preferably a mammalian cell, more preferably a human cell, even more preferably a prostate cell) that expresses androgen receptor. A PSA-TRE is thus responsive to the binding of androgen receptor and comprises at least a portion of a PSA promoter and/or a PSA enhancer (i.e., the ARE or androgen receptor binding site).
As used herein, a “carcinoembryonic antigen (CEA) transcriptional regulatory element”, or “CEA-TRE” is a polynucleotide sequence, preferably a DNA sequence, which selectively increases transcription of an operably linked polynucleotide sequence in a host cell that allows a CEA-TRE to function, such as a cell (preferably a mammalian cell, even more preferably a human cell) that expresses CEA. The CEA-TRE is responsive to transcription factors and/or co-factor(s) associated with CEA-producing cells and comprises at least a portion of the CEA promoter and/or enhancer.
As used herein, an “α-fetoprotein (AFP) transcriptional regulatory element”, or “AFP-TRE” is a polynucleotide sequence, preferably a DNA sequence, which selectively increases transcription (of an operably linked polynucleotide sequence) in a host cell that allows an AFP-TRE to function, such as a cell (preferably a mammalian cell, even more preferably a human cell) that expresses AFP. The AFP-TRE is responsive to transcription factors and/or co-factor(s) associated with AFP-producing cells and comprises at least a portion of the AFP promoter and/or enhancer.
As used herein, an “a mucin gene (MUC) transcriptional regulatory element”, or “MUC1-TRE” is a polynucleotide sequence, preferably a DNA sequence, which selectively increases transcription (of an operably-linked polynucleotide sequence) in a host cell that allows a MUC1-TRE to function, such as a cell (preferably a mammalian cell, even more preferably a human cell) that expresses MUC1. The MUC1-TRE is responsive to transcription factors and/or co-factor(s) associated with MUC1-producing cells and comprises at least a portion of the MUC1 promoter and/or enhancer.
As used herein, a “urothelial cell-specific transcriptional response element”, or “urothelial cell-specific TRE” is polynucleotide sequence, preferably a DNA sequence, which increases transcription of an operably linked polynucleotide sequence in a host cell that allows a urothelial-specific TRE to function, i.e., a target cell. A variety of urothelial cell-specific TREs are known, are responsive to cellular proteins (transcription factors and/or co-factor(s)) associated with urothelial cells, and comprise at least a portion of a urothelial-specific promoter and/or a urothelial-specific enhancer. Methods are described herein for measuring the activity of a urothelial cell-specific TRE and thus for determining whether a given cell allows a urothelial cell-specific TRE to function.
As used herein, a “melanocyte cell-specific transcriptional response element”, or “melanocyte cell-specific TRE” is polynucleotide sequence, preferably a DNA sequence, which increases transcription of an operably linked polynucleotide sequence in a host cell that allows a melanocyte-specific TRE to function, i.e., a target cell. A variety of melanocyte cell-specific TREs are known, are responsive to cellular proteins (transcription factors and/or co-factor(s)) associated with melanocyte cells, and comprise at least a portion of a melanocyte-specific promoter and/or a melanocyte-specific enhancer. Methods are described herein for measuring the activity of a melanocyte cell-specific TRE and thus for determining whether a given cell allows a melanocyte cell-specific TRE to function.
An “E1B 19-kDa region” (used interchangeably with “E1B 19-kDa genomic region”) refers to the genomic region of the adenovirus E1B gene encoding the E1B 19-kDa product. According to wild-type Ad5, the E1B 19-kDa region is a 261 bp region located between nucleotide 1714 and nucleotide 2244. The E1B 19-kDa region has been described in, for example, Rao et al.,
As used herein, a target cell-specific TRE can comprise any number of configurations, including, but not limited to, a target cell-specific promoter; a target cell-specific enhancer; a target cell-specific promoter and a target cell-specific enhancer; a target cell-specific promoter and a heterologous enhancer; a heterologous promoter and a target cell-specific enhancer; and multimers of the foregoing. The promoter and enhancer components of a target cell-specific TRE may be in any orientation and/or distance from the coding sequence of interest, as long as the desired target cell-specific transcriptional activity is obtained. Transcriptional activation can be measured in a number of ways known in the art (and described in more detail below), but is generally measured by detection and/or quantitation of mRNA or the protein product of the coding sequence under control of (i.e., operably linked to) the target cell-specific TRE.
“Replicating preferentially”, as used herein, means that the adenovirus replicates more in a target cell than a non-target cell. Preferably, the adenovirus replicates at a significantly higher rate in target cells than non target cells; preferably, at least about 2-fold higher, preferably, at least about 5-fold higher, more preferably, at least about 10-fold higher, still more preferably at least about 50-fold higher, even more preferably at least about 100-fold higher, still more preferably at least about 400- to 500-fold higher, still more preferably at least about 1000-fold higher, most preferably at least about 1×10
As used herein, the term “vector” refers to a polynucleotide construct designed for transduction/transfection of one or more cell types. Vectors may be, for example, “cloning vectors” which are designed for isolation, propagation and replication of inserted nucleotides, “expression vectors” which are designed for expression of a nucleotide sequence in a host cell, or a “viral vector” which is designed to result in the production of a recombinant virus or virus-like particle, or “shuttle vectors”, which comprise the attributes of more than one type of vector.
An “adenovirus vector” or “adenoviral vector” (used interchangeably) comprises a polynucleotide construct of the invention. A polynucleotide construct of this invention may be in any of several forms, including, but not limited to, DNA, DNA encapsulated in an adenovirus coat, DNA packaged in another viral or viral-like form (such as herpes simplex, and AAV), DNA encapsulated in liposomes, DNA complexed with polylysine, complexed with synthetic polycationic molecules, conjugated with transferrin, and complexed with compounds such as PEG to immunologically “mask” the molecule and/or increase half-life, and conjugated to a nonviral protein. Preferably, the polynucleotide is DNA. As used herein, “DNA” includes not only bases A, T, C, and G, but also includes any of their analogs or modified forms of these bases, such as methylated nucleotides, internucleotide modifications such as uncharged linkages and thioates, use of sugar analogs, and modified and/or alternative backbone structures, such as polyamides. For purposes of this invention, adenovirus vectors are replication-competent in a target cell.
The terms “polynucleotide” and “nucleic acid”, used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. These terms include a single-, double- or triple-stranded DNA, genomic DNA, cDNA, RNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically, biochemically modified, non-natural or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups. Alternatively, the backbone of the polynucleotide can comprise a polymer of synthetic subunits such as phosphoramidates and thus can be a oligodeoxynucleoside phosphoramidate (P-NH2) or a mixed phosphoramidate-phosphodiester oligomer. Peyrottes et al. (1996)
The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thioate, and nucleotide branches. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides, or a solid support. Preferably, the polynucleotide is DNA. As used herein, “DNA” includes not only bases A, T, C, and G, but also includes any of their analogs or modified forms of these bases, such as methylated nucleotides, internucleotide modifications such as uncharged linkages and thioates, use of sugar analogs, and modified and/or alternative backbone structures, such as polyamides.
A polynucleotide or polynucleotide region has a certain percentage (for example, 80%, 85%, 90%, or 95%) of “sequence identity” to another sequence means that, when aligned, that percentage of bases are the same in comparing the two sequences. This alignment and the percent hom*ology or sequence identity can be determined using software programs known in the art, for example those described in
“Under transcriptional control” is a term well understood in the art and indicates that transcription of a polynucleotide sequence, usually a DNA sequence, depends on its being operably (operatively) linked to an element which contributes to the initiation of, or promotes, transcription. “Operably linked” refers to a juxtaposition wherein the elements are in an arrangement allowing them to function.
An “E3 region” (used interchangeably with “E3”) is a term well understood in the art and means the region of the adenoviral genome that encodes the E3 products (discussed herein). Generally, the E3 region is located between about 28583 and 30470 of the adenoviral genome. The E3 region has been described in various publications, including, for example, Wold et al. (1995)
A “portion” of the E3 region means less than the entire E3 region, and as such includes polynucleotide deletions as well as polynucleotides encoding one or more polypeptide products of the E3 region.
As used herein, “cytotoxicity” is a term well understood in the art and refers to a state in which a cell's usual biochemical or biological activities are compromised (i.e., inhibited). These activities include, but are not limited to, metabolism; cellular replication; DNA replication; transcription; translation; uptake of molecules. “Cytotoxicity” includes cell death and/or cytolysis. Assays are known in the art which indicate cytotoxicity, such as dye exclusion,
The term “selective cytotoxicity”, as used herein, refers to the cytotoxicity conferred by an adenovirus vector of the present invention on a cell which allows or induces a target cell-specific TRE to function (a target cell) when compared to the cytotoxicity conferred by an adenoviral vector of the present invention on a cell which does not allow a target cell-specific TRE to function (a non-target cell). Such cytotoxicity may be measured, for example, by plaque assays, by reduction or stabilization in size of a tumor comprising target cells, or the reduction or stabilization of serum levels of a marker characteristic of the tumor cells, or a tissue-specific marker, e.g., a cancer marker.
In the context of adenovirus, a “heterologous polynucleotide” or “heterologous gene” or “transgene” is any polynucleotide or gene that is not present in wild-type adenovirus. Preferably, the transgene will also not be expressed or present in the target cell prior to introduction by the adenovirus vector. Examples of preferred transgenes are provided below.
In the context of adenovirus, a “heterologous” promoter or enhancer is one which is not associated with or derived from an adenovirus gene.
In the context of adenovirus, an “endogenous” promoter, enhancer, or TRE is native to or derived from adenovirus. In the context of promoter, an “inactivation” means that there is a mutation of or deletion in part or all of the of the endogenous promoter, ie, a modification or alteration of the endogenous promoter, such as, for example, a point mutation or insertion, which disables the function of the promoter.
In the context of a target cell-specific TRE, a “heterologous” promoter or enhancer is one which is derived from a gene other than the gene from which a reference target cell-specific TRE is derived.
“Suppressing” tumor growth indicates a growth state that is curtailed when compared to growth without contact with, i.e., transfection by, an adenoviral vector described herein. Tumor cell growth can be assessed by any means known in the art, including, but not limited to, measuring tumor size, determining whether tumor cells are proliferating using a
As used herein, the terms “neoplastic cells”, “neoplasia”, “tumor”, “tumor cells”, “cancer” and “cancer cells”, (used interchangeably) refer to cells which exhibit relatively autonomous growth, so that they exhibit an aberrant growth phenotype characterized by a significant loss of control of cell proliferation (i.e., de-regulated cell division). Neoplastic cells can be malignant or benign.
A “host cell” includes an individual cell or cell culture which can be or has been a recipient of an adenoviral vector(s) of this invention. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation and/or change. A host cell includes cells transfected or infected in vivo or in vitro with an adenoviral vector of this invention.
“Replication” and “propagation” are used interchangeably and refer to the ability of an adenovirus vector of the invention to reproduce or proliferate. These terms are well understood in the art. For purposes of this invention, replication involves production of adenovirus proteins and is generally directed to reproduction of adenovirus. Replication can be measured using assays standard in the art and described herein, such as a burst assay or plaque assay. “Replication” and “propagation” include any activity directly or indirectly involved in the process of virus manufacture, including, but not limited to, viral gene expression; production of viral proteins, nucleic acids or other components; packaging of viral components into complete viruses; and cell lysis.
An “ADP coding sequence” is a polynucleotide that encodes ADP or a functional fragment thereof. In the context of ADP, a “functional fragment” of ADP is one that exhibits cytotoxic activity, especially cell lysis, with respect to adenoviral replication. Ways to measure cytotoxic activity are known in the art and are described herein.
A polynucleotide that “encodes” an ADP polypeptide is one that can be transcribed and/or translated to produce an ADP polypeptide or a fragment thereof. The anti-sense strand of such a polynucleotide is also said to encode the sequence.
An “ADP polypeptide” is a polypeptide containing at least a portion, or region, of the amino acid sequence of an ADP and which displays a function associated with ADP, particularly cytotoxicity, more particularly, cell lysis. As discussed herein, these functions can be measured using techniques known in the art. It is understood that certain sequence variations may be used, due to, for example, conservative amino acid substitutions, which may provide ADP polypeptides.
“Androgen receptor,” or AR, as used herein refers to a protein whose function is to specifically bind to androgen and, as a consequence of the specific binding, recognize and bind to an androgen response element (ARE), following which the AR is capable of regulating transcriptional activity. The AR is a nuclear receptor that, when activated, binds to cellular androgen-responsive element(s). In normal cells the AR is activated by androgen, but in non-normal cells (including malignant cells) the AR may be activated by non-androgenic agents, including hormones other than androgens. Encompassed in the term “androgen receptor” are mutant forms of an androgen receptor, such as those characterized by amino acid additions, insertions, truncations and deletions, as long as the function is sufficiently preserved. Mutants include androgen receptors with amino acid additions, insertions, truncations and deletions, as long as the function is sufficiently preserved. In this context, a functional androgen receptor is one that binds both androgen and, upon androgen binding, an ARE.
A polynucleotide sequence that is “depicted in” a SEQ ID NO means that the sequence is present as an identical contiguous sequence in the SEQ ID NO. The term encompasses portions, or regions of the SEQ ID NO as well as the entire sequence contained within the SEQ ID NO.
A “biological sample” encompasses a variety of sample types obtained from an individual and can be used in a diagnostic or monitoring assay. The definition encompasses blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures or cells derived therefrom, and the progeny thereof. The definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as proteins or polynucleotides. The term “biological sample” encompasses a clinical sample, and also includes cells in culture, cell supernatants, cell lysates, serum, plasma, biological fluid, and tissue samples.
An “individual” is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, farm animals, sport animals, rodents, primates, and pets.
An “effective amount” is an amount sufficient to effect beneficial or desired results, including clinical results. An effective amount can be administered in one or more administrations. For purposes of this invention, an effective amount of an adenoviral vector is an amount that is sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state.
A given TRE is “derived from” a given gene if it is associated with that gene in nature.
“Expression” includes transcription and/or translation.
As used herein, the term “comprising” and its cognates are used in their inclusive sense; that is, equivalent to the term “including” and its corresponding cognates.
“A,” “an” and “the” include plural references unless the context clearly dictates otherwise.
Internal Ribosome Entry Site (IRES)
IRES elements were first discovered in picornavirus mRNAs (Jackson R J, Howell M T, Kaminski A (1990)
The IRES promotes direct internal ribosome entry to the initiation codon of a downstream cistron, leading to cap-independent translation. Thus, the product of a downstream cistron can be expressed from a bicistronic (or multicistronic) mRNA, without requiring either cleavage of a polyprotein or generation of a monocistronic mRNA. Therefore, in one illustrative embodiment of the present invention, an adenovirus vector comprising E1B under translational control of an IRES allows translation of E1B from a bicistronic E1A-E1B mRNA under control of a target cell-specific TRE.
Internal ribosome entry sites are approximately 450 nucleotides in length and are characterized by moderate conservation of primary sequence and strong conservation of secondary structure. The most significant primary sequence feature of the IRES is a pyrimidine-rich site whose start is located approximately 25 nucleotides upstream of the 3′ end of the IRES. See Jackson et al.(1990).
Three major classes of picornavirus IRES have been identified and characterized: (1) the cardio- and aphthovirus class (for example, the encephelomycarditis virus, Jang et al. (1990)
HCV and pestiviruses such as bovine viral diarrhea virus (BVDV) or classical swine fever virus (CSFV) have 341 nt and 370 nt long 5′-UTR respectively. These 5′-UTR fragments form similar RNA secondary structures and can have moderately efficient IRES function (Tsukiyama-Kohara et al. (1992)
Leishmania RNA virus 1 (LRV1) is a double-stranded RNA virus. Its 128 nt long 5′-UTR has IRES activity to facilitate the cap-independent translation, (Maga et al. (1995)
Recent studies showed that both Friend-murine leukemia virus (MLV) 5′-UTR and rat retrotransposon virus-like 30S (VL30) sequences contain IRES structure of retroviral origin (Torrent et al. (1996)
In eukaryotic cells, translation is normally initiated by the ribosome scanning from the capped mRNA 5′ end, under the control of initiation factors. However, several cellular mRNAs have been found to have IRES structure to mediate the cap-independent translation (van der Velde, et al. (1999)
Apart from the oligopyrimidine tract, nucleotide sequence per se does not appear to be important for IRES function. Without wishing to be bound by theory, a possible explanation for the function of an IRES is that it forms secondary and/or tertiary structures which orient particular single-stranded regions of its sequence in a three-dimensional configuration that is conducive to interaction with a mammalian ribosome (either ribosomal protein and/or ribosomal RNA components) and/or initiation factor(s) and/or RNA binding proteins which interact with ribosomes and/or initiation factors. It is also possible that the three-dimensional structure of the IRES is determined or stabilized by one or more RNA-binding proteins. Thus it is possible to devise synthetic IRES sequences having similar single-stranded regions in a similar three-dimensional configuration.
In certain cases, one or more trans-acting cellular proteins may be required for IRES function. For example, the HAV and entero/rhinovirus IRESes function inefficiently in vitro in reticulocyte lysates. Supplementation of a reticulocyte lysate with a cytoplasmic extract from HeLa, Krebs II ascites, or L-cells restores activity of entero/rhinovirus IRESes. See, for example, Brown et al. (1979)
Examples of IRES which can be used in the present invention include those provided in Table 1 and Table 2. An IRES sequence which may be used in the present invention may be tested as follows. A test vector is produced having a reporter gene, such as luciferase, for example, placed under translational control of an IRES to be tested. A desired cell type is transfected with the vector containing the desired IRES-reporter gene and an assay is performed to detect the presence of the reporter gene. In one illustrative example, the test vector comprises a co-transcribed chloramphenicol transferase (CAT) and luciferase encoding gene transcriptionally driven by a CMV promoter wherein the luciferase encoding gene is translationally driven by an IRES to be tested. Host cells are transiently transfected with the test vector by means known to those of skill in the art and assayed for the presence of luciferase.
IRES may be prepared using standard recombinant and synthetic methods known in the art, and as described in the Examples. For cloning convenience, restriction sites may be engineered into the ends of the IRES fragments to be used.
Transcriptional Response Elements (TREs)
The adenovirus vectors of the invention comprise target cell specific TREs which direct preferential expression of an operatively linked gene (or genes) in a particular target cell. A TRE can be tissue-specific, tumor-specific, developmental stage-specific, cell status specific, etc., depending on the type of cell present in the tissue or tumor.
Cell- and tissue-specific transcriptional regulatory elements, as well as methods for their identification, isolation, characterization, genetic manipulation and use for regulation of operatively linked coding sequences, are well known in the art. A TRE can be derived from the transcriptional regulatory sequences of a single gene, or sequences from different genes can be combined to produce a functional TRE. A cell-specific TRE is preferentially functional in a limited population (or type) of cells, e.g., prostate cells or liver cells. Accordingly, in some embodiments, the TRE used is preferentially functional in any of the following cell types: prostate; liver; breast; urothelial cells (bladder); colon; lung; ovarian; pancreas; stomach; and uterine. In other embodiments, in accordance with cell status, the TRE is functional in or during: low oxygen conditions (hypoxia); certain stages of cell cycle, such as S phase; elevated temperature; ionizing radiation.
As is known in the art, activity of TREs can be inducible. Inducible TREs generally exhibit low activity in the absence of inducer, and are up-regulated in the presence of inducer. Inducers include, for example, nucleic acids, polypeptides, small molecules, organic compounds and/or environmental conditions such as temperature, pressure or hypoxia. Inducible TREs may be preferred when expression is desired only at certain times or at certain locations, or when it is desirable to titrate the level of expression using an inducing agent. For example, transcriptional activity from the PSE-TRE, PB-TRE and hKLK2-TRE is inducible by androgen, as described herein and in PCT/US98/04090. Accordingly, in one embodiment of the present invention, an adenovirus vector comprises an inducible heterologous TRE.
TRE multimers are also useful in the disclosed vectors. For example, a TRE can comprise a tandem series of at least two, at least three, at least four, or at least five promoter fragments. Alternatively, a TRE can comprise one or more promoter regions along with one or more enhancer regions. TRE multimers can also comprise promoter and/or enhancer sequences from different genes. The promoter and enhancer components of a TRE can be in any orientation with respect to each other and can be in any orientation and/or any distance from the coding sequence of interest, as long as the desired cell-specific transcriptional activity is obtained.
The disclosed vectors are designed such that replication is preferentially enhanced in target cells in which the TRE(s) is (are) functional. More than one TRE can be present in a vector, as long as the TREs are functional in the same target cell. However, it is important to note that a given TRE can be functional in more than one type of target cell. For example, the CEA-TRE functions in, among other cell types, gastric cancer cells, colorectal cancer cells, pancreatic cancer cells and lung cancer cells.
A TRE for use in the present vectors may or may not comprise a silencer. The presence of a silencer (i.e., a negative regulatory element known in the art) can assist in shutting off transcription (and thus replication) in non-target cells. Thus, presence of a silencer can confer enhanced cell-specific vector replication by more effectively preventing replication in non-target cells. Alternatively, lack of a silencer may stimulate replication in target cells, thus conferring enhanced target cell-specificity.
As is readily appreciated by one skilled in the art, a TRE is a polynucleotide sequence, and, as such, can exhibit function over a variety of sequence permutations. Methods of nucleotide substitution, addition, and deletion are known in the art, and readily-available functional assays (such as the CAT or luciferase reporter gene assay) allow one of ordinary skill to determine whether a sequence variant exhibits requisite cell-specific transcription regulatory function. Hence, functionally preserved variants of TREs, comprising nucleic acid substitutions, additions, and/or deletions, can be used in the vectors disclosed herein. Accordingly, variant TREs retain function in the target cell but need not exhibit maximal function. In fact, maximal transcriptional activation activity of a TRE may not always be necessary to achieve a desired result, and the level of induction afforded by a fragment of a TRE may be sufficient for certain applications. For example, if used for treatment or palliation of a disease state, less-than-maximal responsiveness may be sufficient if, for example, the target cells are not especially virulent and/or the extent of disease is relatively confined.
Certain base modifications may result in enhanced expression levels and/or cell-specificity. For example, nucleic acid sequence deletions or additions within a TRE can move transcription regulatory protein binding sites closer or farther away from each other than they exist in their normal configuration, or rotate them so they are on opposite sides of the DNA helix, thereby altering spatial relationship among TRE-bound transcription factors, resulting in a decrease or increase in transcription, as is known in the art. Thus, while not wishing to be bound by theory, the present disclosure contemplates the possibility that certain modifications of a TRE will result in modulated expression levels as directed by the TRE, including enhanced cell-specificity. Achievement of enhanced expression levels may be especially desirable in the case of more aggressive forms of neoplastic growth, and/or when a more rapid and/or aggressive pattern of cell killing is warranted (for example, in an immunocompromised individual).
Transcriptional activity directed by a TRE (including both inhibition and enhancement) can be measured in a number of ways known in the art (and described in more detail below), but is generally measured by detection and/or quantitation of mRNA and/or of a protein product encoded by the sequence under control of (i. e., operably linked to) a TRE.
As discussed herein, a TRE can be of varying lengths, and of varying sequence composition. The size of a heterologous TRE will be determined in part by the capacity of the viral vector, which in turn depends upon the contemplated form of the vector (see infra). Generally minimal sizes are preferred for TREs, as this provides potential room for insertion of other sequences which may be desirable, such as transgenes (discussed infra) and/or additional regulatory sequences. In a preferred embodiment, such an additional regulatory sequence is an IRES. However, if no additional sequences are contemplated, or if, for example, an adenoviral vector will be maintained and delivered free of any viral packaging constraints, larger TRE sequences can be used as long as the resultant adenoviral vector remains replication-competent.
An adenoviral vector can be packaged with extra sequences totaling up to about 5% of the genome size, or approximately 1.8 kb, without requiring deletion of viral sequences. If non-essential sequences are removed from the adenovirus genome, an additional 4.6 kb of insert can be tolerated (i.e., for a total insertion capacity of about 6.4 kb). Examples of non-essential adenoviral sequences that can be deleted are E3, and E4 sequences other than those which encode E4 ORF6.
To minimize non-specific replication, endogenous (e. g., adenovirus) TREs are preferably removed from the vector. Besides facilitating target cell-specific replication, removal of endogenous TREs also provides greater insert capacity in a vector, which may be of special concern if an adenoviral vector is to be packaged within a virus particle. Even more importantly, deletion of endogenous TREs prevents the possibility of a recombination event whereby a heterologous TRE is deleted and the endogenous TRE assumes transcriptional control of its respective adenovirus coding sequences (thus allowing non-specific replication). In one embodiment, an adenoviral vector is constructed such that the endogenous transcription control sequences of adenoviral genes are deleted and replaced by one or more heterologous TREs. However, endogenous TREs can be maintained in the adenovirus vector(s), provided that sufficient cell-specific replication preference is preserved. These embodiments are constructed by inserting heterologous TREs between an endogenous TRE and a replication gene coding segment. Requisite cell-specific replication preference is determined by conducting assays that compare replication of the adenovirus vector in a cell which allows function of the heterologous TREs with replication in a cell which does not.
Generally, a TRE will increase replication of a vector in a target cell by at least about 2-fold, preferably at least about 5-fold, preferably at least about 10-fold more preferably at least about 20-fold, more preferably at least about 50-fold, more preferably at least about 100-fold, more preferably at least about 200-fold, even more preferably at least about 400- to about 500- fold, even more preferably at least about 1000-fold, compared to basal levels of replication in the absence of a TRE. The acceptable differential can be determined empirically (by measurement of mRNA levels using, for example, RNA blot assays, RNase protection assays or other assays known in the art) and will depend upon the anticipated use of the vector and/or the desired result.
Replication-competent adenovirus vectors directed at specific target cells can be generated using TREs that are preferentially functional in a target cell. In one embodiment of the present invention, the target cell is a tumor cell. Non-limiting examples of tumor cell-specific heterologous TREs, and their respective target cells, include: probasin (PB), target cell, prostate cancer (PCT/US98/04132); α-fetoprotein (AFP), target cell liver cancer (PCT/US98/04084); mucin-like glycoprotein DF3 (MUC1), target cell, breast carcinoma (PCT/US98/04080); carcinoembryonic antigen (CEA), target cells, colorectal, gastric, pancreatic, breast, and lung cancers (PCT/US98/04133); plasminogen activator urokinase (uPA) and its receptor gene, target cells, breast, colon, and liver cancers (PCT/US98/04080); E2F1 (cell cycle S-phase specific promoter); target cell, tumors with disrupted retinoblastoma gene function, and HER-2/neu (c-erbB2/neu), target cell, breast, ovarian, stomach, and lung cancers (PCT/US98/04080); tyrosinase, target cell, melanoma cells as described herein and uroplakins, target cell, bladder cells as described herein. Methods for identification, isolation, characterization and utilization of additional target cell-specific TREs are readily available to those of skill in the art.
In addition, tumor-specific TREs can be used in conjunction with tissue-specific TREs from the following exemplary genes (tissue in which the TREs are specifically functional are in parentheses): hypoxia responsive element, vascular endothelial growth factor receptor (endothelium), albumin (liver), factor VII (liver), fatty acid synthase (liver), Von Willebrand factor (brain endothelium), alpha-actin and myosin heavy chain (both in smooth muscle), synthetase I (small intestine) Na+—K+—Cl
In one embodiment of the present invention, a target cell-specific, heterologous TRE is tumor cell-specific. A vector can comprise a single tumor cell-specific TRE or multiple heterologous TREs which are tumor cell-specific and functional in the same cell. In another embodiment, a vector comprises one or more heterologous TREs which are tumor cell-specific and additionally comprises one or more heterologous TREs which are tissue specific, whereby all TREs are functional in the same cell.
Prostate-Specific TREs
In one embodiment, adenovirus vectors comprise heterologous TREs that are prostate cell specific. For example, TREs that function preferentially in prostate cells and can be used to target adenovirus replication to prostate neoplasia, include, but are not limited to, TREs derived from the prostate-specific antigen gene (PSA-TRE) (Henderson U.S. Pat. No. 5,698,443); the glandular kallikrein-1 gene (from the human gene, hKLK2-TRE) (PCT US98/16312), and the probasin gene (PB-TRE) (PCT/US98/04132). All three of these genes are preferentially expressed in prostate cells and their expression is androgen-inducible. Generally, expression of genes responsive to androgen induction is mediated by an androgen receptor (AR).
Prostate-Specific Antigen (PSA)
PSA is synthesized exclusively in prostatic epithelial cells and is synthesized in these cells whether they are normal, hyperplastic, or malignant. This tissue-specific expression of PSA has made it an excellent biomarker for benign prostatic hyperplasia (BPH) and prostatic carcinoma (CaP). Normal serum levels of PSA are typically below 5 ng/ml, with elevated levels indicative of BPH or CaP. Lundwall et al. (1987)
The region of the PSA gene that provides androgen-dependent cell specificity, particularly in prostate cells, involves approximately 6.0 kilobases (kb). Schuur et al. (1996)
Human Glandular Kallikrein (hKLK2)
Human glandular kallikrein (hKLK2, encoding the hK2 protein) is expressed exclusively in the prostate and its expression is up-regulated by androgens, primarily through transcriptional activation. Wolf et al. (1992)
The activity of the hKLK2 promoter has been described and a region up to nt −2256 relative to the transcription start site was previously disclosed. Schedlich et al. (1987)
Thus, a hKLK2 enhancer can be operably linked to an hKLK2 promoter or a heterologous promoter to form a hKLK2 transcriptional regulatory element (hKLK2-TRE). A hKLK2-TRE can then be operably linked to a heterologous polynucleotide to confer hKLK2-TRE-specific transcriptional regulation on the linked gene, thus increasing its expression.
Probasin
The rat probasin (PB) gene encodes an androgen and zinc-regulated protein first characterized in the dorsolateral prostate of the rat. Dodd et al. (1983)
A PB-TRE has been shown to exist in an approximately 0.5 kb fragment of sequence upstream of the probasin coding sequence, from about nt −426 to about nt +28 relative to the transcription start site. This minimal promoter sequence from the PB gene appears to provide sufficient information to direct prostate-specific developmental- and hormone-regulated expression of an operably linked heterologous gene in transgenic mice. Greenberg et al. (1994)
Alpha-Fetoprotein
α-fetoprotein (AFP) is an oncofetal protein, the expression of which is primarily restricted to developing tissues of endodermal origin (yolk sac, fetal liver, and gut), although the level of its expression varies greatly depending on the tissue and the developmental stage. AFP is of clinical interest because the serum concentration of AFP is elevated in a majority of hepatoma patients, with high levels of AFP found in patients with advanced disease. High serum AFP levels in patients appear to be due to AFP expression in hepatocellular carcinoma (HCC), but not in surrounding normal liver. Thus, expression of the AFP gene appears to be characteristic of hepatoma cells. An AFP-TRE is described in for example PCT/US98/04084.
According to published reports, the AFP-TRE is responsive to cellular proteins (transcription factors and/or co-factor(s)) associated with AFP-producing cells, such as AFP-binding protein (see, for example, U.S. Pat. No. 5,302,698) and comprises at least a portion of an AFP promoter and/or an AFP enhancer. Cell-specific TREs from the AFP gene have been identified. For example, the cloning and characterization of human AFP-specific enhancer activity is described in Watanabe et al. (1987)
Within the APP regulatory region, a human AFP enhancer region is located between about nt −3954 and about nt −3335, relative to the transcription start site of the AFP gene. The human AFP promoter encompasses a region from about nt −174 to about nt +29. Juxtapositioning of these two genetic elements, yields a fully functional AFP-TRE. Ido et al. (1995)
Suitable target cells for vectors containing AFP-TREs are any cell type that allow an AFP-TRE to function. Preferred are cells that express or produce AFP, including, but not limited to, tumor cells expressing AFP. Examples of such cells are hepatocellular carcinoma (HCC) cells, gonadal and other germ cell tumors (especially endodermal sinus tumors), brain tumor cells, ovarian tumor cells, acinar cell carcinoma of the pancreas (Kawamoto et al. (1992)
AFP production can be measured (and hence AFP-producing cells can be identified) using immunoassays standard in the art, such as RIA, ELISA or protein immunoblotting (Western blots) to determine levels of AFP protein production; and/or RNA blotting (Northern blots) to determine AFP mRNA levels. Alternatively, such cells can be identified and/or characterized by their ability to activate transcriptionally an AFP-TRE (i.e., allow an AFP-TRE to function).
See also co-owned PCT W098/39465 regarding AFP-TREs. As described in more detail therein, an AFP-TRE can comprise any number of configurations, including, but not limited to, an AFP promoter; an AFP enhancer; an AFP promoter and an AFP enhancer; an AFP promoter and a heterologous enhancer; a heterologous promoter and an AFP enhancer; and multimers of the foregoing. The promoter and enhancer components of an AFP-TRE can be in any orientation and/or distance from the coding sequence of interest, as long as the desired AFP cell-specific transcriptional activity is obtained. An adenovirus vector of the present invention can comprise an AFP-TRE endogenous silencer element or the AFP-TRE endogenous silencer element can be deleted.
Urokinase Plasminogen Activator
The protein urokinase plasminogen activator (uPA) and its cell surface receptor, urokinase plasminogen activator receptor (uPAR), are expressed in many of the most frequently-occurring neoplasms and appear to represent important proteins in cancer metastasis. Both proteins are implicated in breast, colon, prostate, liver, renal, lung and ovarian cancer. Sequence elements that regulate uPA and uPAR transcription have been extensively studied. Riccio et al. (1985)
Carcinoembryonic Antigen (CEA)
CEA is a 180,000 Dalton, tumor-associated, glycoprotein antigen present on endodermally-derived neoplasms of the gastrointestinal tract, such as colorectal, gastric (stomach) and pancreatic cancer, as well as other adenocarcinomas such as breast and lung cancers. CEA is of clinical interest because circulating CEA can be detected in the great majority of patients with CEA-positive tumors. In lung cancer, about 50% of total cases have circulating CEA, with high concentrations of CEA (greater than 20 ng/ml) often detected in adenocarcinomas. Approximately 50% of patients with gastric carcinoma are serologically positive for CEA.
The 5′-flanking sequence of the CEA gene has been shown to confer cell-specific activity. The CEA promoter region, approximately the first 424 nucleotides upstream of the transcriptional start site in the 5′ flanking region of the gene, was shown to confer cell-specific activity by virtue of providing higher promoter activity in CEA-producing cells than in non-producing HeLa cells. Schrewe et al. (1990)
CEA-TREs for use in the vectors disclosed herein are derived from mammalian cells, including, but not limited to, human cells. Thus, any of the CEA-TREs TREs can be used as long as the requisite desired functionality is displayed by the vector.
Mucin
The protein product of the MUC1 gene (known as mucin, MUC1 protein; episialin; polymorphic epithelial mucin or PEM; EMA; DF3 antigen; NPGP; PAS-O; or CA15.3 antigen) is normally expressed mainly at the apical surface of epithelial cells lining the glands or ducts of the stomach, pancreas, lungs, trachea, kidney, uterus, salivary glands, and mammary glands. Zotter et al. (1988)
Overexpression of the MUC1 gene in human breast carcinoma cells MCF-7 and ZR-75-1 appears to occur at the transcriptional level. Kufe et al. (1984) supra; Kovarik (1993)
MUC1-TREs are derived from mammalian cells, including but not limited to, human cells. Preferably, the MUC1-TRE is human. In one embodiment, the MUC1-TRE contains the entire 0.9 kb 5′ flanking sequence of the MUC1 gene. In other embodiments, MUC1-TREs comprise the following sequences (relative to the transcription start site of the MUC1 gene) operably-linked to a promoter: about nt −725 to about nt +31, about nt −743 to about nt +33, about nt −750 to about nt +33, and about nt −598 to about nt +485.
c-erbB2/HER-2/neu
The c-erbB2/neu gene (HER-2/neu or HER) is a transforming gene that encodes a 185 kD epidermal growth factor receptor-related transmembrane glycoprotein. In humans, the c-erbB2/neu protein is expressed during fetal development and, in adults, the protein is weakly detectable (by immunohistochemistry) in the epithelium of many normal tissues. Amplification and/or over-expression of the c-erbB2/neu gene has been associated with many human cancers, including breast, ovarian, uterine, prostate, stomach and lung cancers. The clinical consequences of overexpression of the c-erbB2/neu protein have been best studied in breast and ovarian cancer. c-erbB2/neu protein over-expression occurs in 20 to 40% of intraductal carcinomas of the breast and 30% of ovarian cancers, and is associated with a poor prognosis in subcategories of both diseases.
Human, rat and mouse c-erbB2/neu TREs have been identified and shown to confer transcriptional activity specific to c-erbB2/neu-expressing cells. Tal et al. (1987)
Melanocyte-Specific TRE
It has been shown that some genes which encode melanoma proteins are frequently expressed in melanoma/melanocytes, but silent in the majority of normal tissues. A variety of melanocyte-specific TRE are known, are responsive to cellular proteins (transcription factors and/or co-factor(s)) associated with melanocytes, and comprise at least a portion of a melanocyte-specific promoter and/or a melanocyte-specific enhancer. Known transcription factors that control expression of one or more melanocyte-specific genes include the microphthalmia associated transcription factor MITF. Yasumoto et al. (1997)
Methods are described herein for measuring the activity of a melanocyte-specific TRE and thus for determining whether a given cell allows a melanocyte-specific TRE to function.
In some embodiments, the melanocyte-specific TREs used in this invention are derived from mammalian cells, including but not limited to, human, rat, and mouse. Any melanocyte-specific TREs may be used in the adenoviral vectors of the invention. Rodent and human 5′ flanking sequences from genes expressed specifically or preferentially in melanoma cells have been described in the literature and are thus made available for practice of this invention and need not be described in detail herein. The following are some examples of melanocyte-specific TREs which can be used. A promoter and other control elements in the human tyrosinase gene 5′ flanking region have been described and sequences have been deposited as GenBank Accession Nos. X16073 and D10751. Kikuchi et al. (1989)
In some embodiments, a melanocyte-specific TRE comprises sequences derived from the 5′ flanking region of a human tyrosinase gene depicted in Table 3. In some of these embodiments, the melanocyte-specific TRE comprises tyrosinase nucleotides from about −231 to about +65 relative to the transcription start site (from about nucleotide 244 to about nucleotide 546 of SEQ ID NO: 10) and may further comprise nucleotides from about −1956 to about −1716 relative to the human tyrosinase transcription start site (from about nucleotide 6 to about nucleotide 243 of SEQ ID NO: 10). A melanocyte-specific TRE can comprise nucleotides from about—−231 to about +65 juxtaposed to nucleotides from about −1956 to about −1716. It has been reported that nucleotides from about −1956 to about −1716 relative to the human tyrosinase transcription start site can confer melanocyte-specific expression of an operably linked reporter gene with either a hom*ologous or a heterologous promoter. Accordingly, in some embodiments, a melanocyte-specific TR-E comprises nucleotides from about −1956 to about −1716 operably linked to a heterologous promoter.
A melanocyte-specific TRE can also comprise multimers. For example, a melanocyte-specific TRE can comprise a tandem series of at least two, at least three, at least four, or at least five tyrosinase promoter fragments. Alternatively, a melanocyte-specific TRE could have one or more tyrosinase promoter regions along with one or more tyrosinase enhancer regions. These multimers may also contain heterologous promoter and/or enhancer sequences.
Cell Status-Specific TREs
Cell status-specific TREs for use in the adenoviral vectors of the present invention can be derived from any species, preferably a mammal. A number of genes have been described which are expressed in response to, or in association with, a cell status. Any of these cell status-associated genes may be used to generate a cell status-specific TRE.
An example of a cell status is cell cycle. An exemplary gene whose expression is associated with cell cycle is E2F-1, a ubiquitously expressed, growth-regulated gene, which exhibits peak transcriptional activity in S phase. Johnson et al. (1994)
Accordingly, in one embodiment, the invention provides an E3-containing adenoviral vector in which an adenoviral gene (preferably a gene necessary for replication) is under transcriptional control of a cell status-specific TRE, wherein the cell status-specific TRE comprises a cell cycle-activated TRE. In one embodiment, the cell cycle-activated TRE is an E2F1 TRE.
Another group of genes that are regulated by cell status are those whose expression is increased in response to hypoxic conditions. Bunn and Poyton (1996)
Accordingly, in one embodiment, an adenovirus vector comprises an adenovirus gene, preferably an adenoviral gene essential for replication, under transcriptional control of a cell status-specific TRE comprising an HRE. In one embodiment, the cell status-specific TRE comprises the HRE depicted in Table 3.
Other cell status-specific TREs include heat-inducible (i.e., heat shock) promoters, and promoters responsive to radiation exposure, including ionizing radiation and UV radiation. For example, the promoter region of the early growth response-1 (Egr-1) gene contains an element(s) inducible by ionizing radiation. Hallahan et al. (1995)
The cell status-specific TREs listed above are provided as non-limiting examples of TREs that would function in the instant invention. Additional cell status-specific TREs are known in the art, as are methods to identify and test cell status specificity of suspected cell status-specific TREs.
Urothelial Cell-Specific TREs
Any urothelial cell-specific TRE may be used in the adenoviral vectors of the invention. A number of urothelial cell-specific proteins have been described, among which are the uroplakins. Uroplakins (UP), including UPIa and UPIb (27 and 28 kDa, respectively), UPII (15 kDa), and UPIII (47 kDa), are members of a group of integral membrane proteins that are major proteins of urothelial plaques. These plaques cover a large portion of the apical surface of mammalian urothelium and may play a role as a permeability barrier and/or as a physical stabilizer of the urothelial apical surface. Wu et al. (1994)
Preferred urothelial cell-specific TREs include TREs derived from the uroplakins UPIa, UPIb, UPII, and LUPIII, as well as urohingin. A uroplakin TRE may be from any species, depending on the intended use of the adenovirus, as well as the requisite functionality is exhibited in the target or host cell. Significantly, adenovirus constructs comprising a urothelial cell-specific TREs have observed that such constructs are capable of selectively replicating in urothelial cells as opposed to smooth muscle cells, which adjoin urothelial cells in the bladder.
Uroplakin
Urothelial-specific TREs derived from the hUPII gene are described herein. Accordingly, in some embodiments, an adenovirus vector of the invention comprises an adenovirus gene, preferably an adenoviral gene essential for replication, under transcriptional control of a urothelial cell-specific TRE which comprises the 2.2 kb sequence from the 5′ flanking region of hUPII gene, as shown in Table 3. In other embodiments, an adenovirus vector of the invention comprises an adenovirus gene, preferably an adenoviral gene essential for replication, under transcriptional control of a urothelial cell-specific TRE which comprises a 1.8 kb sequence from the 5′ flanking region of hUPII gene, from nucleotides 430 to 2239 as shown in Table 3. In other embodiments, the urothelial cell-specific TRE comprises a functional portion of the 2.2 kb sequence depicted in Table 3, or a functional portion of the 1.8 kb sequence of nucleotides 430 to 2239 of the sequence depicted in Table 3, such as a fragment of 2000 bp or less, 1500 bp or less, or 1000 bp or less, 600 bp less, or at least 200 bp which includes the 200 bp fragment of the hUPII 5′-flanking region.
A 3.6 kb 5′-flanking sequence located from the mouse UPII (mUPII) gene which confers urothelial cell-specific transcription on heterologous genes is one urothelial cell-specific TRE useful in vectors of the instant invention (Table 3). Smaller TREs (i.e., 3500 bp or less, more preferably less than about 2000 bp, 1500 bp, or 1000 bp) are preferred. Smaller TREs derived from the mUPII 3.6 kb fragment are one group of preferred urothelial cell-specific TREs. In particular, Inventors have identified an approximately 600 bp fragment from the 5′ flanking DNA of the mUPII gene, which contains 540 bp of 5′ untranslated region (UTR) of the mUPII gene, that confers urothelial cell-specific expression on heterologous genes.
Accordingly, in some embodiments, an adenovirus vector of the invention comprises an adenovirus gene, preferably an adenoviral gene essential for replication, under transcriptional control of a urothelial cell-specific TRE which comprises the 3.6 kb sequence from the 5′ flanking region of mouse UPII gene, as shown in Table 3. In other embodiments, the urothelial cell-specific TRE comprises a functional portion of the 3.6 kb sequence depicted in Table 3, such as a fragment of 3500 bp or less, 2000 bp or less, 1500 bp or less, or 1000 bp or less which includes the 540 bp fragment of 5′ UTR. The urothelial cell-specific TRE may also be a sequence which is substantially identical to the 3.6 kb mUPII 5′-flanking region or any of the described fragments thereof.
As an example of how urothelial cell-specific TRE activity can be determined, a polynucleotide sequence or set of such sequences can be generated using methods known in the art, such as chemical synthesis, site-directed mutagenesis, PCR, and/or recombinant methods. The sequence(s) to be tested is inserted into a vector containing an appropriate reporter gene, including, but not limited to, chloramphenicol acetyl transferase (CAT), β-galactosidase (encoded by the lacZ gene), luciferase (encoded by the luc gene), a green fluorescent protein, alkaline phosphatase, and horse radish peroxidase. Such vectors and assays are readily available, from, inter alia, commercial sources. Plasmids thus constructed are transfected into a suitable host cell to test for expression of the reporter gene as controlled by the putative target cell-specific TRE using transfection methods known in the art, such as calcium phosphate precipitation, electroporation, liposomes (lipofection) and DEAE dextran. Suitable host cells include any urothelial cell type, including but not limited to, KU-1, MYP3 (a non-tumorigenic rat urothelial cell line), 804G (rat bladder carcinoma cell line), cultured human urothelial cells (HUC), HCV-29, UM-UC-3, SW780, RT4, HL60, KG-1, and KG1A. Non-urothelial cells, such as LNCaP, HBL-100, HLF, HLE, 3T3, Hep3B, HuH7, CADO-LC9, and HeLa are used as a control. Results are obtained by measuring the level of expression of the reporter gene using standard assays. Comparison of expression between urothelial cells and control indicates presence or absence of transcriptional activation.
Comparisons between or among various urothelial cell-specific TREs can be assessed by measuring and comparing levels of expression within a single urothelial cell line. It is understood that absolute transcriptional activity of a urothelial cell-specific TRE will depend on several factors, such as the nature of the target cell, delivery mode and form of the urothelial cell-specific TRE, and the coding sequence that is to be selectively transcriptionally activated. To compensate for various plasmid sizes used, activities can be expressed as relative activity per mole of transfected plasmid. Alternatively, the level of transcription (i.e., mRNA) can be measured using standard Northern analysis and hybridization techniques. Levels of transfection (i.e., transfection efficiencies) are measured by co-transfecting a plasmid encoding a different reporter gene under control of a different TRE, such as the CMV immediate early promoter. This analysis can also indicate negative regulatory regions, i.e., silencers.
Alternatively a putative urothelial cell-specific TRE can be assessed for its ability to confer adenoviral replication preference for cells that allow a urothelial cell-specific TRE to function. For this assay, constructs containing an adenovirus gene essential to replication operatively linked to a putative urothelial cell-specific TRE are transfected into urothelial cells. Viral replication in those cells is compared, for example, to viral replication by wild type adenovirus in those cells and/or viral replication by the construct in non-urothelial cells.
TRE Configurations
A TRE as used in the present invention can be present in a variety of configurations. A TRE can comprise multimers. For example, a TRE can comprise a tandem series of at least two, at least three, at least four, or at least five target cell-specific TREs. These multimers may also contain heterologous promoter and/or enhancer sequences.
Optionally, a transcriptional terminator or transcriptional “silencer” can be placed upstream of the target cell-specific TRE, thus preventing unwanted read-through transcription of the coding segment under transcriptional control of the target cell-specific TRE. Also, optionally, the endogenous promoter of the coding segment to be placed under transcriptional control of the target cell-specific TRE can be deleted.
A target cell-specific TRE may or may not lack a silencer. The presence of a silencer (i.e., a negative regulatory element) may assist in shutting off transcription (and thus replication) in non-permissive cells (i.e., a non-target cell). Thus, presence of a silencer may confer enhanced target cell-specific replication by more effectively preventing adenoviral vector replication in non-target cells. Alternatively, lack of a silencer may assist in effecting replication in target cells, thus conferring enhanced target cell-specific replication due to more effective replication in target cells.
It is also understood that the invention includes a target cell-specific TRE regulating the transcription of a bicistronic mRNA in which translation of the second mRNA is associated by an IRES. An adenovirus vector may further include an additional heterologous TRE which may or may not be operably linked to the same gene(s) as the target cell-specific TRE. For example a TRE (such as a cell type-specific or cell status-specific TRE) may be juxtaposed to a second type of target-cell-specific TRE. “Juxtaposed” means a target cell-specific TRE and a second TRE transcriptionally control the same gene. For these embodiments, the target cell-specific TRE and the second TRE may be in any of a number of configurations, including, but not limited to, (a) next to each other (i.e., abutting); (b) both 5′ to the gene that is transcriptionally controlled (i.e., may have intervening sequences between them); (c) one TRE 5′ and the other TRE 3′ to the gene.
As is readily appreciated by one skilled in the art, a target cell-specific TRE is a polynucleotide sequence, and, as such, can exhibit function over a variety of sequence permutations. Methods of nucleotide substitution, addition, and deletion are known in the art, and readily available functional assays (such as the CAT or luciferase reporter gene assay) allow one of ordinary skill to determine whether a sequence variant exhibits requisite target cell-specific transcription function. Hence, the invention also includes functionally-preserved variants of the TRE nucleic acid sequences disclosed herein, which include nucleic acid substitutions, additions, and/or deletions. The variants of the sequences disclosed herein may be 80%, 85%, 90%, 95%, 98%, 99% or more identical, as measured by, for example, ALIGN Plus (Scientific and Educational Software, Pennsylvania), preferably using efault parameters, which are as follows: mismatch=2; open gap=0; extend gap=2 to any of the urothelial cell-specific TRE sequences disclosed herein. Variants of target cell-specific TRE sequences may also hybridize at high stringency, that is at 68° C. and 0.1×SSC, to any of the target cell-specific TRE sequences disclosed herein.
In terms of hybridization conditions, the higher the sequence identity required, the more stringent are the hybridization conditions if such sequences are determined by their ability to hybridize to a sequence of TRE disclosed herein. Accordingly, the invention also includes polynucleotides that are able to hybridize to a sequence comprising at least about 15 contiguous nucleotides (or more, such as about 25, 35, 50, 75 or 100 contiguous nucleotides) of a TRE disclosed herein. The hybridization conditions would be stringent, i.e., 80° C. (or higher temperature) and 6M SSC (or less concentrated SSC). Another set of stringent hybridization conditions is 68° C. and 0.1×SSC. For discussion regarding hybridization reactions, see below.
Hybridization reactions can be performed under conditions of different “stringency”. Conditions that increase stringency of a hybridization reaction of widely known and published in the art. See, for example, Sambrook et al. (1989) at page 7.52. Examples of relevant conditions include (in order of increasing stringency): incubation temperatures of 25° C., 37° C., 50° C. and 68° C.; buffer concentrations of 10×SSC, 6×SSC, 1×SSC, 0.1×SSC (where SSC is 0.15 M NaCl and 15 mM citrate buffer) and their equivalents using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 minutes to 24 hours; 1, 2, or more washing steps; wash incubation times of 1, 2, or 15 minutes; and wash solutions of 6×SSC, 1×SSC, 0.1×SSC, or deionized water. An exemplary set of stringent hybridization conditions is 68° C. and 0.1×SSC.
“T
where [X
While not wishing to be bound by a single theory, the inventors note that it is possible that certain modifications will result in modulated resultant expression levels, including enhanced expression levels. Achievement of modulated resultant expression levels, preferably enhanced expression levels, may be especially desirable in the case of certain, more aggressive forms of cancer, or when a more rapid and/or aggressive pattern of cell killing is warranted (due to an immunocompromised condition of the individual, for example).
Determination of TRE Activity
Activity of a TRE can be determined, for example, as follows. A TRE polynucleotide sequence or set of such sequences can be generated using methods known in the art, such as chemical synthesis, site-directed mutagenesis, PCR, and/or recombinant methods. The sequence(s) to be tested can be inserted into a vector containing a promoter (if no promoter element is present in the TRE) and an appropriate reporter gene encoding a reporter protein, including, but not limited to, chloramphenicol acetyl transferase (CAT), β-galactosidase (encoded by the lacZ gene), luciferase (encoded by the luc gene), alkaline phosphatase (AP), green fluorescent protein (GFP), and horseradish peroxidase (HRP). Such vectors and assays are readily available, from, inter alia, commercial sources. Plasmids thus constructed are transfected into a suitable host cell to test for expression of the reporter gene as controlled by the putative TRE using transfection methods known in the art, such as calcium phosphate precipitation, electroporation, liposomes, DEAE dextran-mediated transfer, particle bombardment or direct injection. TRE activity is measured by detection and/or quantitation of reporter gene-derived mRNA and/or protein. Reporter protein product can be detected directly (e.g., immunochemically) or through its enzymatic activity, if any, using an appropriate substrate. Generally, to determine cell specific activity of a TRE, a TRE-reporter gene construct is introduced into a variety of cell types. The amount of TRE activity is determined in each cell type and compared to that of a reporter gene construct lacking the TRE. A TRE is determined to be cell-specific if it is preferentially functional in one cell type, compared to a different type of cell.
Adenovirus Early Genes
The adenovirus vectors of the invention comprise two or more genes which are co-transcribed under the control of a target cell-specific TRE wherein the second gene is under translational control of an IRES. One or more of the genes can be an adenovirus gene, preferably an adenovirus gene essential for replication. Any gene that is essential for adenovirus replication, such as E1A, E1B, E2, E4 or any of the late genes, is useful. The adenovirus may also comprise E3. In addition, one or more of the genes can be a transgene or heterologous gene. Any of the various adenovirus serotypes can be used, such as, for example, Ad2, Ad5, Ad12 and Ad40. For purposes of illustration, the Ad5 serotype is exemplified herein.
The E1A gene is expressed immediately (between 0 and 2 hours) after viral infection, before any other viral genes. E1A protein is a trans-acting positive transcriptional regulatory factor, and is required for the expression of the other early viral genes E1B, E2, E3, E4, and the promoter-proximal major late genes. Despite the nomenclature, the promoter proximal genes driven by the major late promoter are also expressed during early times after Ad5 infection. Flint (1982)
The E1B protein is necessary in trans for transport of late mRNA from the nucleus to the cytoplasm. Defects in E1B expression result in poor expression of late viral proteins and an inability to shut off host cell protein synthesis. The promoter of E1B has been implicated as the defining element of difference in the host range of Ad40 and Ad5: clinically Ad40 is an enterovirus, whereas Ad5 causes acute conjunctivitis. Bailey et al. (1993)
Adenovirus E1B 19-kDa (19K) protein is a potent inhibitor of apoptosis and cooperates with E1A to produce oncogenic transformation of primary cells (Rao, et al., 1992,
In a preferred embodiment, expression of the E1A and E1B regions of the Ad genome is facilitated in a cell-specific fashion by placing a cell-specific TRE upstream of E1A and a internal ribosome entry site between E1A and E1B.
The E2 region of adenovirus encodes proteins related to replication of the adenoviral genome, including the 72 kD DNA-binding protein, the 80 kD precursor terminal protein and the viral DNA polymerase. The E2 region of Ad5 is transcribed in a rightward orientation from two promoters, termed E2 early and E2 late, mapping at 76.0 and 72.0 map units, respectively. While the E2 late promoter is transiently active during late stages of infection and is independent of the E1A transactivator protein, the E2 early promoter is crucial during the early phases of viral replication.
The E2 early promoter of Ad5 is located between nucleotides 27,050 and 27,150, and consists of a major and a minor transcription initiation site (the latter accounting for about 5% of E2 transcripts), two non-canonical TATA boxes, two E2F transcription factor binding sites and an ATF transcription factor binding site. For a detailed review of E2 promoter architecture see Swaminathan et al. (1995)
The E2 late promoter overlaps with the coding sequences of a gene encoded by the counterstrand and is therefore not amenable for genetic manipulation. However, the E2 early promoter overlaps by only a few base pairs with sequences on the counterstrand which encode a 33 kD protein. Notably, an SpeI restriction site (Ad5 position 27,082) is part of the stop codon for the above mentioned 33 kD protein and conveniently separates the major E2 early transcription initiation site and TATA box from the upstream E2F and ATF binding sites. Therefore, insertion of a heterologous TRE having SpeI ends into the SpeI site disrupts the endogenous E2 early promoter of Ad5 and allows TRE-regulated expression of E2 transcripts.
An E3 region refers to the region of the adenoviral genome that encodes the E3 products. The E3 region has been described in various publications, including, for example, Wold et al. (1995)
The E4 gene has a number of transcription products and encodes two polypeptides (the products of open reading frames (ORFs) 3 and 6) which are responsible for stimulating the replication of viral genomic DNA and stimulating late gene expression, through interaction with heterodimers of cellular transcription factors E2F-1 and DP-1. The ORF 6 protein requires interaction with the E1B 55 kD protein for activity while the ORF 3 protein does not. In the absence of functional ORF 3- and ORF 6-encoded proteins, efficiency of plaque formation is less than 10
To further increase cell-specificity of replication, it is possible to take advantage of the interaction between the E4 ORF 6 gene product and the E1B 55 kD protein. For example, if E4 ORFs 1-3 are deleted, viral DNA replication and late gene synthesis becomes dependent on E4 ORF6 protein. By generating such a deletion in a vector in which the E1B region is regulated by a cell-specific TRE, a virus is obtained in which both E1B and E4 functions are dependent on the cell-specific which regulates E1B.
Late genes relevant to the disclosed vectors are L1, L2 and L3, which encode proteins of the virion. All of these genes (typically coding for structural proteins) are probably required for adenoviral replication. All late genes are under the control of the major late promoter (MLP), which is located in Ad5 between nucleotides 5986 and 6048.
In one embodiment, an adenovirus early gene is under transcriptional control of a cell specific, heterologous TRE. In additional embodiments, the early gene is selected from the group including E1A, E1B, E2, E3, E4. In another embodiment, an adenovirus late gene is under transcriptional control of a cell specific, heterologous TRE. In further embodiments, two or more early genes are under the control of heterologous TREs that function in the same target cell. The heterologous TREs can be the same or different, or one can be a variant of the other. In additional embodiments, two or more late genes are under the control of heterologous TREs that function in the same target cell. The heterologous TREs can be the same or different, or one can be a variant of the other. In yet another embodiment, one or more early gene(s) and one or more late gene(s) are under transcriptional control of the same or different heterologous TREs, wherein the TREs function in the same target cell.
In some embodiments of the present invention, the adenovirus vector comprises the essential gene E1A and the E1A promoter is deleted. In other embodiments, the adenovirus vector comprises the essential gene E1A and the E1A enhancer I is deleted. In yet other embodiments, the E1A promoter is deleted and E1A enhancer I is deleted. In other embodiments, an internal ribosome entry site (IRES) is inserted upstream of E1B (so that E1B is translationally linked), and a target cell-specific TRE is operably linked to E1A. In still other embodiments, an (IRES) is inserted upstream of E1B (so that E1B is translationally linked), and target cell-specific TRE is operably linked to E1A, which may or may not maintain the E1A promoter and/or enhancer I (i.e., the E1A promoter and/or enhancer I may be, but not necessarily be, deleted). In yet other embodiments, the 19-kDa region of E1B is deleted.
For adenovirus vectors comprising a second gene under control of an IRES, it is preferred that the endogenous promoter of a gene under translational control of an IRES be deleted so that the endogenous promoter does not interfere with transcription of the second gene. It is preferred that the second gene be in frame with the IRES if the IRES contains an initiation codon. If an initiation codon, such as ATG, is present in the IRES, it is preferred that the initiation codon of the second gene is removed and that the IRES and second gene are in frame. Alternatively, if the IRES does not contain an initiation codon or if the initiation codon is removed from the IRES, the initiation codon of the second gene is used.
Adenovirus Death Protein (ADP) Gene and Gene Product
In the construction of adenovirus vectors, the E3 region is often deleted to facilitate insertion of one or more TREs and/or transgenes. In some embodiments, however, the adenovirus death protein (ADP), encoded within the E3 region, is retained in an adenovirus vector. The ADP gene, under control of the major late promoter (MLP), appears to code for a protein (ADP) that is important in expediting host cell lysis. Tollefson et al. (1992)
An ADP coding sequence is obtained preferably from Ad2 (since this is the strain in which the ADP has been most fully characterized) using techniques known in the art, such as PCR. Preferably, the Y leader (which is an important sequence for correct expression of late genes) is also obtained and placed in operative linkage to the ADP coding sequence. The ADP coding sequence (with or without the Y leader) is then introduced into an adenoviral genome, for example, in the E3 region, where expression of the ADP coding sequence will be driven by the MLP. The ADP coding sequence can, of course, also be inserted in other locations of the adenovirus genome, such as the E4 region. Alternatively, the ADP coding sequence can be operably linked to a heterologous TRE, including, but not limited to, another viral TRE or a target cell-specific TRE (see infra). In another embodiment, the ADP gene is present in a viral genome such that it is transcribed as part of a multi-cistronic mRNA in which its translation is associated with an IRES.
E3-Containing Target Cell-Specific Adenoviral Vectors
In some embodiments, the adenovirus vectors contain an E3 region, or a portion of an E3 region. Inclusion of the E3 region of adenovirus can enhance cytotoxicity of the target cell-specific adenoviral vectors of the present invention. Adenoviral vectors containing an E3 region may maintain their high level of specificity and can be (a) significantly more cytotoxic; (b) produce higher virus yield including extracellular virus yield; (c) form larger plaques; (d) produce rapid cell death; and (e) kill tumors more efficiently in vivo than vectors lacking the E3 region. The adenoviral vectors of this invention may contain the E3 region or a portion of the E3 region. It is understood that, as inclusion of E3 confers observable and measurable functionality on the adenoviral vectors, for example, increased replication and production, functionally equivalent (in which functionality is essentially maintained, preserved, or even enhanced or diminished) variants of E3 may be constructed. For example, portions of B3 may be used. A portion may be, non-inclusively, either of the following: (a) deletion, preferably at the 3′ end; (b) inclusion of one or more various open reading frames of E3. Five proteins which are encoded by the Ad-E3 region have been identified and characterized: (1) a 19-kDa glycoprotein (gp19 k) is one of the most abundant adenovirus early proteins, and is known to inhibit transport of the major histocompatibility complex class I molecules to the cell surface, thus impairing both peptide recognition and clearance of Ad-infected cells by cytotoxic T lymphocytes (CTLs); (2) E3 14.7 k protein and the E3 10.4k/14.5 k complex of proteins inhibit the cytotoxic and inflammatory responses mediated by tumor necrosis factor (TNF); (3) E3 10.4 k/14.5 k protein complex down regulates the epidermal growth factor receptor, which may inhibit inflammation and activate quiescent infected cells for efficient virus replication; (4) E3 11.6 k protein (adenoviral death protein, ADP) from adenovirus 2 and 5 appears to promote cell death and release of virus from infected cells. The functions of three E3-encoded proteins—3.6 k, 6.7 k and 12.5 k—are unknown. A ninth protein having a molecular weight of 7.5 kDa has been postulated to exist, but has not been detected in cells infected with wild-type adenovirus. Wold et al. (1995)
In the adenovirus vectors of the present invention, E3 may or may not be under transcriptional control of native adenoviral transcriptional control element(s). The E3 promoter is located within the coding sequence for virion protein VIII, an essential protein which is highly conserved among adenovirus serotypes. In some embodiments, E3 is under transcriptional control of a heterologous TRE, including, but not limited to, a target cell-specific TRE. Accordingly, in one embodiment, the invention provides an adenoviral vector, preferably replication competent, that comprises E3 region (or a portion of E3) under transcriptional control of a target cell-specific TRE. In other embodiments, the E3 region is under transcriptional control of a native adenoviral TRE, and the vector further comprises an adenoviral gene essential for replication under transcriptional control of a target cell-specific TRE. In other embodiments, the E3 region is under transcriptional control of a target cell-specific TRE, and the vector further comprises an adenoviral gene essential for replication under transcriptional control of a target cell-specific TRE.
Transgenes Under Transcriptional Control of a Target Cell-Specific TRE
Various other replication-competent adenovirus vectors can be made according to the present invention in which, in addition to having a single or multiple adenovirus gene(s) under control of a target cell-specific TRE, a trans gene(s) is/are also under control of a target cell-specific TRE and optionally under translational control of an IRES. Transgenes include, but are not limited to, therapeutic transgenes and reporter genes.
Reporter Genes
For example, a target cell-specific TRE can be introduced into an adenovirus vector immediately upstream of and operably linked to an early gene such as E1A or E1B, and this construct may further comprise a second co-transcribed gene under translational control of an IRES. The second gene may be a reporter gene. The reporter gene can encode a reporter protein, including, but not limited to, chloramphenicol acetyl transferase (CAT), β-galactosidase (encoded by the lacZ gene), luciferase, alkaline phosphatase, a green fluorescent protein, and horse radish peroxidase. For detection of a putative cancer cell(s) in a biological sample, the biological sample may be treated with modified adenoviruses in which a reporter gene (e.g., luciferase) is under control of a target cell-specific TRE. The target cell-specific TRE will be transcriptionally active in cells that allow the target cell-specific TRE to function, and luciferase will be produced. This production will allow detection of target cells, including cancer cells in, for example, a human host or a biological sample. Alternatively, an adenovirus can be constructed in which a gene encoding a product conditionally required for survival (e.g., an antibiotic resistance marker) is under transcriptional control of a target cell-specific TRE. When this adenovirus is introduced into a biological sample, the target cells will become antibiotic resistant. An antibiotic can then be introduced into the medium to kill the non-cancerous cells.
Therapeutic Transgenes
Transgenes also include genes which may confer a therapeutic effect, such as enhancing cytotoxicity so as to eliminate unwanted target cells. In this way, various genetic capabilities may be introduced into target cells, particularly cancer cells. For example, in certain instances, it may be desirable to enhance the degree and/or rate of cytotoxic activity, due to, for example, the relatively refractory nature or particular aggressiveness of the cancerous target cell. This could be accomplished by coupling the target cell-specific cytotoxic activity with cell-specific expression of, for example, HSV-tk and/or cytosine deaminase (cd), which renders cells capable of metabolizing 5-fluorocytosine (5-FC) to the chemotherapeutic agent 5-fluorouracil (5-FU). Using these types of transgenes may also confer a bystander effect.
Other desirable transgenes that may be introduced via an adenovirus vector(s) include genes encoding cytotoxic proteins, such as the A chains of diphtheria toxin, ricin or abrin (Palmiter et al. (1987)
Host Cells
The present invention also provides host cells comprising (i.e., transformed with) the adenoviral vectors described herein. Both prokaryotic and eukaryotic host cells can be used as long as sequences requisite for maintenance in that host, such as appropriate replication origin(s), are present. For convenience, selectable markers are also provided. Host systems are known in the art and need not be described in detail herein. Prokaryotic host cells include bacterial cells, for example,
Compositions and Kits
The present invention also includes compositions, including pharmaceutical compositions, containing the adenoviral vectors described herein. Such compositions are useful for administration in vivo, for example, when measuring the degree of transduction and/or effectiveness of cell killing in an individual. Compositions can comprise an adenoviral vector(s) of the invention and a suitable solvent, such as a physiologically acceptable buffer. These are well known in the art. In other embodiments, these compositions further comprise a pharmaceutically acceptable excipient. These compositions, which can comprise an effective amount of an adenoviral vector of this invention in a pharmaceutically acceptable excipient, are suitable for systemic or local administration to individuals in unit dosage forms, sterile parenteral solutions or suspensions, sterile non-parenteral solutions or oral solutions or suspensions, oil in water or water in oil emulsions and the like. Formulations for parenteral and nonparenteral drug delivery are known in the art and are set forth in
The present invention also encompasses kits containing an adenoviral vector(s) of this invention. These kits can be used for diagnostic and/or monitoring purposes, preferably monitoring. Procedures using these kits can be performed by clinical laboratories, experimental laboratories, medical practitioners, or private individuals. Kits embodied by this invention allow someone to detect the presence of bladder cancer cells in a suitable biological sample, such as biopsy specimens.
The kits of the invention comprise an adenoviral vector described herein in suitable packaging. The kit may optionally provide additional components that are useful in the procedure, including, but not limited to, buffers, developing reagents, labels, reacting surfaces, means for detection, control samples, instructions, and interpretive information.
Preparation of the Adenovirus Vectors of the Invention
The adenovirus vectors of this invention can be prepared using recombinant techniques that are standard in the art. Generally, a target cell-specific TRE is inserted 5′ to the adenoviral gene of interest, preferably an adenoviral replication gene, more preferably one or more early replication genes (although late gene(s) can be used). A target cell-specific TRE can be prepared using oligonucleotide synthesis (if the sequence is known) or recombinant methods (such as PCR and/or restriction enzymes). Convenient restriction sites, either in the natural adeno-DNA sequence or introduced by methods such as PCR or site-directed mutagenesis, provide an insertion site for a target cell-specific TRE. Accordingly, convenient restriction sites for annealing (i.e., inserting) a target cell-specific TRE can be engineered onto the 5′ and 3′ ends of a UP-TRE using standard recombinant methods, such as PCR.
Polynucleotides used for making adenoviral vectors of this invention may be obtained using standard methods in the art, such as chemical synthesis, recombinant methods and/or obtained from biological sources.
Adenoviral vectors containing all replication-essential elements, with the desired elements (e.g., E1A) under control of a target cell-specific TRE, are conveniently prepared by hom*ologous recombination or in vitro ligation of two plasmids, one providing the left-hand portion of adenovirus and the other plasmid providing the right-hand region, one or more of which contains at least one adenovirus gene under control of a target cell-specific TRE. If hom*ologous recombination is used, the two plasmids should share at least about 500 bp of sequence overlap. Each plasmid, as desired, may be independently manipulated, followed by cotransfection in a competent host, providing complementing genes as appropriate, or the appropriate transcription factors for initiation of transcription from a target cell-specific TRE for propagation of the adenovirus. Plasmids are generally introduced into a suitable host cell such as 293 cells using appropriate means of transduction, such as cationic liposomes. Alternatively, in vitro ligation of the right and left-hand portions of the adenovirus genome can also be used to construct recombinant adenovirus derivative containing all the replication-essential portions of adenovirus genome. Berkner et al. (1983)
For convenience, plasmids are available that provide the necessary portions of adenovirus. Plasmid pXC.1 (McKinnon (1982)
For manipulation of the early genes, the transcription start site of Ad5 E1A is at 498 and the ATG start site of the E1A coding segment is at 560 in the virus genome. This region can be used for insertion of a target cell-specific TRE. A restriction site may be introduced by employing polymerase chain reaction (PCR), where the primer that is employed may be limited to the Ad5 genome, or may involve a portion of the plasmid carrying the Ad5 genomic DNA. For example, where pBR322 is used, the primers may use the EcoRI site in the pBR322 backbone and the XbaI site at nt 1339 of Ad5. By carrying out the PCR in two steps, where overlapping primers at the center of the region introduce a nucleotide sequence change resulting in a unique restriction site, one can provide for insertion of target cell-specific TRE at that site.
A similar strategy may also be used for insertion of a target cell-specific TRE element to regulate E1B. The E1B promoter of Ad5 consists of a single high-affinity recognition site for Sp1 and a TATA box. This region extends from Ad5 nt 1636 to 1701. By insertion of a target cell-specific TRE in this region, one can provide for cell-specific transcription of the E1B gene. By employing the left-hand region modified with the cell-specific response element regulating E1A, as the template for introducing a target cell-specific TRE to regulate E1B, the resulting adenovirus vector will be dependent upon the cell-specific transcription factors for expression of both E1A and E1B. In additional embodiments, the 19-kDa region of E1B is deleted.
Similarly, a target cell-specific TRE can be inserted upstream of the E2 gene to make its expression cell-specific. The E2 early promoter, mapping in Ad5 from 27050-27150, consists of a major and a minor transcription initiation site, the latter accounting for about 5% of the E2 transcripts, two non-canonical TATA boxes, two E2F transcription factor binding sites and an ATF transcription factor binding site (for a detailed review of the E2 promoter architecture see Swaminathan et al.,
The E2 late promoter overlaps with the coding sequences of a gene encoded by the counterstrand and is therefore not amenable for genetic manipulation. However, the E2 early promoter overlaps only for a few base pairs with sequences coding for a 33 kD protein on the counterstrand. Notably, the SpeI restriction site (Ad5 position 27082) is part of the stop codon for the above mentioned 33 kD protein and conveniently separates the major E2 early transcription initiation site and TATA-binding protein site from the upstream transcription factor binding sites E2F and ATF. Therefore, insertion of a target cell-specific TRE having SpeI ends into the SpeI site in the 1-strand would disrupt the endogenous E2 early promoter of Ad5 and should allow target cell-restricted expression of E2 transcripts.
For E4, one must use the right hand portion of the adenovirus genome. The E4 transcription start site is predominantly at about nt 35605, the TATA box at about nt 35631 and the first AUG/CUG of ORF I is at about nt 35532. Virtanen et al. (1984)
Adenoviral constructs containing an E3 region can be generated wherein hom*ologous recombination between an E3-containing adenoviral plasmid, for example, BHGE3 (Microbix Biosystems Inc., Toronto) and a non-E3-containing adenoviral plasmid, is carried out.
Alternatively, an adenoviral vector comprising an E3 region can be introduced into cells, for example 293 cells, along with an adenoviral construct or an adenoviral plasmid construct, where they can undergo hom*ologous recombination to yield adenovirus containing an E3 region. In this case, the E3-containing adenoviral vector and the adenoviral construct or plasmid construct contain complementary regions of adenovirus, for example, one contains the left-hand and the other contains the right-hand region, with sufficient sequence overlap as to allow hom*ologous recombination.
Alternatively, an E3-containing adenoviral vector of the invention can be constructed using other conventional methods including standard recombinant methods (e.g., using restriction nucleases and/or PCR), chemical synthesis, or a combination of any of these. Further, deletions of portions of the E3 region can be created using standard techniques of molecular biology.
Insertion of an IRES into a vector is accomplished by methods and techniques that are known in the art and described herein supra, including but not limited to, restriction enzyme digestion, ligation, and PCR. A DNA copy of an IRES can be obtained by chemical synthesis, or by making a cDNA copy of, for example, a picornavirus IRES. See, for example, Duke et al. (1995)
Methods of packaging polynucleotides into adenovirus particles are known in the art and are also described in co-owned PCT PCT/US98/04080.
Delivery of Adenovirus Vectors
The adenoviral vectors can be used in a variety of forms, including, but not limited to, naked polynucleotide (usually DNA) constructs. Adenoviral vectors can, alternatively, comprise polynucleotide constructs that are complexed with agents to facilitate entry into cells, such as cationic liposomes or other cationic compounds such as polylysine; packaged into infectious adenovirus particles (which may render the adenoviral vector(s) more immunogenic); packaged into other particulate viral forms such as HSV or AAV; complexed with agents (such as PEG) to enhance or dampen an immune response; complexed with agents that facilitate in vivo transfection, such as DOTMA™, DOTAP™, and polyamines.
If an adenoviral vector comprising an adenovirus polynucleotide is packaged into a whole adenovirus (including the capsid), the adenovirus itself may also be selected to further enhance targeting. For example, adenovirus fibers mediate primary contact with cellular receptor(s) aiding in tropism. See, e.g., Amberg et al. (1997)
The adenoviral vectors may be delivered to the target cell in a variety of ways, including, but not limited to, liposomes, general transfection methods that are well known in the art, such as calcium phosphate precipitation, electroporation, direct injection, and intravenous infusion. The means of delivery will depend in large part on the particular adenoviral vector (including its form) as well as the type and location of the target cells (i.e., whether the cells are in vitro or in vivo).
If used in packaged adenoviruses, adenovirus vectors may be administered in an appropriate physiologically acceptable carrier at a dose of about 10
Methods Using the Adenovirus Vectors of the Invention
The subject vectors can be used for a wide variety of purposes, which will vary with the desired or intended result. Accordingly, the present invention includes methods using the adenoviral vectors described above.
In one embodiment, methods are provided for conferring selective cytotoxicity in cells that allow a target cell-specific TRE to function, preferably target cells, comprising contacting such cells with an adenovirus vector described herein. Cytotoxicity can be measured using standard assays in the art, such as dye exclusion,
In another embodiment, methods are provided for propagating an adenovirus specific for cells which allow a target cell-specific TRE to function, preferably target cells, preferably cancer cells. These methods entail combining an adenovirus vector with the cells, whereby said adenovirus is propagated.
Another embodiment provides methods for killing cells that allow a target cell-specific TRE to function in a mixture of cells, comprising combining the mixture of cells with an adenovirus vector of the present invention. The mixture of cells is generally a mixture of normal cells and cancerous cells that allow a target cell-specific TRE to function, and can be an in vivo mixture or in vitro mixture.
The invention also includes methods for detecting cells which allow a target cell-specific TRE to function, such as cancer cells, in a biological sample. These methods are particularly useful for monitoring the clinical and/or physiological condition of an individual (i.e., mammal), whether in an experimental or clinical setting. In one method, cells of a biological sample are contacted with an adenovirus vector, and replication of the adenoviral vector is detected. Alternatively, the sample can be contacted with an adenovirus in which a reporter gene is under control of a target cell-specific TRE. When such an adenovirus is introduced into a biological sample, expression of the reporter gene indicates the presence of cells that allow a target cell-specific TRE to function. Alternatively, an adenovirus can be constructed in which a gene conditionally required for cell survival is placed under control of a target cell-specific TRE. This gene may encode, for example, antibiotic resistance. Later the biological sample is treated with an antibiotic. The presence of surviving cells expressing antibiotic resistance indicates the presence of cells capable of target cell-specific TRE function. A suitable biological sample is one in which cells that allow a target cell-specific TRE to function, such as cancer cells, may be or are suspected to be present. Generally, in mammals, a suitable clinical sample is one in which cancerous cells that allow a target cell-specific TRE to function, such as carcinoma cells, are suspected to be present. Such cells can be obtained, for example, by needle biopsy or other surgical procedure. Cells to be contacted may be treated to promote assay conditions, such as selective enrichment, and/or solubilization. In these methods, cells that allow a target cell-specific TRE to function can be detected using in vitro assays that detect adenoviral proliferation, which are standard in the art. Examples of such standard assays include, but are not limited to, burst assays (which measure virus yield) and plaque assays (which measure infectious particles per cell). Propagation can also be detected by measuring specific adenoviral DNA replication, which are also standard assays.
The invention also provides methods of modifying the genotype of a target cell, comprising contacting the target cell with an adenovirus vector described herein, wherein the adenoviral vector enters the cell.
The invention further provides methods of suppressing tumor cell growth, preferably a tumor cell that allows a target cell-specific TRE to function, comprising contacting a tumor cell with an adenoviral vector of the invention such that the adenoviral vector enters the tumor cell and exhibits selective cytotoxicity for the tumor cell. For these methods, the adenoviral vector may or may not be used in conjunction with other treatment modalities for tumor suppression, such as chemotherapeutic agents (such as those listed below), radiation and/or antibodies.
The invention also provides methods of lowering the levels of a tumor cell marker in an individual, comprising administering to the individual an adenoviral vector of the present invention, wherein the adenoviral vector is selectively cytotoxic toward cells that allow a target cell-specific TRE to function. Tumor cell markers include, but are not limited to, CK-20. Methods of measuring the levels of a tumor cell marker are known to those of ordinary skill in the art and include, but are not limited to, immunological assays, such as enzyme-linked immunosorbent assay (ELISA), using antibodies specific for the tumor cell marker. In general, a biological sample is obtained from the individual to be tested, and a suitable assay, such as an ELISA, is performed on the biological sample. For these methods, the adenoviral vector may or may not be used in conjunction with other treatment modalities for tumor suppression, such as chemotherapeutic agents (such as those listed below), radiation and/or antibodies.
The invention also provides methods of treatment, in which an effective amount of an adenoviral vector(s) described herein is administered to an individual. Treatment using an adenoviral vector(s) is indicated in individuals with cancer as described above. Also indicated are individuals who are considered to be at risk for developing cancer (including single cells), such as those who have had disease which has been resected and those who have had a family history of cancer. Determination of suitability of administering adenoviral vector(s) of the invention will depend, inter alia, on assessable clinical parameters such as serological indications and histological examination of tissue biopsies. Generally, a pharmaceutical composition comprising an adenoviral vector(s) in a pharmaceutically acceptable excipient is administered. Pharmaceutical compositions are described above. For these methods, the adenoviral vector may or may not be used in conjunction with other treatment modalities for tumor suppression, such as chemotherapeutic agents (such as those listed below), radiation and/or antibodies.
The amount of adenoviral vector(s) to be administered will depend on several factors, such as route of administration, the condition of the individual, the degree of aggressiveness of the disease, the particular target cell-specific TRE employed, and the particular vector construct (i.e., which adenovirus gene(s) is under target cell-specific TRE control) as well as whether the adenoviral vector is used in conjunction with other treatment modalities.
If administered as a packaged adenovirus, from about 10
The adenoviral vectors of the invention can be used alone or in conjunction with other active agents, such as chemotherapeutics, that promote the desired objective. Examples of chemotherapeutics which are suitable for suppressing bladder tumor growth are BGC (bacillus Calmett-Guerin); mitomycin-C; cisplatin; thiotepa; doxorubicin; methotrexate; pacl*taxel (TAXOL™); ifosfamide; gallium nitrate; gemcitabine; carboplatin; cyclosphasphamid; vinblastine; vincristin; fluorouracil; etoposide; bleomycin. Examples of combination therapies include (CISCA (cyclophosphamide, doxorubicin, and cisplatin); CMV (cisplatin, methotrexate, vinblastine); MVMJ (methodtrextate, vinblastine, mitoxantrone, carboplain); CAP (cyclophosphamide, doxorubicin, cisplatin); MVAC (methotrexate, vinblastine, doxorubicin, cisplatin). Radiation may also be combined with chemotherapeutic agent(s), for example, radiation with cisplatin. Administration of the chemotherapeutic agents is generally intravesical (directly into the bladder) or intravenous.
The following examples are provided to illustrate but not limit the invention.
Construction of a Replication-Competent Adenovirus Vector Comprising an AFP-TRE and an EMCV IRES
The encephalomyocarditis virus (ECMV) IRES as depicted in Table 1 was introduced between the E1A and E1B regions of a replication-competent adenovirus vector specific for cells expressing AFP as follows. Table 1 shows the 519 base pair IRES segment which was PCR amplified from Novagen's pCITE vector by primers A/B as listed in Table 4. A 98 base pair deletion in the E1A promoter region was created in PXC.1, a plasmid which contains the left-most 16 mu of Ad5. Plasmid pXC.1 (McKinnon (1982)
| TABLE 4 | |||
| Primer | Sequence | Note | |
| A. | 5′-GACGTCGACTAATTCCGGTTATTTTCCA | SEQ ID NO: 19 | For PCR EMCV IRES, GTCGAC is a Sa1I site. |
| B. | 5′-GACGTCGACATCGTGTTTTTCAAAGGAA | SEQ ID NO: 20 | For PCR EMCV IRES, GTCGAC is a Sa1I site. |
| C. | 5′-CCTGAGACGCCCGACATCACCTGTG | SEQ ID NO: 21 | Ad5 sequence to 1314 to 1338. |
| D. | 5′- | SEQ ID NO: 22 | Antisense of Ad5 sequence 1572 to 1586. GTCGAC is |
| Sa1I site. Underline region overlaps with E. | |||
| E. | 5′- | SEQ ID NO: 23 | Ad5 sequence 1714 to 1728. GTCGAC is a Sa1I site. |
| Underline region overlaps with D. | |||
| F. | 5′-CACAAACCGCTCTCCACAGATGCATG | SEQ ID NO: 24 | Antisense of Ad5 sequence 2070 to 2094. |
For generating a liver cancer-specific virus, an about 0.8 kb AFP promoter fragment as shown in Table 3 was placed into the PinA1 site of CP627 thereby yielding plasmid CP686. Full-length viral genomes were obtained by recombination between CP686 and a plasmid containing a right arm of an adenovirus genome. The right arms used in virus recombination were pBHGE3 (Microbix Biosystems Inc.), containing an intact E3 region, and pBHG11 or pBHG10 (Bett et al. (1994) containing a deletion in the E3 region.
The virus obtained by recombination of CP686 with a right arm containing an intact E3 region was named CV890. The virus obtained by recombination of CP686 with a right arm containing a deleted E3 region (pBHG 10) was named CV840. The structure of all viral genomes was confirmed by conducting PCR amplifications that were diagnostic for the corresponding specific regions.
Therefore, adenovirus vector designated CV890 comprises 0.8 kb AFP promoter, E1A, a deletion of the E1A promoter, EMCV IRES, E1B a deletion of the E1B promoter and an intact E3 region. Adenovirus vector CV840 comprises AFP promoter, E1A, a deletion of the E1A promoter, EMCV IRES, E1B, a deletion of the E1B promoter and a deleted E3 region.
| TABLE 5 | |
| Plasmid | |
| designation | Brief description |
| CP306 | An E1A promoter deleted plasmid derived from pXC.1 |
| CP624 | Overlap PCR product from CP306 to generate 100 bp deletion and introduce a Sal1 |
| site at E1A and E1B junction; E1A and E1B promoter deleted in E1A/E1B intergenic | |
| region. | |
| CP625 | EMCV IRES element ligated to PCR-blunt vector (Invitrogen pCR ® blunt vector). |
| CP627 | IRES element derived from CP625 by Sal1 digestion and ligated to CP624 Sal1 site |
| placing IRES upstream from E1B. | |
| CP628 | Probasin promoter derived from CP251 by PinA1 digestion and cloned into PinA1 site |
| on CP627. | |
| CP629 | HCMV lE promoter amplified from pCMV beta (Clontech) with PinA1 at 5′ and 3′ |
| ends ligated into CP627 PinA1 site. | |
| CP630 | A 163 bp long VEGF IRES fragment (Table 1) cloned into the Sal1 site on CP628. |
| CP686 | AFP promoter from CP219 digested with PinA1 and cloned into PinA1 site on CP627. |
Construction of a Replication-Competent Adenovirus Vector with a Probasin TRE and an EMCV IRES
The probasin promoter as shown in Table 3 was inserted at the PinAI site of plasmid CP627 (see Example 1) to generate CP628, which contains a probasin promoter upstream of E1A and an EMCV IRES between E1A and E1B. Full-length viral genomes were obtained by recombination between CP628 and a plasmid containing a right arm of an adenovirus genome. The right arms used in virus recombination were pBHGE3, containing an intact E3 region, and pBHG11 or pBHG10 containing a deletion in the E3 region. The structure of all viral genomes was confirmed by conducting PCR amplifications that were diagnostic for the corresponding specific regions.
Therefore, adenovirus designated CV 834 comprises probasin promoter, E1A, a deletion of the E1A promoter, EMCV IRES, E1B, a deletion of the E1B endogenous promoter and a deleted E3 region.
Construction of a Replication-Competent Adenovirus Vector with a hCMV-TRE and an EMCV IRES
The hCMV immediate early gene (IE) promoter from plasmid CP629, originally derived from pCMVBeta (Clonetech, Palo Alto) was inserted at the PinAI site of plasmid CP627 (see Example 1) to generate CP629, containing a CMV IE promoter upstream of E1A and an IRES between E1A and E1B. Full-length viral genomes were obtained by recombination between CP629 and a plasmid containing a right arm of an adenovirus genome. The right arms used in virus recombination were pBHGE3, containing an intact E3 region, and pBHG11 or pBHG10 containing a deletion in the E3 region. The structure of all viral genomes was confirmed by conducting PCR amplifications that were diagnostic for the corresponding specific regions.
Therefore, adenovirus vector designated CV835 comprises hCMV-IE promoter, E1A, a deletion of the E1A promoter, EMCV IRES, E1B a deletion in the E1B endogenous promoter and a deleted E3 region. CV835 lacks the hCMV enhancer and is therefore not tissue specific. By adding the hCMV IE enhancer sequence to CV835, the vector is made tissue specific.
Replication of IRES-Containing Adenovirus Vectors with Different TREs Controlling E1 Expression
The viral replication of adenovirus vectors comprising the probasin promoter (CV836 and CV834) generally considered a weak promoter, and the human cytomegalovirus immediate early gene (HCMV-IE) promoter (CV837 and CV835), generally considered a strong promoter, were characterized in the virus yield assay.
Probasin promoter containing adenovirus vectors (see PCT/US98/04132), CV836 and CV834, and HCMV-IE promoter containing adenovirus vectors, CV837 and CV835, were tested against a panel of cell lines for viral replication (indicative of lethality) and specificity. Cell lines 293 (the producer line), LNCap and HepG2 were plated at 0.5×10
The data demonstrate that the presence of an IRES element in the intergenic region between E1A and E1B does not significantly affect viral replication, as compared to control viruses lacking an IRES, such as a wild-type AD5 with a deletion in the E3 region. In CV834, the loss of tissue cytotoxicity could be caused by the weakness of the probasin promoter in the virus structure.
Comparison of Dual TRE Vectors with Single TRE/IRES-Containing Vectors
Two liver cancer-specific adenovirus vectors, CV790 and CV733 (also designated CN790 and CN733, respectively), were generated and characterized. See PCT/US98/04084. These viruses contain two AFP TREs, one upstream of E1A and one upstream of E1B. They differ in that CV790 contains an intact E3 region, while the E3 region is deleted in CV733. Replication of these two viruses was compared with that of the newly generated IRES-containing viruses, CV890 and CV840 (see Example 1).
Virus replication was compared, in different cell types, using a virus yield assay as described in Example 4. Cells were infected with each type of virus and, 72 hrs after infection, virus yield was determined by a plaque assay.
Uroplakin Adenoviral Constructs Containing an EMCV IRES
A number of E3-containing viral constructs were prepared which contained uroplakin II sequences (mouse and/or human) as well as an EMCV internal ribosome entry site (IRES). The viral constructs are summarized in Table 6. All of these vectors lacked an E1A promoter and retained the E1A enhancer.
The 519 base pair EMCV IRES segment was PCR amplified from Novagen's pCITE vector by primers A/B:
primer A: 5′-GACGTCGACTAATTCCGGTTATTTTCCA SEQ ID NO: 19
primer B 5′-GACGTCGACATCGTGTTTTTCAAAGGAA SEQ ID NO: 20 (GTCGAC is a Sail site).
The EMCV IRES element was ligated to PCR blunt vector (Invitrogen pCR® blunt vector).
CP1066
The 1.9 kb-(−1885 to +1) fragment of mouse UPII from CP620 was digested with AflIII (blunted) and HindIII and inserted into pGL3-Basic from CP620 which had been digested with XhoI (blunted) and Hindlll to generate CP1066.
CP1086
The 1.9kb mouse UPII insert was digested with PinAI and ligated with CP269 (CMV driving E1A and IRES driving E1B with the deletions of E1A/E1B endogenous promoter) which was similarly cut by PinAI.
CP1087
The 1 kb (−1128 to +1) human UPII was digested with PinAI from CP665 and inserted into CP629 which had been cut by PinAI and purified (to elute CMV).
CP 1088
The 2.2 kb (−2225 to +1) human UPII was amplified from CP657 with primer 127.2.1 (5′-AGGACCGGTCACTATAGGGCACGCGTGGT-3′ (SEO ID NO: 25)) PLUS 127.2.2 (5′-AGGACCGGTGGGATGCTGGGCTGGGAGGTGG-3′ (SEO ID NO: 26′)) and digested with PinAI and ligated with CP629 cut with PinAI.
CP627 is an Ad5 plasmid with an internal ribosome entry site (IRES) from encephelomycarditis virus (EMCV) at the junction of E1A and E1B. First, CP306 (Yu et al., 1999) was amplified with primer pairs 96.74.3/96.74.6 and 96.74.4/96.74.5.
The two PCR products were mixed and amplified with primer pairs 96.74.3 and 96.74.5. The resultant PCR product contains a 100 bp deletion in E1A-E1B intergenic region and a new SaII site at the junction. EMCV IRES fragment was amplified from pCITE-3a(+) (Novagen) using primers 96.74.1 and 96.74.2. The SaII fragment containing IRES was placed into SaII site to generate CP627 with the bicistronic E1A-IRES-E1B cassette. CP629 is a plasmid with CMV promoter amplified from pCMVbeta (Clontech) with primer 99.120.1 and 99.120.2 and cloned into PinAI site of CP627.
CP657 is a plasmid with 2.2 kb 5′ flanking region of human UP II gene in pGL3-Basic (Promega). The 2.2 kb hUPII was amplified by PCR from GenomeWalker product with primer 100.113.1 and 100.113.2 and TA-cloned into pGEM-T to generate CP655.
The 2.2 kb insert digested from SacII (blunt-ended) and KpnI was cloned into pGL3-Basic at HindIII (blunted) and KpnI to create CP657.
CP1089
The 1 kb (−965 to +1) mouse LTPII was digested by PinAI from CP263 and inserted into CN422 (PSE driving E1A and GKE driving E1B with the deletions of E1A/E1B endogenous promoter) cut by PinAI and purified and farther digested with EagI and ligated with 1 kb (−1128 to +1) human UPII cut from CP669 with EagI.
CP1129
The 1.8 kb hUPII fragment with PinAI site was amplified from CP657 with primer 127.50.1 and 127.2.2 and cloned into PinAI site of CP629.
CP1131
CP686 was constructed by replacing the CMV promoter in CP629 with an AFP fragment from CP219. A 1.4 kb DNA fragment was released from CP686 by digesting it with BssHII, filling with Klenow, then digesting with Bg1II. This DNA fragment was then cloned into a similarly cut CP686 to generate CP1199. In CP1199, most of the E1B 19-KDa region was deleted. The 1.8 kb hUPII fragment with PinAI site was amplified from CP657 by PCR with primer 127.50.1 and 127.2.2 and inserted into similarly digested CP1199 to create CP1131.
The plasmids above were all co-transfected with pBHGE3 to generate CV874 (from CP1086), CV875 (from CP1087), CV876 (from 1088) and CV877 (from CP1089), CV882 (from CP1129) and CV884 (from CP1131). CP1088, CP1129 and CP1131 were cotransfected with pBHGE3 for construction of CV876, CV892 and CV884, respectively by lipofectAMINE (Gibco/BRL) for 11-14 days. pBHGE3 was purchased from Microbix, Inc., and was described previously. The cells were lysed by three freeze-thaw cycles and plaqued on 293 cells for a week. The single plaques were picked and amplified by infection in 293 cells for 3-5 days. The viral DNAs were isolated from the lysates and the constructs were confirmed by PCR with primer 31.166.1/51.176 for CV876 and primer 127.50.1/51.176 for CV882 and CV884 at E1 region and primer 32.32.1/2 for all three viruses at E3 region.
| TABLE 6 | |||||
| Name | Vector | Ad 5 Vector | E1A TRE | E1B TRE | E3 |
| CV874 | CP1086 | pBHGE3 | 1.9 kb mUPII | IRES | intact |
| CV875 | CP1087 | pBHGE3 | 1.0 kb hUPII | IRES | intact |
| CV876 | CP1088 | pBHGE3 | 2.2 kb hUPII | IRES | intact |
| CV877 | CP1089 | pBHGE3 | 1.0 kb mUPII | 1.0 kb hUPII | intact |
| (E1B promoter | |||||
| deleted) | |||||
| CV882 | CP1129 | pBHGE3 | 1.8 kb hUPII | IRES | intact |
| CV884 | CP1131 | pBHGE3 | 1.8 kb hUPii | IRES (E1B 19- | intact |
| kDa deleted) | |||||
| Primer sequences: | |||
| 96.74.1 | GACGTCGACATCGTGTTTTTCAAAGGAA | SEQ ID NO: 20 | |
| 96.74.2 | GACGTCGACTAATTCCGGTTATTTTCCA | SEQ ID NO: 19 | |
| 96.74.3 | CCTGAGACGCCCGACATCACCTGTG | SEQ ID NO: 21 | |
| 96.74.4 | TGCTGAATGGTCGACATGGAGGCTTGGGAG | SEQ ID NO: 23 | |
| 96.74.5 | CACAACCGCTCTCCACAGATGCATG | SEQ ID NO: 24 | |
| 96.74.6 | GTCGACCATTCAGCAAACAAAGGCGTTAAC | SEQ ID NO: 22 | |
| 100.113.1 | AGGGGTACCCACTATAGGGCACGCGTGGT | SEQ ID NO: 27 | |
| 100.113.2 | ACCCAAGCTTGGGATGCTGGGCTGGGAGGTGG | SEQ ID NO: 28 | |
| 127.2.2 | AGGACCGGTGGGATGCTGGGCTGGGAGGTGG | SEQ ID NO: 26 | |
| 127.50.1 | AGGACCGGTCAGGCTTCACCCCAGACCCAC | SEQ ID NO: 29 | |
| 31.166.1 | TGCGCCGGTGTACACAGGAAGTGA | SEQ ID NO: 30 | |
| 32.32.1 | GAGTTTGTGCCATCGGTCTAC | SEQ ID NO: 31 | |
| 32.32.2 | AATCAATCCTTAGTCCTCCTG | SEQ ID NO: 32 | |
| 51.176 | GCAGAAAAATCTTCCAAACACTCCC | SEQ ID NO: 33 | |
| 99.120.1 | ACGTACACCGGTCGTTACATAACTTAC | SEQ ID NO: 34 | |
| 99.120.2 | CTAGCAACCGGTCGGTTCACTAAACG | SEQ ID NO: 35 | |
Construction of a Replication-Competent Adenovirus Vector with a Tyrosinase TRE and EMCV IRES
CP621 is a plasmid containing a human tyrosinase enhancer and promoter elements in a PinA1 fragment. This fragment is ligated to the PinA1 site on CP627 to generate CP1078. CP1078 is combined with pBHGE3 to generate a new melanoma specific virus, CV859. Table 3 depicts the polynucleotide sequence of the PinA1 fragment which contains a tyrosinase promoter and enhancer.
Construction of a Replication-Competent Adenovirus Vector with a Probasin-TRE and a VEGF IRES
Using a strategy similar to that described in Example 1, the IRES fragment from the mouse vascular endothelial growth factor (VEGF) gene is amplified and cloned into CP628 at the SalI site. Table 1 depicts the IRES fragment obtainable from vascular endothelial growth factor (VEGF) mRNA. In order to clone this fragment into the E1a/E1b intergenic region, two pieces of long oligonucleotide are synthesized. The sense oligonucleotide is shown in the Table, whereas the second piece is the corresponding antisense one. After annealing the two together to create a duplex, the duplex is subjected to SalI digestion and the resulting fragment is cloned into the SalI site on CP628. The resulting plasmid, CP630, has a probasin promoter in front of E1a and an VEGF IRES element in front of E1b. This plasmid is used to construct a prostate cancer-specific virus comprising the VEGF IRES element.
Construction of a Replication-Competent Adenovirus Vector with an AFP-TRE and a VEGF IRES
Using a strategy similar to Example 1, a PinAI fragment which contains AFP TRE can be obtained. This AFP TRE is cloned into the PinA1 site in front of E1A on CP628 yielding plasmid CP1077. This plasmid has the AFP TRE for E1 transcriptional control and the VEGF IRES element before E1b. CP1077 can be recombined with pBHGE3 to generate a liver-specific adenovirus, designated as CV858.
Construction of a Replication-Competent Adenovirus Vector with a hKLK2-TRE and a EMCV IRES
Using a strategy similar to Example 1, the TRE fragment from human glandular kallikrein II as shown in Table 3 was cloned into the PinAI site in CP627. The resultant plasmid, CP1079, is cotransfected with pBHGE3 to create CV860.
Treatment of Hep3B Tumor Xenografts with Replication-Competent Hepatoma Specific CV790 and Doxorubicin and Hepatoma Specific CV890 and Doxorubicin
CV790 is an AFP producing hepatocellular carcinoma specific adenovirus, with E1A and E1B under the control of an identical AFP promoter and enhancer (822 base pair promoter shown in Table 3) with an E3 region. The CV890 adenovirus construct is also a hepatoma or liver-specific adenoviral mutant with the E1A and E1B genes under transcriptional control of 822 bp AFP promoter (827 bp including nucleotides for restriction site), wherein E1B is under translational control of EMCV IRES and having an intact E3 region. The structure of CV890 therefore reads as AFP/E1A, IRES/E1B, E2, E3, E4. In vivo studies of the efficacy of combinations of CV790 and doxorubicin and CV890 and doxorubicin were performed according to the protocols described in detail in Example 4, with minor alterations which are described below.
Xenografts in the study of CV790 and CV890 combined with chemotherapeutic agents utilized liver carcinoma Hep3B cells. Virus, CV790 or CV890, was administered by a single intravenous injection of 1×10
Furthermore, both CV790/doxorubicin and CV890/doxorubicin treatment of the hepatoma showed synergistic results. Four days after treatment with either CV790/doxorubicin or CV890/doxorubicin the relative tumor volume was less than 10%. Unlike mice treated with either virus alone or doxorubicin alone, after day 4, the relative tumor volume did not increase for either the either CV790/doxorubicin or CV890/doxorubicin treated mice. At day 6 in the control mice, the relative tumor volume was approximately 1000% in the CV790 study and approximately 600% in the CV890 study. The relative tumor volumes of mice treated with virus alone were 250% (CV790) and 520% (CV890) while the relative tumor volumes for mice treated with doxorubicin alone were 450% with 280% in the CV790 study and 500% in the CV890 study.
In Vitro Characterization of Melanocyte-Specific TRE-Containing Adenoviral Constructs
An especially useful objective in the development of melanocyte cell-specific adenoviral vectors is to treat patients with melanoma. Methods are described below for measuring the activity of a melanocyte-specific TRE and thus for determining whether a given cell allows a melanocyte-specific TRE to function.
Cells and Culture Methods
Host cells such as, HepG2 (liver); Lovo (colon); LNCaP (prostate); PMEL (melanoma); SKMel (melanoma); G361 (melanoma) and MeWo cells are obtained at passage 9 from the American Type Culture Collection (Rockville, Md.). MeWo cells are maintained in RPMI 1640 medium (RPMI) supplemented with 10% fetal bovine serum (FBS; Intergen Corp.), 100 units/mL of penicillin, and 100 units/mL streptomycin. MeWo cells being assayed for luciferase expression are maintained in 10% strip-serum (charcoal/dextran treated fetal bovine serum to remove T3, T4, and steroids; Gemini Bioproduct, Inc., Calabasas, Calif.) RPMI.
Transfections of MeWo Cells
For transfections, MeWo cells are plated out at a cell density of 5×10
Plague Assays
To determine whether the adenoviral constructs described above replicate preferentially in melanocytes, plaque assays are performed. Plaquing efficiency is evaluated in the following cell types: melanoma cells (MeWo), prostate tumor cell lines (LNCaP), breast normal cell line (HBL-100), ovarian tumor cell line (OVCAR-3, SK-OV-3), and human embryonic kidney cells (293). 293 cells serve as a positive control for plaquing efficiency, since this cell line expresses Ad5 E1A and E1B proteins. For analyzing constructs comprising a melanocyte-specific TRE, cells that allow a melanocyte-specific TRE to function, such as the cell lines provided above and cells that do not allow such function, such as HuH7, HeLa, PA-1, or G361, are used. The plaque assay is performed as follows: Confluent cell monolayers are seeded in 6-well dishes eighteen hours before infection. The monolayers are infected with 10-fold serial dilutions of each virus. After infecting monolayers for four hours in serum-free media (MEM), the medium is removed and replaced with a solution of 0.75% low melting point agarose and tissue culture media. Plaques are scored two weeks after infection.
Construction of a Replication-competent Adenovirus Vector With a CEA-TRE and a EMCV IRES
Using a strategy similar to Example 1, the TRE fragment from Carcinembryonic antigen (CEA)(Table 3, SEQ ID NO: 14) is used to construct virus designated CV873. A PinAI fragment containing the CEA-TRE was cloned into the PinAI site in front of E1A CP627 for the transcriptional control. The resultant plasmid CP1080 is used together with pBHGE3 to generate CV873.
In Vitro and In Vivo Assays of Anti-Tumor Activity An especially useful objective in the development of urothelial cell-specific adenoviral vectors is to treat patients with bladder cancer. An initial indicator of the feasibility is to test the vector(s) for cytotoxic activity against cell lines and tumor xenografts grown subcutaneously in Balb/c nu/nu mice.
In Vitro Characterization of CV876
Virus Yield Assay for CV876
5×10
Unlike wt. Ad5, CV802 which grows well in all of the cells tested, CV876 replicates much better in permissive cells (293, RT-4 and SW780) than in non-permissive cells (PA-1, G361, MKN1, HBL-100 and primary cells) by about 100-10000 fold. Noticeably, the replication in SW780 for CV876 is about 100 fold less than CV802, which indicates the limitation of this virus in efficacy.
Growth Curve Experiment for CV876
5×10
Very similar as in virus yield assay, CV876 replicates well only in RT-4 but not in primary cells and PA-1 over a 120 h period of time. However, CV876 does show a delay of replication in RT-4 compared to CV802.
Cytopathic Effect Assay for CV876
5×10
CV802 shows efficacy in all the cells tested while CV876 only kills the permissive cells (293, RT-4 and SW780) but not the non-permissive cells (PA-1, MKN-1 and LNCap).
MTT Assay for CV876
2×10
Similar as the results in CPE assay, CV876 shows efficacy only in permissive cells but not in non-permissive cells. Again, in RT-4 and SW780, CV876 kills the cells much slower than CV802.
In Vitro Characterization of CV882
Virus Yield Assay for CV882
5×10
The replication of CV882 in permissive cells (293, RT-4 and SW780) is comparable to CV802 (the difference is less than 100 fold) while it shows over 1000-1000000 fold difference in non-permissive cells (G361, LNCap, HBL-100, MKN1, PA-1 and primary cells).
Growth Curve Experiment for CV882
5×10
Very similar as in virus yield assay, CV882 replicates well only in RT-4 but not in primary cells and PA-1 over a 120 h period of time. Additionally, CV882 shows better replication in RT-4 compared to CV876.
Cytopathic Effect Assay for CV882
5×10
CV802 shows efficacy in all the cells tested while CV882 only kills the permissive cells (293, RT-4 and SW780) but not the non-permissive cells (HBL-100, G361, PA-1 and Fibroblast cells).
MTT Assay for CV882
2×10
Similar as the results in CPE assay, CV882 shows efficacy only in permissive cells but not in non-permissive cells.
In Vitro Characterization of CV884
Virus Yield Assay for CV884
5×10
The replication of CV884 is very similar as CV802 in permissive cells (293, RT-4 and SW780) but shows over 1000 fold difference with CV802 in non-permissive cells (G361, LNCap, HBL-100, MKN1, PA-1 and primary cells). CV884 shows better efficacy than CV876 and CV882 without losing much specificity.
Growth Curve Experiment for CV884
5×10
Very similar as in virus yield assay, CV884 replicates very well only in RT-4 (similar as CV802) but not in primary cells and PA-1. Again, the replication of CV884 is better than CV882 and CV876.
Cytopathic Effect Assay for CV884
5×10
CV802 shows efficacy in all the cells tested while CV884 only kills the permissive cells (293, RT-4 and SW780) but not the non-permissive cells (G361, PA-I and Fibroblast cells).
MTT Assay for CV884
2×10
Similar as the results in CPE assay, CV884 shows strong efficacy (similar as wt. Ad5) only in permissive cells but not in non-permissive cells.
In Vivo Activity of CV808
Mice were given subcutaneous (SC) injections of 1×10
While it is highly possible that a therapeutic based on the viruses described here would be given intralesionally (i.e., direct injection), it would also be desirable to determine if intravenous (IV) administration of adenovirus vector can affect tumor growth. If so, then it is conceivable that the virus could be used to treat metastatic tumor deposits inaccessible to direct injection. For this experiment, groups of mice bearing bladder epithelial tumors are inoculated with 10
Synergistic Effect of CV 890 with Chemotherapeutics
Materials and Methods
Cells. Hepatocellular carcinoma cell lines HepG2, Hep3B, PLC/PRF/5, SNU449, and Sk-Hep-1, Chang liver cell (human normal liver cells), as well as other tumor cell lines PA-1 (ovarian carcinoma), UM-UC-3 (bladder carcinoma), SW 780 (bladder carcinoma), HBL100 (breast epithelia), Colo 201 (Colon adenocarcinoma), U 118 MG (glioblastoma) and LNCaP (prostate carcinoma) were obtained from the American Type Culture Collection. HuH-7 (liver carcinoma) was a generous gift of Dr. Patricia Marion (Stanford University). 293 cells (human embryonic kidney containing the E1 region of Adenovirus) were purchased from Microbix, Inc. (Toronto, Canada). The primary cells nBdSMC (normal human bladder smooth muscle cells), nHLFC (normal human lung fibroblast cells), and nHMEC (normal human mammary epithelial cells) were purchased from Clonetics (San Diego, Calif.). All tumor cell lines were maintained in RPMI 1640 (Bio Whittaker, Inc.) supplemented with 10% fetal bovine serum (Irvine Scientific), 100 U/ml penicillin and 100 ug/ml streptomycin. Primary cells were maintained in accordance with vendor instructions (Clonetics, San Diego). Cells were tested for the expression of AFP by immunoassay (Genzyme Diagnostics, San Carlos, Calif.).
Virus yield and one-step growth curves. Six well dishes (Falcon) were seeded with 5×10
The one-step growth curves time points were harvested at various time points after infection. Two independent infections of each virus cell-combination were titered in duplicate on 293 cells (Yu et al., 1999,
Northern blot analysis. Hep3B or HBL100 cells were infected at an MOI of 20 PFU/cell (plaque forming unit per cell) with either CV802 or CV890 and harvested 24 hours post infection. Total cell RNA was purified using the RNeasy protocol (Qiagen). The Northern blot was conducted using NorthernMax Plus reagents (Ambion, Austin, Tex.). 5 ug of RNA was fractionated on a 1% agarose, formaldehyde-based denaturing gel and transferred to a BrightStar-Plus (Ambion) positively charged membrane by capillary transfer. The antisense RNA probes for E1A (adenovirus genome 501 bp to 1141 bp) or E1B (1540 bp-3910 bp) were PCR products cloned in pGEM-T easy (Promega) and transcription labeled with [α
Western blot analysis. Hep3B or HBL100 cells were infected at MOI of 20 PFU/cell with either CV802 or CV890 and harvested 24 hours post infection. Cells were washed with cold PBS and lysed for 30 min on ice in (50 mM Tris, pH8.0, 150 mM NaCl, 1% IGEPAL CA360 a NP40 equivalent (Sigma), 0.5% sodium deoxycholate, and protease inhibitor co*cktail from (Roche, Palo Alto, Calif.). After 30 min centrifugation at 4C, the supernatant was harvested and the protein concentration determined with protein assay ESL kit (Roche). Fifty micrograms of protein per lane were separated on 816% SDS-PAGE and electroblotted onto Hybond ECL membrane (Amersham Pharmacia, Piscataway, N.J.). The membrane was blocked overnight in PBST (PBS with 0.1% Tween-20) supplemented with 5% nonfat dry milk. Primary antibody incubation was done at room temperature for 2-3 hrs with PBST/1% milk diluted antibody, followed by wash and 1 hr incubation with diluted horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology Inc., Santa Cruz, Calif.). Enhanced chemiluminescence (ECL; Amersham Pharmacia) was used for the detection. E1A antibody (clone M58) was from NeoMarkers (Fremont, Calif.), E1B-21 kD antibody was from Oncogene (Cambridge, Mass.). All antibodies were used according manufacturer's instruction.
Cell viability assay and statistical analysis. To determine the cell killing effect of virus and chemotherapeutic agent in combination treatment, a cell viability assay was conducted as previously described with modifications (Denizot, 1986, Journal Immunology. Methods, 89:271-277). On 96 well plates, cells of interest were seeded at 10,000 calls per well 48 hr prior to infection. Cells were then treated with virus alone, drug alone, or in combination. Cell viability was measured at different time points by removing the media, adding 50 μl of 1 mg/ml solution of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
For statistical analysis, CurveExpert (shareware by Daniel Hyams, version 1.34) was used to plot the dose-response curves for virus and drugs. Based upon the dose-response curves, the isobolograms were made according to the original theory of Steel and Peckham (1993,
Animal studies. Six to eight week old athymic BALB/C nu/nu mice were obtained from Simonson Laboratories (Gilroy, Calif.) and acclimated to laboratory conditions one week prior to tumor implantation. Xenografts were established by injecting 1×10
Transcription and Translation of E1A/E1B Bicistronic Cassette of CV890 in Different Cells.
In wild type adenovirus infection, E1A and E1B genes produce a family of alternatively spliced products. It has been found that there are five E1A mRNAs, among them 12S (880 nucleotides, nts) and 13S (1018 nts) mRNAs are the dominant ones that are expressed both early and late after infection. The 12S and 13S mRNAs encode the gene product of 243 amino acids (243R) and 289 amino acids (289R) respectively (reviewed by Shenk, 1996). The two major E1B transcripts that code for 19 kD and 55 kD proteins are 12S (1031 nts) and 22S (2287 nts) mRNAs. E1B 12S mRNA only codes the 19 kD product, whereas the 22S mRNA codes for both 19 kD and 55 kD products due to different initiation sites during translation. In the current study, the generation of E1A-IRES-E1B bicistronic cassette was expected to change the pattern of E1A and E1B transcripts in viral infection. Therefore, Northern blot analysis was conducted to evaluate the steady-state level of E1A and E1B transcripts. First, CV802 or CV890 were infected to Hep3B (AFP) or HBL100 (AFP) cells for 24 hours. The total RNA samples were separated on agarose gels and processed for Northern blot by hybridizing to antisense RNA probes. The Northern blot with E1A probe visualized the 12S and 13S mRNAs in both wild type CV802 infected cells. For CV890, E1A transcripts can only be seen in Hep3B cells, indicating the conditional transcription of E1A. It is of interest to find that in CV890, there is only one large transcript (about 3.51 Kb), whereas the 12S and 13S mRNAs are no longer present. This large transcript indicates the continuous transcription of E1A-IRES-E1B bicistronic cassette, suggesting an alteration of viral E1A splicing pattern in CV890. Transcription of E1B from CV890 also appears to be AFP-dependent. It is clear that both 12S and 22S mRNAs of EBB were present in wild type CV802 samples, whereas the 128 mRNA and an enlarged 22S mRNA (3.5 Kb) appeared in CV890 infected cells. Obviously, the identity of this enlarged mRNA is the same 3.5 Kb transcript as visualized in E1A blot, which is from the transcription of E1A/E1B bicistronic cassette. Therefore, the E1B mRNA is tagged after E1A mRNA in this large transcript. This large transcript contains all the coding information for E1A, E1B 19 kD and E1B 55 kD. The mRNA splice pattern that appears in CV802 is not valid in CV890, the 12S mRNA with E1B probe disappeared. Meanwhile, in the E1B Northern blot, due to the selection of our E1B probe (1540 bp-3910 bp), mRNA of the Adenovirus gene IX (3580 bp-4070 bp), the hexon-associated protein, was also detected. In CV890 infected Hep3B cells, gene IX expression is equivalent to that of CV802, whereas in CV890 infected HBL100, its expression was also completely shut down. This result further demonstrated that the AFP controlled E1A/E1B expression is the key for late gene expression as well as viral replication.
Results of the same samples in the Western blot also indicate that CV890 has AFP dependent expression of E1A and E1B. Under our experimental conditions, E1A expression level of CV890 in Hep3B cells is similar to that of CV802. However, when E1B 19 kD protein was detected, it was found that the expression level was much lower than CV802 E1A. Previously, it has been addressed that IRES-mediated second gene has less expression (Mizuguchi et al., 2000,
In Vitro Replication Specificity of CV890 in Tumor Cells and Primary Cells.
From in vitro comparison of virus yield, CV890 has a better specificity profile than CV732 (CV732 is an AFP-producing, cell-specific adenovirus variant in which the E1A gene is under control of AFP-TRE). In order to gain further insights of using CV890 in liver cancer therapy, more tumor cell lines and primary cells were tested to characterize in vitro virus replication. First, all cells in the study were analyzed for their AFP status by AFP immune assay. Based on AFP produced in the cells and media, all the cells were divided into three groups, high (>2.5 μg/10
In another experiment, CV890 was compared to CV802 for their single step growth curves on different cells. Results demonstrated that CV890 has a similar growth kinetics to wild-type CV802 in AFP
In Vivo Specificity and Efficacy of CV890.
CV890 specificity was also evaluated in animals bearing prostate cancer LNCaP xenografts. In this in vivo test, nude mice with prostate xenograft were intravenously injected with either CV890 or CV787, a prostate cancer specific adenovirus variant (Yu et al., 1999,
To evaluate in vivo antitumor efficacy of CV890, different studies were carried out in the nude mouse model harboring human hepatoma xenografts. First, BALB/c nu/nu mice with HepG2 or Hep3B xenografts were established, animals were further challenged with single dose or multiple doses of CV890 into the tumor mass (intratumoral administration, IT) or via their tail vein (intravenous administration, IV). Tumor volume and the level of serum AFP were monitored weekly after the start of treatment, and hence the efficacy of the treatment was determined. The in vitro cytotoxicity study has demonstrated that CV890 has a better cytolytic effect than CV732. In order to further examine their antitumor activity, we first conducted animal study to compare CV890 to CV732. Animals harboring 300 mm
Synergistic Antitumor Efficacy of CV890 in Combination with Chemotherapeutic Agents
In this example, different chemotherapeutic agents were tested in combination with CV890 for their in vitro killing effect in Hep3B or HepG2 cells. Drug concentrations were optimized to the extent that they would not generate extensive cytotoxic effect on their own. Under such conditions, some agents had shown higher cell killing effect in combination with CV890. Among them, doxorubicin, a drug currently used in treatment of HCC showed synergistic cytotoxicity with CV890. In experiments using doxorubicin together with CV890 on Hep3B cells, doxorubicin at 10 ng/ml did not generate cytotoxicity, whereas CV890 at an MOI of 0.01 (pfu/cell) only had about 35% of cell killed at day 9. However, when both were applied together, 90% cells were killed 9 days after treatment. In order to determine the potential synergistic effect from the combination treatment, the MTT cell viability data were subjected to further statistical analysis.
Although CV890 alone has good antitumor activity, we applied combination therapy with doxorubicin for in vivo evaluation of synergy. Animals harboring 300 mm
The strong efficacy in the combination treatment shows that single IV injection of CV890 in combination of doxorubicin can eradicate aggressive Hep3B xenografts in most of the animals.
| TABLE 7 | |||
| AFP production in different tumor cells | |||
| AFP | |||
| CELLS | (ng/10 | ||
| Hep3B | 2645 | High | |
| HepG2 | 3140 | ||
| HuH7 | 4585 | ||
| SNU449 | 60 | Low | |
| PLC/PRF/5 | 600 | ||
| Chang | 0 | None | |
| SK-Hep1 | 0 | ||
| HBL100 | 0 | ||
| PA-1 | 0 | ||
| LoVo | 0 | ||
| TABLE 1 | |||
| IRES SEQUENCES | |||
| A 519 base pair TIRES obtainable from | |||
| encephelomycarditis virus (EMCV). | |||
| 1 | GAC | SEQ ID NO:1 | |
| SalI | |||
| 51 | TGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCATTCCTAGGG | ||
| 101 | GTCTTTCCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAG | ||
| 151 | GAAGCAGTTCCTCTGGAAGCTTCTTGAAGACAAACAACGTCTGTAGCGAC | ||
| 201 | CCTTTGCAGGCAGCGGAACCCCCCACCTGGCGACAGGTGCCTCTGCGGCC | ||
| 251 | AAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCCAGTGC | ||
| 301 | CACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGGCTCTCCTCAAG | ||
| 351 | CGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACCCCATTGTATGG | ||
| 401 | GATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGG | ||
| 451 | TTAAAAAACGTCTAGGCCCCCCGAACCACGGGGACGTGGTTTTCCTTTGA | ||
| SalI | |||
| 501 | AAAACACGAT | ||
| An IRES obtainable from vascular endothelial growth | |||
| factor (VEGF). | |||
| 1 | ACCTA | SEQ ID NO:2 | |
| Sal I | |||
| 51 | CGGCCCGGGCCTCGGTTCCAGAAGGGAGAGGAGCCCGCCAAGGCGCGCAA | ||
| 101 | GAGAGCGGGCTGCCTCGCAGTCCGAGCCGGAGAGGGAGCGCGAGCCGCGC | ||
| 151 | CGGCCCCGGACGGCCTCCGAAACCATG | ||
| Sal I | |||
| A 5′UTR region of HCV. | |||
| 1 | GCCAGCCCCCTGATGGGGGCGACACTCCGCCATGAATCACTCCCCTGTGAGGAACTACTG | SEQ ID NO:3 | |
| 61 | TCTTCACGCAGAAAGCGTCTAGCCATGGCGTTAGTATGAGTGTCGTGCAGCCTCCAGGAC | ||
| 121 | CCCCCCTCCCGGGAGAGCCATAGTGGTCTGCGGAACCGGTGAGTACACCGGAATTGCCAG | ||
| 181 | GACGACCGGGTCCTTTCTTGGATTAACCCGCTCAATGCCTGGAGATTTGGGCGTGCCCCC | ||
| 241 | GCAAGACTGCTAGCCGAGTAGTGTTGGGTCGCGAAAGGCCTTGTGGTACTGCCTGATAGG | ||
| 301 | GTGCTTGCGAGTGCCCCGGGAGGTCTCGTAGACCGTGCACC (341) | ||
| 5′UTR region of BiP SEQ ID NO:4 | |||
| 1 | CCCGGGGTCACTCCTGCTGGACCTACTCCGACCCCCTAGGCCGGGAGTGAAGGCGGGACT | SEQ ID NO:4A | |
| 61 | TCTGCGGTTACCAGCGGAAATGCCTCGGGGTCAGAAGTCGCAGGAGAGATAGACAGCTGC | ||
| 121 | TGAACCAATGGGACCAGCGGATGGGGCGGATGTTATCTACCATTGGTGAACGTTAGAAAC | ||
| 181 | GAATAGCAGCCAATGAATCAGCTGGGGGGGCGGAGCAGTGACGTTTATTGCGGAGGGGGC | ||
| 241 | CGCTTCGAATCGGCGGCGGCCAGCTTGGTGGCCTGGGCCAATGAACGGCCTCCAACGAGC | ||
| 301 | AGGGCCTTCACCAATCGGCGGCCTCCACGACGGGGCTGGGGGAGGGTATATAAGCCGAGT | ||
| 361 | AGGCGACGGTGAGGTCGACGCCGGCCAAGACAGCACAGACAGATTGACCTATTGGGGTGT | ||
| 421 | TTCGCGAGTGTGAGAGGGAAGCGCCGCGGCCTGTATTTCTAGACCTGCCCTTCGCCTGGT | ||
| 481 | TCGTGGCGCCTTGTGACCCCGGGCCCCTGCCGCCTGCAAGTCGAAATTGCGCTGTGCTCC | ||
| 541 | TGTGCTACGGCCTGTGGCTGGACTGCCTGCTGCTGCCCAACTGGCTGGCAAGATG (595) | ||
| A 5′UTR of PDGF SEQ ID NO:5 | |||
| 1 | GTTTGCACCTCTCCCTGCCCGGGTGCTCGAGCTGCCGTTGCAAAGCCAACTTTGGAAAAA | SEQ ID NO:5 | |
| 61 | GTTTTTTGGGGGAGACTTGGGCCTTGAGGTGCCCAGCTCCGCGCTTTCCGATTTTGGGGG | ||
| 121 | CTTTCCAGAAAATGTTGCAAAAAAGCTAAGCCGGCGGGCAGAGGAAAACGCCTGTAGCCG | ||
| 181 | GCGAGTGAAGACGAACCATCGACTGCCGTGTTCCTTTTCCTCTTGGAGGTTGGAGTCCCC | ||
| 241 | TGGGCGCCCCCACACCCCTAGACGCCTCGGCTGGTTCGCGACGCAGCCCCCCGGCCGTGG | ||
| 301 | ATGCTGCACTCGGGCTCGGGATCCGCCCAGGTAGCCGGCCTCGGACCCAGGTCCTGCGCC | ||
| 361 | CAGGTCCTCCCCTGCCCCCCAGCGACGGAGCCGGGGCCGGGGGCGGCGGCGCCGGGGGCA | ||
| 421 | TGCGGGTGAGCCGCGGCTGCAGAGGCCTGAGCGCCTGATCGCCGCGGACCTGAGCCGAGC | ||
| 481 | CCACCCCCCTCCCCAGCCCCCCACCCTGGCCGCGGGGGCGGCGCGCTCGATCTACGCGTC | ||
| 541 | CGGGGCCCCGCGGGGCCGGGCCCGGAGTCGGCATG (575) | ||
| TABLE 2 | ||
| LITERATURE REFERENCES FOR IRES | ||
| IRES Host | Example | Reference |
| Picornavirus | HAV | Glass et al., 1993. Virol 193:842-852 |
| EMCV | Jang & Wimmer, 1990. Gene Dev 4:1560-1572 | |
| Poliovirus | Borman et al., 1994. EMBO J 13:3149-3157 | |
| HCV and | HCV | Tsukiyama-Kohara et al., 1992. J Virol 66:1476-1483 |
| pestivirus | ||
| BVDV | Frolov I et al., 1998. RNA. 4:1418-1435 | |
| Leishmania | LRV-1 | Maga et al., 1995. Mol Cell Biol 15:4884-4889 |
| virus | ||
| Retroviruses | MoMLV | Torrent et al., 1996. Hum Gene Ther 7:603-612 |
| VL30 (Harvey | ||
| murine sarcoma | ||
| virus) | ||
| REV | Lopez-Lastra et al., 1997. Hum Gene Ther | |
| 8:1855-1865 | ||
| Eukaryotic | BiP | Macejak & Sarnow, 1991. Nature 353:90-94 |
| mRNA | ||
| antennapedia | Oh et al., 1992. Gene & Dev 6:1643-1653 | |
| mRNA | ||
| FGF-2 | Vagner et al., 1995. Mol Cell Biol 15:35-44 | |
| PDGF-B | Bernstein et al., 1997. J Biol Chem 272:9356- | |
| 9362 | ||
| IGFII | Teerink et al., 1995. Biochim Biophys Acta | |
| 1264:403-408 | ||
| eIF4G | Gan & Rhoads, 1996. J Biol Chem 271:623-626 | |
| VEGF | Stein et al., 1998. Mol Cell Biol 18:3112-3119; | |
| Huez et al., 1998. Mol Cell Biol 18:6178-6190 | ||
| TABLE 3 | |
| TRE SEQUENCES | |
| Nucleotide sequence of a human uroplakin II 5′flanking | |
| region. Position +1 (the translational start site) | |
| is denoted with an asterisk. SEQ ID NO:6 (number 1 of | |
| SEQ ID NO:6 corresponds to position -2239 with respect | |
| to the translational start site). | |
| TCGATAGGTA CCCACTATAG GGCACGCGTG GTCGACGGCC CGGGCTGGTC | |
| 1 50 | |
| TGGCAACTTC AAGTGTGGGC CTTTCAGACC GGCATCATCA GTGTTACGGG | |
| 51 100 | |
| GAAGTCACTA GGAATGCAGA ATTGATTGAG CACGGTGGCT CACACCTGTA | |
| 101 150 | |
| ATCCCAACAC TCTGGGAGGC CAAGGCAGGT GGATCACTTG TGGTCAGGAG | |
| 151 200 | |
| TTTGAGACCA GCCTGGCCAA CATGGTGAAA CCTCATCTCT ACTAAAAATA | |
| 201 250 | |
| CAAAAATTAG CTGGGAATGG TGGCACATGC CTATAATCCC AGTTACTCAG | |
| 251 300 | |
| GAGGCTGAGG CAGGAGAATC ATTTGAACCT GGGAGGCAGA GGTTGCAGTG | |
| 301 350 | |
| AGCCGAGATC ACGCCACTGC ACTCCAGCCT GGGTGACACA GCGAGACTCT | |
| 351 400 | |
| GTCTCAAAAA AAAAAAAATG CAGAATTTCA GGCTTCACCC CAGACCCACT | |
| 401 450 | |
| GCATGACTGC ATGAGAAGCT GCATCTTAAC AAGATCCCTG GTAATTCATA | |
| 451 500 | |
| CGCATATTAA ATTTGGAGAT GCACTGGCGT AAGACCCTCC TACTCTCTGC | |
| 501 550 | |
| TTAGGCCCAT GAGTTCTTCC TTTACTGTCA TTCTCCACTC ACCCCAAACT | |
| 551 600 | |
| TTGAGCCTAC CCTTCCCACC TTGGCGGTAA GGACACAACC TCCCTCACAT | |
| 601 650 | |
| TCCTACCAGG ACCCTAAGCT TCCCTGGGAC TGAGGAAGAT AGAATAGTTC | |
| 651 700 | |
| GTGGAGCAAA CAGATATACA GCAACAGTCT CTGTACAGCT CTCAGGCTTC | |
| 701 750 | |
| TGGAAGTTCT ACAGCCTCTC CCGACAAAGT ATTCCACTTT CCACAAGTAA | |
| 751 800 | |
| CTCTATGTGT CTGAGTCTCA GTTTCCACTT TTCTCTCTCT CTCTCTCTCT | |
| 801 850 | |
| CAACTTTCTG AGACAGAGTT TCACTTAGTC GCCCAGGCTG GAGTGCAGGG | |
| 851 900 | |
| GCACAATCTC GGCTCACTGC AACCTCCACC TCCTGGGTTC AAGTGTTTCT | |
| 901 950 | |
| CCTGTCTCAG CCTCCCGAGT AGCTGGGATT ACAGGCACAC ACCACCGCGT | |
| 951 1000 | |
| TAGTTTTTGT ATTTTTGGTA GAGATGGTGT TTCGCCATAT TGGCCAGGCT | |
| 1001 1050 | |
| GATCTCGAAC TCCTGACCTC AGGTGATCCG CCCACCTCGG CCTCCCAAAG | |
| 1051 1100 | |
| TGCTGGGATT ACAGGCATGA GCCACCACGC CCGGCTGATC TCTTTTCTAT | |
| 1101 1150 | |
| TTTAATAGAG ATCAAACTCT CTGTGTTGCC TAGGCTGGTC TTGAACTCCT | |
| 1151 1200 | |
| GGCCTCCAGT GATCCTCCCA CCTTGGCCTC CCAAAGTGTT GACATTACAG | |
| 1201 1250 | |
| GCATGAGCCA CTGTGCCTGG CCTCAGTTCT ACTACAAAAG GAAGCCAGTA | |
| 1251 1300 | |
| CCAGCTACCA CCCAGGGTGG CTGTAGGGCT ACAATGGAGC ACACAGAACC | |
| 1301 1350 | |
| CCTACCCAGG GCCCGGAAGA AGCCCCGACT CCTCTCCCCT CCCTCTGCCC | |
| 1351 1400 | |
| AGAACTCCTC CGCTTCTTTC TGATGTAGCC CAGGGCCGGA GGAGGCAGTC | |
| 1401 1450 | |
| AGGGAAGTTC TGTCTCTTTT TCATGTTATC TTACGAGGTC TCTTTTCTCC | |
| 1451 1500 | |
| ATTCTCAGTC CAACAAATGG TTGCTGCCCA AGGCTGACTG TGCCCACCCC | |
| 1501 1550 | |
| CAACCCCTGC TGGCCAGGGT CAATGTCTGT CTCTCTGGTC TCTCCACAAG | |
| 1551 1600 | |
| TCTTCCATGG CCACCTTCGT CCCCACCCTC CAGAGGAATC TGAAACCGCA | |
| 1601 1650 | |
| TGTGCTCCCT GGCCCCCACA GCCCCTGCCT CTCCCAGAGC AGCAGTACCT | |
| 1651 1700 | |
| AAGCCTCAGT GCACTCCAAG AATTGAAACC CTCAGTCTGC TGCCCCTCCC | |
| 1701 1750 | |
| CACCAGAATG TTTCTCTCCC ATTCTTACCC ACTCAAGGCC CTTTCAGTAG | |
| 1751 1800 | |
| CCCCTTGGAG TATTCTCTTC CTACATATCA GGGCAACTTC CAAACTCATC | |
| 1801 1850 | |
| ACCCTTCTGA GGGGTGGGGG AAAGACCCCC ACCACATCGG GGGAGCAGTC | |
| 1851 1900 | |
| CTCCAAGGAC TGGCCAGTCT CCAGATGCCC GTGCACACAG GAACACTGCC | |
| 1901 1950 | |
| TTATGCACGG GAGTCCCAGA AGAAGGGGTG ATTTCTTTCC CCACCTTAGT | |
| 1951 2000 | |
| TACACCATCA AGACCCAGCC AGGGCATCCC CCCTCCTGGC CTGAGGGCCA | |
| 2001 2050 | |
| GCTCCCCATC CTGAAAAACC TGTCTGCTCT CCCCACCCCT TTGAGGCTAT | |
| 2051 2100 | |
| AGGGCCCAAG GGGCAGGTTG GACTGGATTC CCCTCCAGCC CCTCCCGCCC | |
| 2101 2150 | |
| CCAGGACAAA ATCAGCCACC CCAGGGGCAG GGCCTCACTT GCCTCAGGAA | |
| 2151 2200 | |
| CCCCAGCCTG CCAGCACCTA TTCCACCTCC CAGCCCAGCA | |
| 2201 2239 | |
| Nucleotide sequence of a mouse uroplakin II 5′flanking region. The | |||
| translational start site is denoted with an asterisk. SEQ ID NO:7 (number | |||
| 1 of SEQ ID NO:7 corresponds to position -3592 with respect to the trans- | |||
| lational start site). | |||
| CTCGAGGATCTCGGCCCTCTTTCTGCATCCTTGTCCTAAATCATTTTCAT | |||
| 1 50 | |||
| ATCTTGCTAGACCTCAGTTTGAGAGAAACGAACCTTCTCATTTTCAAGTT | |||
| 51 100 | |||
| GAAAAAAAAAAGAGGTTCAAAGTGGCTCACTCAAAGTTACAAGCCAACAC | |||
| 101 150 | |||
| TCACCACTACGAGTACAATGGCCACCATTAGTGCTGGCATGCCCCAGGAG | |||
| 151 200 | |||
| ACAGGCATGCATATTATTCTAGATGACTGGGAGGCAGAGGGGTGGCCTAG | |||
| 201 250 | |||
| TGAGGTCAGACTGTGGACAGATCAGGCAGATGTGGGTTCTGATCCCAATT | |||
| 251 300 | |||
| CCTCAGGCCGCAGAACTACTGTGGTTCAAGAAGGGGACAAAAGGACTGCA | |||
| 301 350 | |||
| GTCCGGAACAGGAGGTCCATTTGAGAGCTGACTGAGCAGAAGAGGAAAGT | |||
| 351 400 | |||
| GAAGAACTTCTGGGGCAAGAGCTTACCCTACTTTACAGCTTTGTTGTCTT | |||
| 401 450 | |||
| CTTTACTCCAGGGGCGTCCCTGGTACTCAGTAAATGTCTGTTGGCTTGAG | |||
| 451 500 | |||
| GAACATATGTGTAAGGAGGAAGGAGAGGGAACTTGAGGGAGTTAAGACTC | |||
| 501 550 | |||
| AAGAATCAATCAAGGAGAGGACAGCAGAGAAGACAGGGTTTGGGAGAGAG | |||
| 551 600 | |||
| ACTCCAGACATTGGCCCTGGTTCCCTTCTTGGCCACTGTGAAACCCTCCA | |||
| 601 650 | |||
| GAGGAACTGAGTGCTGTGGCTTTAAATGATCTCAGCACTGTCAGTGAAGC | |||
| 651 700 | |||
| GCTCTGCTCAAAGAGTTATCCTCTTGCTCCTGTGCCGGGGCCTCCCCCTC | |||
| 701 750 | |||
| CTCTCAGCTCCCAAACCCTTCTCAGCCACTGTGATGGCATAATTAGATGC | |||
| 751 800 | |||
| GAGAGCTCAGACCGTCAGGTCTGCTCCAGGAACCACCCATTTTCCCCAAC | |||
| 801 850 | |||
| CCCAGAGAAAGGTCCTAGTGGAAAAGTGGGGGCCACTGAAGGGCTGATGG | |||
| 851 900 | |||
| GGTTCTGTCCTTTCCCCCATGCTGGGTGGACTTAAAGTCTGCGATGTGTG | |||
| 900 950 | |||
| TAGGGGGTAGAAGACAACAGAACCTGGGGGCTCCGGCTGGGAGCAGGAGG | |||
| 951 1000 | |||
| AACTCTCACCAGACGATCTCCAAATTTACTGTGCAATGGACGATCAGGAA | |||
| 1001 1050 | |||
| ACTGGTTCAGATGTAGCTTCTGATACAGTGGGTCTGAGGTAAAACCCGAA | |||
| 1051 1100 | |||
| ACTTAATTTCTTTCAAAAATTTAAAGTTGCATTTATTATTTTATATGTGT | |||
| 1101 1150 | |||
| GCCCATATGTGTGCCACAGTGTCTATGTGGAGGTCAGAGGGCAAGTTGTG | |||
| 1151 1200 | |||
| GGCATTGGCTCTCTCCTTTCATAATGTGGCTTCTGGGGACCAAAATGTCA | |||
| 1201 1250 | |||
| GGCATGGTGGCAAGAGCTTTTACCTGTTGAGCCATCTCATGGTTTCGTAA | |||
| 1251 1300 | |||
| AACTTCCTATGACGCTTACAGGTAACGCAGAGACACAGACTCACATTTGG | |||
| 1301 1350 | |||
| AGTTAGCAGATGCTGTATTGGTGTAAACACTCATACACAGACACACACAC | |||
| 1351 1400 | |||
| ATACTCATACACACACACACACACTTATCACATGCACACACATACTCGTA | |||
| 1401 1450 | |||
| TACACACAGACACACACACATGCACTCTCACATTCACATATTCATACACA | |||
| 1451 1500 | |||
| TCCACACACACACTCATCCACACACACAGACACACATACTCATCCACACA | |||
| 1501 1550 | |||
| CACACACACACATACTCATACACACACACAGACACACATACTCATACACA | |||
| 1551 1600 | |||
| CACACAGACACACACATATAATCATACATACACAGACACACTCATACATG | |||
| 1601 1650 | |||
| TGCACACACACACTCATCCACACACACACACTCATACACACACACACTCA | |||
| 1651 1700 | |||
| TACACACACACACTCATACACACACACACGAGGTTTTTCTCAGGCTGCCT | |||
| 1701 1750 | |||
| TTGGGTGGAGACTGGAACTGATTTCTGTTTTTCAGCTCCTTGGCTTTTTG | |||
| 1751 1800 | |||
| TCCCTTTAGATGAGATCTCCTCCTCACTTTACACACAGAAAGATCACACA | |||
| 1801 1850 | |||
| CGAGGGAGAACTGGCGGTGCGGAAGAGGGCTACACGGTAGGGTGTCAGGG | |||
| 1851 1900 | |||
| TCAGGAGATCTTCCTGGCAAGTCTCAAACCTCCACATAGCACAGTGTTTA | |||
| 1901 1950 | |||
| CGTGAGGATTTAGGAGGAATCAGGAAGAGGATTGGTTTACTGCAGAGCAG | |||
| 1951 2000 | |||
| ACCATATAGGTCCACTCCTAAGCCCCATTTGAAATTAGAAGTGAGACAGT | |||
| 2001 2050 | |||
| GTGGGATAAAAAGAGCAGATCTCTGGTCACATTTTTAAAGGGATATGAGG | |||
| 2051 3000 | |||
| GTCCTGTGCCTTTAAGCCTTCCCATCTCCCTCCAATCCCCCCTCACCTTC | |||
| 2101 2150 | |||
| CCCACCCTAACCCTCCCCAGGTTTCTGGAGGAGCAGAGTTGCGTCTTCTC | |||
| 2151 2200 | |||
| CCTGCCCTGCCGAGCTGCTCACTGGCTGCTCTAGAGGCTGTGCTTTGCGG | |||
| 2201 2250 | |||
| TCTCCATGGAAACCATTAGTTGCTAAGCAACTGGAGCATCATCTGTGCTG | |||
| 2251 2300 | |||
| AGCTCAGGTCCTATCGAGTTCACCTAGCTGAGACACCCACGCCCCTGCAG | |||
| 2301 2350 | |||
| CCACTTTGCAGTGACAAGCCTGAGTCTCAGGTTCTGCATCTATAAAAACG | |||
| 2351 2400 | |||
| AGTAGCCTTTCAGGAGGGCATGCAGAGCCCCCTGGCCAGCGTCTAGAGGA | |||
| 2401 2450 | |||
| GAGGTGACTGAGTGGGGCCATGTCACTCGTCCATGGCTGGAGAACCTCCA | |||
| 2451 2500 | |||
| TCAGTCTCCCAGTTAGCCTGGGGCAGGAGAGAACCAGAGGAGCTGTGGCT | |||
| 2501 2550 | |||
| GCTGATTGGATGATTTACGTACCCAATCTGTTGTCCCAGGCATCGAACCC | |||
| 2551 2600 | |||
| CAGAGCGACCTGCACACATGCCACCGCTGCCCCGCCCTCCACCTCCTCTG | |||
| 2601 2650 | |||
| CTCCTGGTTACAGGATTGTTTTGTCTTGAAGGGTTTTGTTGTTGCTACTT | |||
| 2651 2700 | |||
| TTTGCTTTGTTTTTTCTTTTTTAACATAAGGTTTCTCTGTGTAGCCCTAG | |||
| 2701 2750 | |||
| CTGTCCTGGAACTCACTCTGTAGACCAGGCTGGCCTCAAACTCAGAAATC | |||
| 2751 2800 | |||
| CACCTTCCTCCCAAGTGCTGGGATTAAAGGCATTCGCACCATCGCCCAGC | |||
| 2801 2850 | |||
| CCCCGGTCTTGTTTCCTAAGGTTTTCCTGCTTTACTCGCTACCCGTTGCA | |||
| 2851 2900 | |||
| CAACCGCTTGCTGTCCAAGTCTGTTTGTATCTACTCCACCGCCCACTAGC | |||
| 2901 2950 | |||
| CTTGCTGGACTGGACCTACGTTTACCTGGAAGCCTTCACTAACTTCCCTT | |||
| 2951 3000 | |||
| GTCTCCACCTTCTGGAGAAATCTGAAGGCTCACACTGATACCCTCCGCTT | |||
| 3001 3050 | |||
| CTCCCAGAGTCGCAGTTTCTTAGGCCTCAGTTAAATACCAGAATTGGATC | |||
| 3051 3100 | |||
| TCAGGCTCTGCTATCCCCACCCTACCTAACCAACCCCCTCCTCTCCCATC | |||
| 3101 3150 | |||
| CTTACTAGCCAAAGCCCTTTCAACCCTTGGGGCTTTTCCTACACCTACAC | |||
| 3151 3200 | |||
| ACCAGGGCAATTTTAGAACTCATGGCTCTCCTAGAAAACGCCTACCTCCT | |||
| 3201 3250 | |||
| TGGAGACTGACCCTCTACAGTCCAGGAGGCAGACACTCAGACAGAGGAAC | |||
| 3251 3300 | |||
| TCTGTCCTTCAGTCGCGGGAGTTCCAGAAAGAGCCATACTCCCCTGCAGA | |||
| 3301 3350 | |||
| GCTAACTAAGCTGCCAGGACCCAGCCAGAGCATCCCCCTTTAGCCGAGGG | |||
| 3351 3400 | |||
| CCAGCTCCCCAGAATGAAAAACCTGTCTGGGGCCCCTCCCTGAGGCTACA | |||
| 3401 3450 | |||
| GTCGCCAAGGGGCAAGTTGGACTGGATTCCCAGCAGCCCCTCCCACTCCG | |||
| 3451 3500 | |||
| AGACAAAATCAGCTACCCTGGGGCAGGCCTCATTGGCCCCAGGAAACCCC | |||
| 3501 3550 | |||
| AGCCTGTCAGCACCTGTTCCAGGATCCAGTCCCAGCGCAGTA | |||
| 3551 3592 | |||
| AFP-TRE | |||
| 1 | GCATTGCTGTGAACTCTGTACTTAGACTAAACTTTGAGCAATAACACACATAGATTGAG | SEQ ID NO:8 | |
| 61 | GATTGTTTGCTGTTAGCATACAAACTCTGGTTCAAAGCTCCTCTTTATTGCTTGTCTTGG | ||
| 121 | AAAATTTGCTGTTCTTCATGGTTTCTCTTTTCACTGCTATCTATTTTTCTCAACCACTCA | ||
| 181 | CATGGCTACAATAACTGTCTGCAAGCTTATGATTCCCAAATATCTATCTCTAGCCTCAAT | ||
| 241 | CTTGTTCCAGAAGATAAAAAGTAGTATTCAAATGCACATCAACGTCTCCACTTGGAGGGC | ||
| 301 | TTAAAGACGTTTCAACATACAAACCGGGGAGTTTTGCCTGGAATGTTTCCTAAAATGTGT | ||
| 361 | CCTGTAGCACATAGGGTCCTCTTGTTCCTTAAAATCTAATTACTTTTAGCCCAGTGCTCA | ||
| 421 | TCCCACCTATGGGGAGATGAGAGTGAAAAGGGAGCCTGATTAATAATTACACTAAGTCAA | ||
| 481 | TAGGCATAGAGCCAGGACTGTTTGGGTAAACTGGTCACTTTATCTTAAACTAAATATATC | ||
| 541 | CAAAACTGAACATGTACTTAGTTACTAAGTCTTTGACTTTATCTCATTCATACCACTCAG | ||
| 601 | CTTTATCCAGGCCACTTATGAGCTCTGTGTCCTTGAACATAAAATACAAATAACCGCTAT | ||
| 661 | GCTGTTAATTATTGGCAAATGTCCCATTTTCAACCTAAGGAAATACCATAAAGTAACAGA | ||
| 721 | TATACCAACAAAAGGTTACTAGTTAACAGGCATTGCCTGAAAAGAGTATAAAAGAATTTC | ||
| 781 | AGCATGATTTTCCATATTGTGCTTCCACCACTGCCAATAACA (822) | ||
| Probasin-TRE | |||
| -426 | |||
| 5′-AAGCTTCCACAAGTGCATTTAGCCTCTCCAGTATTGCTGATGAATCCACAGT | SEQ ID NO:9 | ||
| TCAGGTTCAATGGCGTTCAAAACTTGATCAAAAATGACCAGACTTTATATTTA | |||
| CACCAACATCTATCTGATTGGAGGAATGGATAATAGTCATCATGTTTAAACAT | |||
| CTACCATTCCAGTTAAGAAAATATGATAGC | |||
| ARE-1 | |||
| ATAGGGACATAAAGCCCACAAATAAAAATATGCCTGAAGAATGGGACAGGC | |||
| ATTGGGCATTGTCCATGCCTA | |||
| ARE-2 | |||
| GATGACACAATGTCAATGTCTGTGTACAACTGCCAACTGGGATGCAAGACAC | |||
| TGCCCATG | |||
| CAAT box TATAA box | |||
| +1 +28 | |||
| GCAC | |||
| Transcription site | |||
| Tyrosinase-TRE | |||
| PinA1 end | |||
| 1 | SEQ ID NO:10 | ||
| 51 | TTATGAAATGCCAACATGTGGTTACAAGTAATGCAGACCCARGGCTCCCC | ||
| 101 | AGGGACAAGAAGTCTTGTGTTAACTCTTTGTGGCTCTGAAAGAAAGAGAG | ||
| 151 | AGAGAAAAGATTAAGCCTCCTTGTGGAGATCATGTGATGACTTCCTGATT | ||
| 201 | CCAGCCAGAGCGAGCATTTCCATGGAAACTTCTCTTCCTCTTCACTCGAG | ||
| 251 | ATTACTAACCTTATTGTTAATATTCTAACCATAAGAATTAAACTATTAAT | ||
| 301 | GGTGAATAGAGTTTTTCACTTTAACATAGGCCTATCCCACTGGTGGGATA | ||
| 351 | CGAGCCAATTCGAAAGAAAAAGTCAGTCATGTGCTTTTCAGAGGATGAAA | ||
| 401 | GCTTAAGATAAAGACTAAAAGTGTTTGATGCTGGAGGTGGGAGTGGTATT | ||
| 451 | ATATAGGTCTCAGCCAAGACATGTGATAATCACTGTAGTAGTAGCTGGAA | ||
| 501 | AGAGAAATCTGTGACTCCAATTAGCCAGTTCCTGCAGACCTTGTGA | ||
| PinA1 end | |||
| Human glandular kallikrein-TRE | |||
| gaattcagaa ataggggaag gttgaggaag gacactgaac tcaaagggga tacagtgatt 60 | SEQ ID NO:11 | ||
| ggtttatttg tcttctcttc acaacattgg tgctggagga attcccaccc tgaggttatg | |||
| 120 | |||
| aagatgtctg aacacccaac acatagcact ggagatatga gctcgacaag agtttctcag | |||
| 180 | |||
| ccacagagat tcacagccta gggcaggagg acactgtacg ccaggcagaa tgacatggga | |||
| 240 | |||
| attgcgctca cgattggctt gaagaagcaa ggactgtggg aggtgggctt tgtagtaaca | |||
| 300 | |||
| agagggcagg gtgaactctg attcccatgg gggaatgtga tggtcctgtt acaaattttt | |||
| 360 | |||
| caagctggca gggaataaaa cccattacgg tgaggacctg tggagggcgg ctgccccaac | |||
| 420 | |||
| tgataaagga aatagccagg tgggggcctt tcccattgta ggggggacat atctggcat | |||
| 480 | |||
| agaagccttt gagacccttt agggtacaag tactgaggca gcaaataaaa tgaaatctta | |||
| 540 | |||
| tttttcaact ttatactgca tgggtgtgaa gatatatttg tttctgtaca gggggtgagg | |||
| 600 | |||
| gaaaggaggg gaggaggaaa gttcctgcag gtctggtttg gtcttgtgat ccagggggtc | |||
| 660 | |||
| ttggaactat ttaaattaaa ttaaattaaa acaagcgact gttttaaatt aaattaaatt | |||
| 720 | |||
| aaattaaatt ttactttatt ttatcttaag ttctgggcta catgtgcagg acgtgcagct | |||
| 780 | |||
| ttgttacata ggtaaacgtg tgccatggtg gtttgctgta cctatcaacc catcacctag | |||
| 840 | |||
| gtattaagcc cagcatgcat tagctgtttt tcctgacgct ctccctctcc ctgactccca | |||
| 900 | |||
| caacaggccc cagtgtgtgt tgttcccctc cctgtgtcca tgtgttctca ttgttcagct | |||
| 960 | |||
| cccacttata agtgagaaca tgtggtgttt ggttttctgt ttctgtgtta gtttgctgag | |||
| 1020 | |||
| gataatggct tccacctcca tccatgttcc tgcaaaggac gtgatcttat tcttttttat | |||
| 1080 | |||
| ggttgcatag aaattgtttt tacaaatcca attgatattg tatttaatta caagttaatc | |||
| 1140 | |||
| taattagcat actagaagag attacagaag atattaggta cattgaatga ggaaatatat | |||
| 1200 | |||
| aaaataggac gaaggtgaaa tattaggtag gaaaagtata atagttgaaa gaagtaaaaa | |||
| 1260 | |||
| aaaatatgca tgagtagcag aatgtaaaag aggtgaagaa cgtaatagtg actttttaga | |||
| 1320 | |||
| ccagattgaa ggacagagac agaaaaattt taaggaattg ctaaaccatg tgagtgttag | |||
| 1380 | |||
| aagtacagtc aataacatta aagcctcagg aggagaaaag aataggaaag gaggaaatat | |||
| 1440 | |||
| gtgaataaat agtagagaca tgtttgatgg attttaaaat atttgaaaga cctcacatca | |||
| 1500 | |||
| aaggattcat accgtgccat tgaagaggaa gatggaaaag ccaagaagcc agatgaaagt | |||
| 1560 | |||
| tagaaatatt attggcaaag cttaaatgtt aaaagtccta gagagaaagg atggcagaaa | |||
| 1620 | |||
| tattggcggg aaagaatgca gaacctagaa tataaattca tcccaacagt ttggtagtgt | |||
| 1680 | |||
| gcagctgtag ccttttctag ataatacact attgtcatac atcgcttaag cgagtgtaaa | |||
| 1740 | |||
| atggtctcct cactttattt atttatatat ttatttagtt ttgagatgga gcctcgctct | |||
| 1800 | |||
| gtctcctagg ctggagtgca atagtgcgat accactcact gcaacctctg cctcctctgt | |||
| 1860 | |||
| tcaagtgatt ttcttacctc agcctcccga gtagctggga ttacaggtgc gtgccaccac | |||
| 1920 | |||
| acccggctaa tttttgtatt ttttgtagag acggggtttt gccatgttgg ccaggctggt | |||
| 1980 | |||
| cttgaactcc tgacatcagg tgatccacct gccttggcct cctaaagtgc tgggattaca | |||
| 2040 | |||
| ggcatgagcc accgtgccca accactttat ttatttttta tttttatttt taaatttcag | |||
| 2100 | |||
| cttctatttg aaatacaggg ggcacatata taggattgtt acatgggtat attgaactca | |||
| 2160 | |||
| ggtagtgatc atactaccca acaggtaggt tttcaaccca ctccccctct tttcctcccc | |||
| 2220 | |||
| attctagtag tgtgcagtgt ctattgttct catgtttatg tctatgtgtg ctccaggttt | |||
| 2280 | |||
| agctcccacc tgtaagtgag aacgtgtggt atttgatttt ctgtccctgt gttaattcac | |||
| 2340 | |||
| ttaggattat ggcttccagc tccattcata ttgctgtaaa ggatatgatt catttttcat | |||
| 2400 | |||
| ggccatgcag tattccatat tgcgtataga tcacattttc tttctttttt ttttttgaga | |||
| 2460 | |||
| cggagtcttg ctttgctgcc taggctggag tgcagtagca cgatctcggc tcactgcaag | |||
| 2520 | |||
| cttcacctcc ggggttcacg tcattcttct gtctcagctt cccaagtagc tgggactaca | |||
| 2580 | |||
| ggcgcccgcc accacgtccg gctaattttt ttgtgtgttt ttagtagaga tgggggtttc | |||
| 2640 | |||
| actgtgttag ccaggatggt cttgatctcc tgaccttgtg gtccacctgc ctcggtctcc | |||
| 2700 | |||
| caaagtgctg ggattacagg ggtgagccac tgcgcccggc ccatatatac cacattttct | |||
| 2760 | |||
| ttaaccaatc caccattgat gggcaactag gtagattcca tggattccac agttttgcta | |||
| 2820 | |||
| ttgtgtgcag tgtggcagta gacatatgaa tgaatgtgtc tttttggtat aatgatttgc | |||
| 2880 | |||
| attcctttgg gtatacagtc attaatagga gtgctgggtt gaacggtggc tctgtttaaa | |||
| 2940 | |||
| attctttgag aattttccaa actgtttgcc atagagagca aactaattta catttccacg | |||
| 3000 | |||
| aacagtatat aagcattccc ttttctccac agctttgtca tcatggtttt tttttttctt | |||
| 3060 | |||
| tattttaaaa aagaatatgt tgttgttttc ccagggtaca tgtgcaggat gtgcaggttt | |||
| 3120 | |||
| gttacatagg tagtaaacgt gagccatggt ggtttgctgc acctgtcaac ccattacctg | |||
| 3180 | |||
| ggtatgaagc cctgcctgca ttagctcttt tccctaatgc tctcactact gccccaccct | |||
| 3240 | |||
| caccctgaca gggcaaacag acaacctaca gaatgggagg aaatttttgc aatctattca | |||
| 3300 | |||
| tctgacaaag gtcaagaata tccagaatct acaaggaact taagcaaatt tttacttttt | |||
| 3360 | |||
| aataatagcc actctgactg gcgtgaaatg gtatctcatt gtggttttca tttgaatttc | |||
| 3420 | |||
| tctgatgatc agtgacgatg agcatttttt catatttgtt ggctgcttgt acgtcttttg | |||
| 3480 | |||
| agaagtgtct cttcatgcct tttggccact ttaatgggat tattttttgc tttttagttt | |||
| 3540 | |||
| aagttcctta tagattctgg atattagact tcttattgga tgcatagttt gtgaatactc | |||
| 3600 | |||
| tcttccattc tgtaggttgt ctgtttactc tattgatggc ttcttttgct gtgccgaagc | |||
| 3660 | |||
| atcttagttt aattagaaac cacctgccaa tttttgtttt tgttgcaatt gcttttgggg | |||
| 3720 | |||
| acttagtcat aaactctttg ccaaggtctg ggtcaagaag agtatttcct aggttttctt | |||
| 3780 | |||
| ctagaatttt gaaagtctga atgtaaacat ttgcattttt aatgcatctt gagttagttt | |||
| 3840 | |||
| ttgtatatgt gaaaggtcta ctctcatttt ctttccctct ttctttcttt ctttcttttc | |||
| 3900 | |||
| tttctttctt tctttctttc tttctttctt tctttctttc tttctttttg tccttctttc | |||
| 3960 | |||
| tttctttctt tctctttctt tctctctttc tttttttttt ttgatggagt attgctctgt | |||
| 4020 | |||
| tgcccaggct gcagtgcagc ggcacgatct cggctcactg caacctctgc ctcctgggtt | |||
| 4080 | |||
| caactgattc tcctgcatca gccttccaag tagctgggat tataggcgcc cgccaccacg | |||
| 4140 | |||
| cccgactaat ttttgtattt ttagtagaga cggggttgtg ccatgttggc caggctggtt | |||
| 4200 | |||
| tgaaactcct gacctcaaac gatctgcctg ccttggcctc ccaaagtgct gggattacag | |||
| 4260 | |||
| gtgtgagcca ctgtgcccag ccaagaatgt cattttctaa gaggtccaag aacctcaaga | |||
| 4320 | |||
| tattttggga ccttgagaag agaggaattc atacaggtat tacaagcaca gcctaatggc | |||
| 4380 | |||
| aaatctttgg catggcttgg cttcaagact ttaggctctt aaaagtcgaa tccaaaaatt | |||
| 4440 | |||
| tttataaaag ctccagctaa gctaccttaa aaggggcctg tatggctgat cactcttctt | |||
| 4500 | |||
| gctatacttt acacaaataa acaggccaaa tataatgagg ccaaaattta ttttgcaaat | |||
| 4560 | |||
| aaattggtcc tgctatgatt tactcttggt aagaacaggg aaaatagaga aaaatttaga | |||
| 4620 | |||
| ttgcatctga cctttttttc tgaattttta tatgtgccta caatttgagc taaatcctga | |||
| 4680 | |||
| attattttct ggttgcaaaa actctctaaa gaagaacttg gttttcattg tcttcgtgac | |||
| 4740 | |||
| acatttatct ggctctttac tagaacagct ttcttgtttt tggtgttcta gcttgtgtgc | |||
| 4800 | |||
| cttacagttc tactcttcaa attattgtta tgtgtatctc atagttttcc ttcttttgag | |||
| 4860 | |||
| aaaactgaag ccatggtatt ctgaggacta gagatgactc aacagagctg gtgaatctcc | |||
| 4920 | |||
| tcatatgcaa tccactgggc tcgatctgct tcaaattgct gatgcactgc tgctaaagct | |||
| 4980 | |||
| atacatttaa aaccctcact aaaggatcag ggaccatcat ggaagaggag gaaacatgaa | |||
| 5040 | |||
| attgtaagag ccagattcgg ggggtagagt gtggaggtca gagcaactcc accttgaata | |||
| 5100 | |||
| agaaggtaaa gcaacctatc ctgaaagcta acctgccatg gtggcttctg attaacctct | |||
| 5160 | |||
| gttctaggaa gactgacagt ttgggtctgt gtcattgccc aaatctcatg ttaaattgta | |||
| 5220 | |||
| atccccagtg ttcggaggtg ggacttggtg gtaggtgatt cggtcatggg agtagatttt | |||
| 5280 | |||
| cttctttgtg gtgttacagt gatagtgagt gagttctcgt gagatctggt catttaaaag | |||
| 5340 | |||
| tgtgtggccc ctcccctccc tctcttggtc ctcctactgc catgtaagat acctgctcct | |||
| 5400 | |||
| gctttgcctt ctaccataag taaaagcccc ctgaggcctc cccagaagca gatgccacca | |||
| 5460 | |||
| tgcttcctgt acagcctgca gaaccatcag ccaattaaac ctcttttctg tataaattac | |||
| 5520 | |||
| cagtcttgag tatctcttta cagcagtgtg agaacggact aatacaaggg tctccaaaat | |||
| 5580 | |||
| tccaagttta tgtattcttt cttgccaaat agcaggtatt taccataaat cctgtcctta | |||
| 5640 | |||
| ggtcaaacaa ccttgatggc atcgtacttc aattgtctta cacattcctt ctgaatgact | |||
| 5700 | |||
| cctcccctat ggcatataag ccctgggtct tgggggataa tggcagaggg gtccaccatc | |||
| 5760 | |||
| ttgtctggct gccacctgag acacggacat ggcttctgtt ggtaagtctc tattaaatgt | |||
| 5820 | |||
| ttctttctaa gaaactggat ttgtcagctt gtttctttgg cctctcagct tcctcagact | |||
| 5880 | |||
| ttggggtagg ttgcacaacc ctgcccacca cgaaacaaat gtttaatatg ataaatatgg | |||
| 5940 | |||
| atagatataa tccacataaa taaaagctct tggagggccc tcaataattg ttaagagtgt | |||
| 6000 | |||
| aaatgtgtcc aaagatggaa aatgtttgag aactactgtc ccagagattt tcctgagttc | |||
| 6060 | |||
| tagagtgtgg gaatatagaa cctggagctt ggcttcttca gcctagaatc aggagtatgg | |||
| 6120 | |||
| ggctgaagtc tgaagcttgg cttcagcagt ttggggttgg cttccggagc acatatttga | |||
| 6180 | |||
| catgttgcga ctgtgatttg gggtttggta tttgctctga atcctaatgt ctgtccttga | |||
| 6240 | |||
| ggcatctaga atctgaaatc tgtggtcaga attctattat cttgagtagg acatctccag | |||
| 6300 | |||
| tcctggttct gccttctagg gctggagtct gtagtcagtg acccggtctg gcatttcaac | |||
| 6360 | |||
| ttcatataca gtgggctatc ttttggtcca tgtttcaacc aaacaaccga ataaaccatt | |||
| 6420 | |||
| agaacctttc cccacttccc tagctgcaat gttaaaccta ggatttctgt ttaataggtt | |||
| 6480 | |||
| catatgaata atttcagcct gatccaactt tacattcctt ctaccgttat tctacaccca | |||
| 6540 | |||
| ccttaaaaat gcattcccaa tatattccct ggattctacc tatatatggt aatcctggct | |||
| 6600 | |||
| ttgccagttt ctagtgcatt aacatacctg atttacattc ttttacttta aagtggaaat | |||
| 6660 | |||
| aagagtccct ctgcagagtt caggagttct caagatggcc cttacttctg acatcaattg | |||
| 6720 | |||
| agatttcaag ggagtcgcca agatcatcct caggttcagt gattgctggt agccctcata | |||
| 6780 | |||
| taactcaatg aaagctgtta tgctcatggc tatggtttat tacagcaaaa gaatagagat | |||
| 6840 | |||
| gaaaatctag caagggaaga gttgcatggg gcaaagacaa ggagagctcc aagtgcagag | |||
| 6900 | |||
| attcctgttg ttttctccca gtggtgtcat ggaaagcagt atcttctcca tacaatgatg | |||
| 6960 | |||
| tgtgataata ttcagtgtat tgccaatcag ggaactcaac tgagccttga ttatattgga | |||
| 7020 | |||
| gcttggttgc acagacatgt cgaccacctt catggctgaa ctttagtact tagcccctcc | |||
| 7080 | |||
| agacgtctac agctgatagg ctgtaaccca acattgtcac cataaatcac attgttagac | |||
| 7140 | |||
| tatccagtgt ggcccaagct cccgtgtaaa cacaggcact ctaaacaggc aggatatttc | |||
| 7200 | |||
| aaaagcttag agatgacctc ccaggagctg aatgcaaaga cctggcctct ttgggcaagg | |||
| 7260 | |||
| agaatccttt accgcacact ctccttcaca gggttattgt gaggatcaaa tgtggtcatg | |||
| 7320 | |||
| tgtgtgagac accagcacat gtctggctgt ggagagtgac ttctatgtgt gctaacattg | |||
| 7380 | |||
| ctgagtgcta agaaagtatt aggcatggct ttcagcactc acagatgctc atctaatcct | |||
| 7440 | |||
| cacaacatgg ctacagggtg ggcactacta gcctcatttg acagaggaaa ggactgtgga | |||
| 7500 | |||
| taagaagggg gtgaccaata ggtcagagtc attctggatg caaggggctc cagaggacca | |||
| 7560 | |||
| tgattagaca ttgtctgcag agaaattatg gctggatgtc tctgccccgg aaagggggat | |||
| 7620 | |||
| gcactttcct tgacccccta tctcagatct tgactttgag gttatctcag acttcctcta | |||
| 7680 | |||
| tgataccagg agcccatcat aatctctctg tgtcctctcc ccttcctcag tcttactgcc | |||
| 7740 | |||
| cactcttccc agctccatct ccagctggcc aggtgtagcc acagtaccta actctttgca | |||
| 7800 | |||
| gagaactata aatgtgtatc ctacagggga gaaaaaaaaa aagaactctg aaagagctga | |||
| 7860 | |||
| cattttaccg acttgcaaac acataagcta acctgccagt tttgtgctgg tagaactcat | |||
| 7920 | |||
| gagactcctg ggtcagaggc aaaagatttt attacccaca gctaaggagg cagcatgaac | |||
| 7980 | |||
| tttgtgttca catttgttca ctttgccccc caattcatat gggatgatca gagcagttca | |||
| 8040 | |||
| ggtggatgga cacaggggtt tgtggcaaag gtgagcaacc taggcttaga aatcctcaat | |||
| 8100 | |||
| cttataagaa ggtactagca aacttgtcca gtctttgtat ctgacggaga tattatcttt | |||
| 8160 | |||
| ataattgggt tgaaagcaga cctactctgg aggaacatat tgtatttatt gtcctgaaca | |||
| 8220 | |||
| gtaaacaaat ctgctgtaaa atagacgtta actttattat ctaaggcagt aagcaaacct | |||
| 8280 | |||
| agatctgaag gcgataccat cttgcaaggc tatctgctgt acaaatatgc ttgaaaagat | |||
| 8340 | |||
| ggtccagaaa agaaaacggt attattgcct ttgctcagaa gacacacaga aacataagag | |||
| 8400 | |||
| aaccatggaa aattgtctcc caacactgtt cacccagagc cttccactct tgtctgcagg | |||
| 8460 | |||
| acagtcttaa catcccatca ttagtgtgtc taccacatct ggcttcaccg tgcctaacca | |||
| 8520 | |||
| agatttctag gtccagttcc ccaccatgtt tggcagtgcc ccactgccaa ccccagaata | |||
| 8580 | |||
| agggagtgct cagaattccg aggggacatg ggtggggatc agaacttctg ggcttgagtg | |||
| 8640 | |||
| cagagggggc ccatactcct tggttccgaa ggaggaagag gctggaggtg aatgtccttg | |||
| 8700 | |||
| gaggggagga atgtgggttc tgaactctta aatccccaag ggaggagact ggtaaggtcc | |||
| 8760 | |||
| cagcttccga ggtactgacg tgggaatggc ctgagaggtc taagaatccc gtatcctcgg | |||
| 8820 | |||
| gaaggagggg ctgaaattgt gaggggttga gttgcagggg tttgttagct tgagactcct | |||
| 8880 | |||
| tggtgggtcc ctgggaagca aggactggaa ccattggctc cagggtttgg tgtgaaggta | |||
| 8940 | |||
| atgggatctc ctgattctca aagggtcaga ggactgagag ttgcccatgc tttgatcttt | |||
| 9000 | |||
| ccatctactc cttactccac ttgagggtaa tcacctactc ttctagttcc acaagagtgc | |||
| 9060 | |||
| gcctgcgcga gtataatctg cacatgtgcc atgtcccgag gcctggggca tcatccactc | |||
| 9120 | |||
| atcattcagc atctgcgcta tgcgggcgag gccggcgcca tgacgtcatg tagctgcgac | |||
| 9180 | |||
| tatccctgca gcgcgcctct cccgtcacgt cccaaccatg gagctgtgga cgtgcgtccc | |||
| 9240 | |||
| ctggtggatg tggcctgcgt ggtgccaggc cggggcctgg tgtccgataa agatcctaga | |||
| 9300 | |||
| accacaggaa accaggactg aaaggtgcta gagaatggcc atatgtcgct gtccatgaaa | |||
| 9360 | |||
| tctcaaggac ttctgggtgg agggcacagg agcctgaact tacgggtttg ccccagtcca | |||
| 9420 | |||
| ctgtcctccc aagtgagtct cccagatacg aggcactgtg ccagcatcag cttcatctgt | |||
| 9480 | |||
| accacatctt gtaacaggga ctacccagga ccctgatgaa caccatggtg tgtgcaggaa | |||
| 9540 | |||
| gagggggtga aggcatggac tcctgtgtgg tcagagccca gagggggcca tgacgggtgg | |||
| 9600 | |||
| ggaggaggct gtggactggc tcgagaagtg ggatgtggtt gtgtttgatt tcctttggcc | |||
| 9660 | |||
| agataaagtg ctggatatag cattgaaaac ggagtatgaa gaccagttag aatggagggt | |||
| 9720 | |||
| caggttggag ttgagttaca gatggggtaa aattctgctt cggatgagtt tggggattgg | |||
| 9780 | |||
| caatctaaag gtggtttggg atggcatggc tttgggatgg aaataggttt gtttttatgt | |||
| 9840 | |||
| tggctgggaa gggtgtgggg attgaattgg ggatgaagta ggtttagttt tggagataga | |||
| 9900 | |||
| atacatggag ctggctattg catgcgagga tgtgcattag tttggtttga tctttaaata | |||
| 9960 | |||
| aaggaggcta ttagggttgt cttgaattag attaagttgt gttgggttga tgggttgggc | |||
| 10020 | |||
| ttgtgggtga tgtggttgga ttgggctgtg ttaaattggt ttgggtcagg ttttggttga | |||
| 10080 | |||
| ggttatcatg gggatgagga tatgcttggg acatggattc aggtggttct cattcaagct | |||
| 10140 | |||
| gaggcaaatt tcctttcaga cggtcattcc agggaacgag tggttgtgtg ggggaaatca | |||
| 10200 | |||
| ggccactggc tgtgaatatc cctctatcct ggtcttgaat tgtgattatc tatgtccatt | |||
| 10260 | |||
| ctgtctcctt cactgtactt ggaattgatc tggtcattca gctggaaatg ggggaagatt | |||
| 10320 | |||
| ttgtcaaatt cttgagacac agctgggtct ggatcagcgt aagccttcct tctggtttta | |||
| 10380 | |||
| ttgaacagat gaaatcacat tttttttttc aaaatcacag aaatcttata gagttaacag | |||
| 10440 | |||
| tggactctta taataagagt taacaccagg actcttattc ttgattcttt tctgagacac | |||
| 10500 | |||
| caaaatgaga tttctcaatg ccaccctaat tctttttttt tttttttttt tttttgagac | |||
| 10560 | |||
| acagtctggg tcttttgctc tgtcactcag gctggagcgc agtggtgtga tcatagctca | |||
| 10620 | |||
| ctgaaccctt gacctcctgg acttaaggga tcctcctgct tcagcctcct gagtagatgg | |||
| 10680 | |||
| ggctacaggt gcttgccacc acacctggct aattaaattt tttttttttt tttgtagaga | |||
| 10740 | |||
| aagggtctca ctttgttgcc ctggctgatc ttgaacttct gacttcaagt gattcttcag | |||
| 10800 | |||
| ccttggactc ccaaagcact gggattgctg gcatgagcca ctcaccgtgc ctggcttgca | |||
| 10860 | |||
| gcttaatctt ggagtgtata aacctggctc ctgatagcta gacatttcag tgagaaggag | |||
| 10920 | |||
| gcattggatt ttgcatgagg acaattctga cctaggaggg caggtcaaca ggaatccccg | |||
| 10980 | |||
| ctgtacctgt acgttgtaca ggcatggaga atgaggagtg aggaggccgt accggaaccc | |||
| 11040 | |||
| catattgttt agtggacatt ggattttgaa ataataggga acttggtctg ggagagtcat | |||
| 11100 | |||
| atttctggat tggacaatat gtggtatcac aaggttttat gatgagggag aaatgtatgt | |||
| 11160 | |||
| ggggaaccat tttctgagtg tggaagtgca agaatcagag agtagctgaa tgccaacgct | |||
| 11220 | |||
| tctatttcag gaacatggta agttggaggt ccagctctcg ggctcagacg ggtataggga | |||
| 11280 | |||
| ccaggaagtc tcacaatccg atcattctga tatttcaggg catattaggt ttggggtgca | |||
| 11340 | |||
| aaggaagtac ttgggactta ggcacatgag actttgtatt gaaaatcaat gattggggct | |||
| 11400 | |||
| ggccgtggtg ctcacgcctg taatctcatc actttgggag accgaagtgg gaggatggct | |||
| 11460 | |||
| tgatctcaag agttggacac cagcctaggc aacatggcca gaccctctct ctacaaaaaa | |||
| 11520 | |||
| attaaaaatt agctggatgt ggtggtgcat gcttgtggtc tcagctatcc tggaggctga | |||
| 11580 | |||
| gacaggagaa tcggttgagt ctgggagttc aaggctacag ggagctgcga tcacgccgct | |||
| 11640 | |||
| gcactccagc ctgggaaaca gagtgagact gtctcagaat ttttttaaaa aagaatcagt | |||
| 11700 | |||
| gatcatccca acccctgttg ctgttcatcc tgagcctgcc ttctctggct ttgttcccta | |||
| 11760 | |||
| gatcacatct ccatgatcca taggccctgc ccaatctgac ctcacaccgt gggaatgcct | |||
| 11820 | |||
| ccagactgat ctagtatgtg tggaacagca agtgctggct ctccctcccc ttccacagct | |||
| 11880 | |||
| ctgggtgtgg gagggggttg tccagcctcc agcagcatgg ggagggcctt ggtcagcatc | |||
| 11940 | |||
| taggtgccaa cagggcaagg gcggggtcct ggagaatgaa ggctttatag ggctcctcag | |||
| 12000 | |||
| ggaggccccc cagccccaaa ctgcaccacc tggccgtgga caccggt | |||
| 12047 | |||
| HRE-TRE | |||
| ccccgagg cagtgcat gaggctcagg gcgtgcgt gagtcgcagcgagaccccg gggtgcag | SEQ ID NO:12 | ||
| gccgga | |||
| PSA-TRE | |||
| aagcttctag ttttcttttc ccggtgacat cgtggaaagc actagcatct ctaagcaatg 60 | SEQ ID NO:13 | ||
| atctgtgaca atattcacag tgtaatgcca tccagggaac tcaactgagc cttgatgtcc | |||
| 120 | |||
| agagattttt gtgttttttt ctgagactga gtctcgctct gtgccaggct ggagtgcagt | |||
| 180 | |||
| ggtgcaacct tggctcactg caagctccgc ctcctgggtt cacgccattc tcctgcctca | |||
| 240 | |||
| gcctcctgag tagctgggac tacaggcacc cgccaccacg cctggctaat ttttttgtat | |||
| 300 | |||
| ttttagtaga gatggggttt cactgtgtta gccaggatgg tctcagtctc ctgacctcgt | |||
| 360 | |||
| gatctgccca ccttggcctc ccaaagtgct gggatgacag gcgtgagcca ccgcgcctgg | |||
| 420 | |||
| ccgatatcca gagatttttt ggggggctcc atcacacaga catgttgact gtcttcatgg | |||
| 480 | |||
| ttgactttta gtatccagcc cctctagaaa tctagctgat atagtgtggc tcaaaacctt | |||
| 540 | |||
| cagcacaaat cacaccgtta gactatctgg tgtggcccaa accttcaggt gaacaaaggg | |||
| 600 | |||
| actctaatct ggcaggatac tccaaagcat tagagatgac ctcttgcaaa gaaaaagaaa | |||
| 660 | |||
| tggaaaagaa aaagaaagaa aggaaaaaaa aaaaaaaaaa gagatgacct ctcaggctct | |||
| 720 | |||
| gaggggaaac gcctgaggtc tttgagcaag gtcagtcctc tgttgcacag tctccctcac | |||
| 780 | |||
| agggtcattg tgacgatcaa atgtggtcac gtgtatgagg caccagcaca tgcctggctc | |||
| 840 | |||
| tggggagtgc cgtgtaagtg tatgcttgca ctgctgaatg gctgggatgt gtcagggatt | |||
| 900 | |||
| atcttcagca cttacagatg ctcatctcat cctcacagca tcactatggg atgggtatta | |||
| 960 | |||
| ctggcctcat ttgatggaga aagtggctgt ggctcagaaa ggggggacca ctagaccagg | |||
| 1020 | |||
| gacactctgg atgctgggga ctccagagac catgaccact caccaactgc agagaaatta | |||
| 1080 | |||
| attgtggcct gatgtccctg tcctggagag ggtggaggtg gaccttcact aacctcctac | |||
| 1140 | |||
| cttgaccctc tcttttaggg ctctttctga cctccaccat ggtactagga ccccattgta | |||
| 1200 | |||
| ttctgtaccc tcttgactct atgaccccca ccgcccactg catccagctg ggtcccctcc | |||
| 1260 | |||
| tatctctatt cccagctggc cagtgcagtc tcagtgccca cctgtttgtc agtaactctg | |||
| 1320 | |||
| aaggggctga cattttactg acttgcaaac aaataagcta actttccaga gttttgtgaa | |||
| 1380 | |||
| tgctggcaga gtccatgaga ctcctgagtc agaggcaaag gcttttactg ctcacagctt | |||
| 1440 | |||
| agcagacagc atgaggttca tgttcacatt agtacacctt gcccccccca aatcttgtag | |||
| 1500 | |||
| ggtgaccaga gcagtctagg tggatgctgt gcagaagggg tttgtgccac tggtgagaaa | |||
| 1560 | |||
| cctgagatta ggaatcctca atcttatact gggacaactt gcaaacctgc tcagcctttg | |||
| 1620 | |||
| tctctgatga agatattatc ttcatgatct tggattgaaa acagacctac tctggaggaa | |||
| 1680 | |||
| catattgtat cgattgtcct tgacagtaaa caaatctgtt gtaagagaca ttatctttat | |||
| 1740 | |||
| tatctaggac agtaagcaag cctggatctg agagagatat catcttgcaa ggatgcctgc | |||
| 1800 | |||
| tttacaaaca tccttgaaac aacaatccag aaaaaaaaag gtgttactgt ctttgctcag | |||
| 1860 | |||
| aagacacaca gatacgtgac agaaccatgg agaattgcct cccaacgctg ttcagccaga | |||
| 1920 | |||
| gccttccacc ctttctgcag gacagtctca acgttccacc attaaatact tcttctatca | |||
| 1980 | |||
| catcccgctt ctttatgcct aaccaaggtt ctaggtcccg atcgactgtg tctggcagca | |||
| 2040 | |||
| ctccactgcc aaacccagaa taaggcagcg ctcaggatcc cgaaggggca tggctgggga | |||
| 2100 | |||
| tcagaacttc tgggtttgag tgaggagtgg gtccaccctc ttgaatttca aaggaggaag | |||
| 2160 | |||
| aggctggatg tgaaggtact gggggaggga aagtgtcagt tccgaactct taggtcaatg | |||
| 2220 | |||
| agggaggaga ctggtaaggt cccagctccc gaggtactga tgtgggaatg gcctaagaat | |||
| 2280 | |||
| ctcatatcct caggaagaag gtgctggaat cctgaggggt agagttctgg gtatatttgt | |||
| 2340 | |||
| ggcttaaggc tctttggccc ctgaaggcag aggctggaac cattaggtcc agggtttggg | |||
| 2400 | |||
| gtgatagtaa tgggatctct tgattcctca agagtctgag gatcgagggt tgcccattct | |||
| 2460 | |||
| tccatcttgc cacctaatcc ttactccact tgagggtatc accagccctt ctagctccat | |||
| 2520 | |||
| gaaggtcccc tgggcaagca caatctgagc atgaaagatg ccccagaggc cttgggtgtc | |||
| 2580 | |||
| atccactcat catccagcat cacactctga gggtgtggcc agcaccatga cgtcatgttg | |||
| 2640 | |||
| ctgtgactat ccctgcagcg tgcctctcca gccacctgcc aaccgtagag ctgcccatcc | |||
| 2700 | |||
| tcctctggtg ggagtggcct gcatggtgcc aggctgaggc ctagtgtcag acagggagcc | |||
| 2760 | |||
| tggaatcata gggatccagg actcaaaagt gctagagaat ggccatatgt caccatccat | |||
| 2820 | |||
| gaaatctcaa gggcttctgg gtggagggca cagggacctg aacttatggt ttcccaagtc | |||
| 2880 | |||
| tattgctctc ccaagtgagt ctcccagata cgaggcactg tgccagcatc agccttatct | |||
| 2940 | |||
| ccaccacatc ttgtaaaagg actacccagg gccctgatga acaccatggt gtgtacagga | |||
| 3000 | |||
| gtagggggtg gaggcacgga ctcctgtgag gtcacagcca agggagcatc atcatgggtg | |||
| 3060 | |||
| gggaggaggc aatggacagg cttgagaacg gggatgtggt tgtatttggt tttctttggt | |||
| 3120 | |||
| tagataaagt gctgggtata ggattgagag tggagtatga agaccagtta ggatggagga | |||
| 3180 | |||
| tcagattgga gttgggttag ataaagtgct gggtatagga ttgagagtgg agtatgaaga | |||
| 3240 | |||
| ccagttagga tggaggatca gattggagtt gggttagaga tggggtaaaa ttgtgctccg | |||
| 3300 | |||
| gatgagtttg ggattgacac tgtggaggtg gtttgggatg gcatggcttt gggatggaaa | |||
| 3360 | |||
| tagatttgtt ttgatgttgg ctcagacatc cttggggatt gaactgggga tgaagctggg | |||
| 3420 | |||
| tttgattttg gaggtagaag acgtggaagt agctgtcaga tttgacagtg gccatgagtt | |||
| 3480 | |||
| ttgtttgatg gggaatcaaa caatggggga agacataagg gttggcttgt taggttaagt | |||
| 3540 | |||
| tgcgttgggt tgatggggtc ggggctgtgt ataatgcagt tggattggtt tgtattaaat | |||
| 3600 | |||
| tgggttgggt caggttttgg ttgaggatga gttgaggata tgcttgggga caccggatcc | |||
| 3660 | |||
| atgaggttct cactggagtg gagacaaact tcctttccag gatgaatcca gggaagcctt | |||
| 3720 | |||
| aattcacgtg taggggaggt caggccactg gctaagtata tccttccact ccagctctaa | |||
| 3780 | |||
| gatggtctta aattgtgatt atctatatcc acttctgtct ccctcactgt gcttggagtt | |||
| 3840 | |||
| tacctgatca ctcaactaga aacaggggaa gattttatca aattcttttt tttttttttt | |||
| 3900 | |||
| tttttttgag acagagtctc actctgttgc ccaggctgga gtgcagtggc gcagtctcgg | |||
| 3960 | |||
| ctcactgcaa cctctgcctc ccaggttcaa gtgattctcc tgcctcagcc tcctgagttg | |||
| 4020 | |||
| ctgggattac aggcatgcag caccatgccc agctaatttt tgtattttta gtagagatgg | |||
| 4080 | |||
| ggtttcacca atgtttgcca ggctggcctc gaactcctga cctggtgatc cacctgcctc | |||
| 4140 | |||
| agcctcccaa agtgctggga ttacaggcgt cagccaccgc gcccagccac ttttgtcaaa | |||
| 4200 | |||
| ttcttgagac acagctcggg ctggatcaag tgagctactc tggttttatt gaacagctga | |||
| 4260 | |||
| aataaccaac tttttggaaa ttgatgaaat cttacggagt taacagtgga ggtaccaggg | |||
| 4320 | |||
| ctcttaagag ttcccgattc tcttctgaga ctacaaattg tgattttgca tgccacctta | |||
| 4380 | |||
| atcttttttt tttttttttt aaatcgaggt ttcagtctca ttctatttcc caggctggag | |||
| 4440 | |||
| ttcaatagcg tgatcacagc tcactgtagc cttgaactcc tggccttaag agattctcct | |||
| 4500 | |||
| gcttcggtct cccaatagct aagactacag tagtccacca ccatatccag ataattttta | |||
| 4560 | |||
| aattttttgg ggggccgggc acagtggctc acgcctgtaa tcccaacacc atgggaggct | |||
| 4620 | |||
| gagatgggtg gatcacgagg tcaggagttt gagaccagcc tgaccaacat ggtgaaactc | |||
| 4680 | |||
| tgtctctact aaaaaaaaaa aaaatagaaa aattagccgg gcgtggtggc acacggcacc | |||
| 4740 | |||
| tgtaatccca gctactgagg aggctgaggc aggagaatca cttgaaccca gaaggcagag | |||
| 4800 | |||
| gttgcaatga gccgagattg cgccactgca ctccagcctg ggtgacagag tgagactctg | |||
| 4860 | |||
| tctcaaaaaa aaaaaatttt tttttttttt ttgtagagat ggatcttgct ttgtttctct | |||
| 4920 | |||
| ggttggcctt gaactcctgg cttcaagtga tcctcctacc ttggcctcgg aaagtgttgg | |||
| 4980 | |||
| gattacaggc gtgagccacc atgactgacc tgtcgttaat cttgaggtac ataaacctgg | |||
| 5040 | |||
| ctcctaaagg ctaaaggcta aatatttgtt ggagaagggg cattggattt tgcatgagga | |||
| 5100 | |||
| tgattctgac ctgggagggc aggtcagcag gcatctctgt tgcacagata gagtgtacag | |||
| 5160 | |||
| gtctggagaa caaggagtgg ggggttattg gaattccaca ttgtttgctg cacgttggat | |||
| 5220 | |||
| tttgaaatgc tagggaactt tgggagactc atatttctgg gctagaggat ctgtggacca | |||
| 5280 | |||
| caagatcttt ttatgatgac agtagcaatg tatctgtgga gctggattct gggttgggag | |||
| 5340 | |||
| tgcaaggaaa agaatgtact aaatgccaag acatctattt caggagcatg aggaataaaa | |||
| 5400 | |||
| gttctagttt ctggtctcag agtggtgcat ggatcaggga gtctcacaat ctcctgagtg | |||
| 5460 | |||
| ctggtgtctt agggcacact gggtcttgga gtgcaaagga tctaggcacg tgaggctttg | |||
| 5520 | |||
| tatgaagaat cggggatcgt acccaccccc tgtttctgtt tcatcctggg catgtctcct | |||
| 5580 | |||
| ctgcctttgt cccctagatg aagtctccat gagctacaag ggcctggtgc atccagggtg | |||
| 5640 | |||
| atctagtaat tgcagaacag caagtgctag ctctccctcc ccttccacag ctctgggtgt | |||
| 5700 | |||
| gggagggggt tgtccagcct ccagcagcat ggggagggcc ttggtcagcc tctgggtgcc | |||
| 5760 | |||
| agcagggcag gggcggagtc ctggggaatg aaggttttat agggctcctg ggggaggctc | |||
| 5820 | |||
| cccagcccca agctt | |||
| 5835 | |||
| CEA TRE | |||
| aagcttttta gtgctttaga cagtgagctg gtctgtctaa cccaagtgac ctgggctcca | 60 | SEQ ID NO:14 | |
| tactcagccc cagaagtgaa gggtgaagct gggtggagcc aaaccaggca agcctaccct | 120 | ||
| cagggctccc agtggcctga gaaccattgg acccaggacc cattacttct agggtaagga | 180 | ||
| aggtacaaac accagatcca accatggtct ggggggaaag ctgtcaaatg cctaaaaata | 240 | ||
| tacctgggag aggagcaggc aaactatcac tgccccaggt tctctgaaca gaaacagagg | 300 | ||
| ggcaacccaa agtccaaatc caggtgagca ggtgcaccaa atgcccagag atatgacgag | 360 | ||
| gcaagaagtg aaggaaccac ccctgcatca aatgttttgc atgggaagga gaagggggtt | 420 | ||
| gctcatgttc ccaatccagg agaatgcatt tgggatctgc cttcttctca ctccttggtt | 480 | ||
| agcaagacta agcaaccagg actctggatt tggggaaaga cgtttatttg tggaggccag | 540 | ||
| tgatgacaat cccacgaggg cctaggtgaa gagggcagga aggctcgaga cactggggac | 600 | ||
| tgagtgaaaa ccacacccat gatctgcacc acccatggat gctccttcat tgctcacctt | 660 | ||
| tctgttgata tcagatggcc ccattttctg taccttcaca gaaggacaca ggctagggtc | 720 | ||
| tgtgcatggc cttcatcccc ggggccatgt gaggacagca ggtgggaaag atcatgggtc | 780 | ||
| ctcctgggtc ctgcagggcc agaacattca tcacccatac tgacctccta gatgggaatg | 840 | ||
| gcttccctgg ggctgggcca acggggcctg ggcaggggag aaaggacgtc aggggacagg | 900 | ||
| gaggaagggt catcgagacc cagcctggaa ggttcttgtc tctgaccatc caggatttac | 960 | ||
| ttccctgcat ctacctttgg tcattttccc tcagcaatga ccagctctgc ttcctgatct | 1020 | ||
| cagcctccca ccctggacac agcaccccag tccctggccc ggctgcatcc acccaatacc | 1080 | ||
| ctgataaccc aggacccatt acttctaggg taaggagggt ccaggagaca gaagctgagg | 1140 | ||
| aaaggtctga agaagtcaca tctgtcctgg ccagagggga aaaaccatca gatgctgaac | 1200 | ||
| caggagaatg ttgacccagg aaagggaccg aggacccaag aaaggagtca gaccaccagg | 1260 | ||
| gtttgcctga gaggaaggat caaggccccg agggaaagca gggctggctg catgtgcagg | 1320 | ||
| acactggtgg ggcatatgtg tcttagattc tccctgaatt cagtgtccct gccatggcca | 1380 | ||
| gactctctac tcaggcctgg acatgctgaa ataggacaat ggccttgtcc tctctcccca | 1440 | ||
| ccatttggca agagacataa aggacattcc aggacatgcc ttcctgggag gtccaggttc | 1500 | ||
| tctgtctcac acctcaggga ctgtagttac tgcatcagcc atggtaggtg ctgatctcac | 1560 | ||
| ccagcctgtc caggcccttc cactctccac tttgtgacca tgtccaggac cacccctcag | 1620 | ||
| atcctgagcc tgcaaatacc cccttgctgg gtgggtggat tcagtaaaca gtgagctcct | 1680 | ||
| atccagcccc cagagccacc tctgtcacct tcctgctggg catcatccca ccttcacaag | 1740 | ||
| cactaaagag catggggaga cctggctagc tgggtttctg catcacaaag aaaataatcc | 1800 | ||
| cccaggttcg gattcccagg gctctgtatg tggagctgac agacctgagg ccaggagata | 1860 | ||
| gcagaggtca gccctaggga gggtgggtca tccacccagg ggacaggggt gcaccagcct | 1920 | ||
| tgctactgaa agggcctccc caggacagcg ccatcagccc tgcctgagag ctttgctaaa | 1980 | ||
| cagcagtcag aggaggccat ggcagtggct gagctcctgc tccaggcccc aacagaccag | 2040 | ||
| accaacagca caatgcagtc cttccccaac gtcacaggtc accaaaggga aactgaggtg | 2100 | ||
| ctacctaacc ttagagccat caggggagat aacagcccaa tttcccaaac aggccagttt | 2160 | ||
| caatcccatg acaatgacct ctctgctctc attcttccca aaataggacg ctgattctcc | 2220 | ||
| cccaccatgg atttctccct tgtcccggga gccttttctg ccccctatga tctgggcact | 2280 | ||
| cctgacacac acctcctctc tggtgacata tcagggtccc tcactgtcaa gcagtccaga | 2340 | ||
| aaggacagaa ccttggacag cgcccatctc agcttcaccc ttcctccttc acagggttca | 2400 | ||
| gggcaaagaa taaatggcag aggccagtga gcccagagat ggtgacaggc agtgacccag | 2460 | ||
| gggcagatgc ctggagcagg agctggcggg gccacaggga gaaggtgatg caggaaggga | 2520 | ||
| aacccagaaa tgggcaggaa aggaggacac aggctctgtg gggctgcagc ccagggttgg | 2580 | ||
| actatgagtg tgaagccatc tcagcaagta aggccaggtc ccatgaacaa gagtgggagc | 2640 | ||
| acgtggcttc ctgctctgta tatggggtgg gggattccat gccccataga accagatggc | 2700 | ||
| cggggttcag atggagaagg agcaggacag gggatcccca ggataggagg accccagtgt | 2760 | ||
| ccccacccag gcaggtgact gatgaatggg catgcagggt cctcctgggc tgggctctcc | 2820 | ||
| ctttgtccct caggattcct tgaaggaaca tccggaagcc gaccacatct acctggtggg | 2880 | ||
| ttctggggag tccatgtaaa gccaggagct tgtgttgcta ggaggggtca tggcatgtgc | 2940 | ||
| tgggggcacc aaagagagaa acctgagggc aggcaggacc tggtctgagg aggcatggga | 3000 | ||
| gcccagatgg ggagatggat gtcaggaaag gctgccccat cagggagggt gatagcaatg | 3060 | ||
| gggggtctgt gggagtgggc acgtgggatt ccctgggctc tgccaagttc cctcccatag | 3120 | ||
| tcacaacctg gggacactgc ccatgaaggg gcgcctttgc ccagccagat gctgctggtt | 3180 | ||
| ctgcccatcc actaccctct ctgctccagc cactctgggt ctttctccag atgccctgga | 3240 | ||
| cagccctggc ctgggcctgt cccctgagag gtgttgggag aagctgagtc tctggggaca | 3300 | ||
| ctctcatcag agtctgaaag gcacatcagg aaacatccct ggtctccagg actaggcaat | 3360 | ||
| gaggaaaggg ccccagctcc tccctttccc actgagaggg tcgaccctgg gtggccacag | 3420 | ||
| tgacttctgc gtctgtccca gtcaccctga aaccacaaca aaaccccagc cccagaccct | 3480 | ||
| gcaggtacaa tacatgtggg gacagtctgt acccagggga agccagttct ctcttcctag | 3540 | ||
| gagaccgggc ctcagggctg tgcccggggc aggcgggggc agcacgtgcc tgtccttgag | 3600 | ||
| aactcgggac cttaagggtc tctgctctgt gaggcacagc aaggatcctt ctgtccagag | 3660 | ||
| atgaaagcag ctcctgcccc tcctctgacc tcttcctcct tcccaaatct caaccaacaa | 3720 | ||
| ataggtgttt caaatctcat catcaaatct tcatccatcc acatgagaaa gcttaaaacc | 3780 | ||
| caatggattg acaacatcaa gagttggaac aagtggacat ggagatgtta cttgtggaaa | 3840 | ||
| tttagatgtg ttcagctatc gggcaggaga atctgtgtca aattccagca tggttcagaa | 3900 | ||
| gaatcaaaaa gtgtcacagt ccaaatgtgc aacagtgcag gggataaaac tgtggtgcat | 3960 | ||
| tcaaactgag ggatattttg gaacatgaga aaggaaggga ttgctgctgc acagaacatg | 4020 | ||
| catgatctca cacatagagt tgaaagaaag gagtcaatcg cagaatagaa aatgatcact | 4080 | ||
| aattccacct ctataaagtt tccaagagga aaacccaatt ctgctgctag agatcagaat | 4140 | ||
| ggaggtgacc tgtgccttgc aatggctgtg agggtcacgg gagtgtcact tagtgcaggc | 4200 | ||
| aatgtgccgt atcttaatct gggcagggct ttcatgagca cataggaatg cagacattac | 4260 | ||
| tgctgtgttc attttacttc accggaaaag aagaataaaa tcagccgggc gcggtggctc | 4320 | ||
| acgcctgtaa tcccagcact ttagaagcct gaggtgggca gattacttga ggtcaggagt | 4380 | ||
| tcaagaccac cctggccaat atggtgaaac cccggctcta ctaaaaatac aaaaattagc | 4440 | ||
| tgggcatggt ggtgcgcgcc tgtaatccca gctactcggg aggctgaggc tggacaattg | 4500 | ||
| cttggaccca ggaagcagag gttgcagtga gccaagattg tgccactgca ctccagcttg | 4560 | ||
| ggcaacagag ccagactctg taaaaaaaaa aaaaaaaaaa aaaaaaagaa agaaagaaaa | 4620 | ||
| agaaaagaaa gtataaaatc tctttgggtt aacaaaaaaa gatccacaaa acaaacacca | 4680 | ||
| gctcttatca aacttacaca actctgccag agaacaggaa acacaaatac tcattaactc | 4740 | ||
| acttttgtgg caataaaacc ttcatgtcaa aaggagacca ggacacaatg aggaagtaaa | 4800 | ||
| actgcaggcc ctacttgggt gcagagaggg aaaatccaca aataaaacat taccagaagg | 4860 | ||
| agctaagatt tactgcattg agttcattcc ccaggtatgc aaggtgattt taacacctga | 4920 | ||
| aaatcaatca ttgcctttac tacatagaca gattagctag aaaaaaatta caactagcag | 4980 | ||
| aacagaagca atttggcctt cctaaaattc cacatcatat catcatgatg gagacagtgc | 5040 | ||
| agacgccaat gacaataaaa agagggacct ccgtcacccg gtaaacatgt ccacacagct | 5100 | ||
| ccagcaagca cccgtcttcc cagtgaatca ctctaacctc ccctttaatc agccccaggc | 5160 | ||
| aaggctgcct gcgatggcca cacaggctcc aacccgtggg cctcaacctc ccgcagaggc | 5220 | ||
| tctcctttgg ccaccccatg gggagagcat gaggacaggg cagagccctc tgatgcccac | 5280 | ||
| acatggcagg agctgacgcc agagccatgg gggctggaga gcagagctgc tggggtcaga | 5340 | ||
| gcttcctgag gacacccagg cctaagggaa ggcagctccc tggatggggg caaccaggct | 5400 | ||
| ccgggctcca acctcagagc ccgcatggga ggagccagca ctctaggcct ttcctagggt | 5460 | ||
| gactctgagg ggaccctgac acgacaggat cgctgaatgc acccgagatg aaggggccac | 5520 | ||
| cacgggaccc tgctctcgtg gcagatcagg agagagtggg acaccatgcc aggcccccat | 5580 | ||
| ggcatggctg cgactgaccc aggccactcc cctgcatgca tcagcctcgg taagtcacat | 5640 | ||
| gaccaagccc aggaccaatg tggaaggaag gaaacagcat cccctttagt gatggaaccc | 5700 | ||
| aaggtcagtg caaagagagg ccatgagcag ttaggaaggg tggtccaacc tacagcacaa | 5760 | ||
| accatcatct atcataagta gaagccctgc tccatgaccc ctgcatttaa ataaacgttt | 5820 | ||
| gttaaatgag tcaaattccc tcaccatgag agctcacctg tgtgtaggcc catcacacac | 5880 | ||
| acaaacacac acacacacac acacacacac acacacacac acagggaaag tgcaggatcc | 5940 | ||
| tggacagcac caggcaggct tcacaggcag agcaaacagc gtgaatgacc catgcagtgc | 6000 | ||
| cctgggcccc atcagctcag agaccctgtg agggctgaga tggggctagg caggggagag | 6060 | ||
| acttagagag ggtggggcct ccagggaggg ggctgcaggg agctgggtac tgccctccag | 6120 | ||
| ggagggggct gcagggagct gggtactgcc ctccagggag ggggctgcag ggagctgggt | 6180 | ||
| actgccctcc agggaggggg ctgcagggag ctgggtactg ccctccaggg agggggctgc | 6240 | ||
| agggagctgg gtactgccct ccagggaggc aggagcactg ttcccaacag agagcacatc | 6300 | ||
| ttcctgcagc agctgcacag acacaggagc ccccatgact gccctgggcc agggtgtgga | 6360 | ||
| ttccaaattt cgtgccccat tgggtgggac ggaggttgac cgtgacatcc aaggggcatc | 6420 | ||
| tgtgattcca aacttaaact actgtgccta caaaatagga aataacccta ctttttctac | 6480 | ||
| tatctcaaat tccctaagca caagctagca ccctttaaat caggaagttc agtcactcct | 6540 | ||
| ggggtcctcc catgccccca gtctgacttg caggtgcaca gggtggctga catctgtcct | 6600 | ||
| tgctcctcct cttggctcaa ctgccgcccc tcctgggggt gactgatggt caggacaagg | 6660 | ||
| gatcctagag ctggccccat gattgacagg aaggcaggac ttggcctcca ttctgaagac | 6720 | ||
| taggggtgtc aagagagctg ggcatcccac agagctgcac aagatgacgc ggacagaggg | 6780 | ||
| tgacacaggg ctcagggctt cagacgggtc gggaggctca gctgagagtt cagggacaga | 6840 | ||
| cctgaggagc ctcagtggga aaagaagcac tgaagtggga agttctggaa tgttctggac | 6900 | ||
| aagcctgagt gctctaagga aatgctccca ccccgatgta gcctgcagca ctggacggtc | 6960 | ||
| tgtgtacctc cccgctgccc atcctctcac agcccccgcc tctagggaca caactcctgc | 7020 | ||
| cctaacatgc atctttcctg tctcattcca cacaaaaggg cctctggggt ccctgttctg | 7080 | ||
| cattgcaagg agtggaggtc acgttcccac agaccaccca gcaacagggt cctatggagg | 7140 | ||
| tgcggtcagg aggatcacac gtccccccat gcccagggga ctgactctgg gggtgatgga | 7200 | ||
| ttggcctgga ggccactggt cccctctgtc cctgagggga atctgcaccc tggaggctgc | 7260 | ||
| cacatccctc ctgattcttt cagctgaggg cccttcttga aatcccaggg aggactcaac | 7320 | ||
| ccccactggg aaaggcccag tgtggacggt tccacagcag cccagctaag gcccttggac | 7380 | ||
| acagatcctg agtgagagaa cctttaggga cacaggtgca cggccatgtc cccagtgccc | 7440 | ||
| acacagagca ggggcatctg gaccctgagt gtgtagctcc cgcgactgaa cccagccctt | 7500 | ||
| ccccaatgac gtgacccctg gggtggctcc aggtctccag tccatgccac caaaatctcc | 7560 | ||
| agattgaggg tcctcccttg agtccctgat gcctgtccag gagctgcccc ctgagcaaat | 7620 | ||
| ctagagtgca gaggactggg attgtggcag taaaagcagc cacatttgtc tcaggaagga | 7680 | ||
| aagggaggac atgagctcca ggaagggcga tggcgtcctc tagtgggcgc ctcctgttaa | 7740 | ||
| tgagcaaaaa ggggccagga gagttgagag atcagggctg gccttggact aaggctcaga | 7800 | ||
| tggagaggac tgaggtgcaa agagggggct gaagtagggg agtggtcggg agagatggga | 7860 | ||
| ggagcaggta aggggaagcc ccagggaggc cgggggaggg tacagcagag ctctccactc | 7920 | ||
| ctcagcattg acatttgggg tggtcgtgct agtggggttc tgtaagttgt agggtgttca | 7980 | ||
| gcaccatctg gggactctac ccactaaatg ccagcaggac tccctcccca agctctaaca | 8040 | ||
| accaacaatg tctccagact ttccaaatgt cccctggaga gcaaaattgc ttctggcaga | 8100 | ||
| atcactgatc tacgtcagtc tctaaaagtg actcatcagc gaaatccttc acctcttggg | 8160 | ||
| agaagaatca caagtgtgag aggggtagaa actgcagact tcaaaatctt tccaaaagag | 8220 | ||
| ttttacttaa tcagcagttt gatgtcccag gagaagatac atttagagtg tttagagttg | 8280 | ||
| atgccacatg gctgcctgta cctcacagca ggagcagagt gggttttcca agggcctgta | 8340 | ||
| accacaactg gaatgacact cactgggtta cattacaaag tggaatgtgg ggaattctgt | 8400 | ||
| agactttggg aagggaaatg tatgacgtga gcccacagcc taaggcagtg gacagtccac | 8460 | ||
| tttgaggctc tcaccatcta ggagacatct cagccatgaa catagccaca tctgtcatta | 8520 | ||
| gaaaacatgt tttattaaga ggaaaaatct aggctagaag tgctttatgc tcttttttct | 8580 | ||
| ctttatgttc aaattcatat acttttagat cattccttaa agaagaatct atccccctaa | 8640 | ||
| gtaaatgtta tcactgactg gatagtgttg gtgtctcact cccaacccct gtgtggtgac | 8700 | ||
| agtgccctgc ttccccagcc ctgggccctc tctgattcct gagagctttg ggtgctcctt | 8760 | ||
| cattaggagg aagagaggaa gggtgttttt aatattctca ccattcaccc atccacctct | 8820 | ||
| tagacactgg gaagaatcag ttgcccactc ttggatttga tcctcgaatt aatgacctct | 8880 | ||
| atttctgtcc cttgtccatt tcaacaatgt gacaggccta agaggtgcct tctccatgtg | 8940 | ||
| atttttgagg agaaggttct caagataagt tttctcacac ctctttgaat tacctccacc | 9000 | ||
| tgtgtcccca tcaccattac cagcagcatt tggacccttt ttctgttagt cagatgcttt | 9060 | ||
| ccacctcttg agggtgtata ctgtatgctc tctacacagg aatatgcaga ggaaatagaa | 9120 | ||
| aaagggaaat cgcattacta ttcagagaga agaagacctt tatgtgaatg aatgagagtc | 9180 | ||
| taaaatccta agagagccca tataaaatta ttaccagtgc taaaactaca aaagttacac | 9240 | ||
| taacagtaaa ctagaataat aaaacatgca tcacagttgc tggtaaagct aaatcagata | 9300 | ||
| tttttttctt agaaaaagca ttccatgtgt gttgcagtga tgacaggagt gcccttcagt | 9360 | ||
| caatatgctg cctgtaattt ttgttccctg gcagaatgta ttgtcttttc tccctttaaa | 9420 | ||
| tcttaaatgc aaaactaaag gcagctcctg ggccccctcc ccaaagtcag ctgcctgcaa | 9480 | ||
| ccagccccac gaagagcaga ggcctgagct tccctggtca aaataggggg ctagggagct | 9540 | ||
| taaccttgct cgataaagct gtgttcccag aatgtcgctc ctgttcccag gggcaccagc | 9600 | ||
| ctggagggtg gtgagcctca ctggtggcct gatgcttacc ttgtgccctc acaccagtgg | 9660 | ||
| tcactggaac cttgaacact tggctgtcgc ccggatctgc agatgtcaag aacttctgga | 9720 | ||
| agtcaaatta ctgcccactt ctccagggca gatacctgtg aacatccaaa accatgccac | 9780 | ||
| agaaccctgc ctggggtcta caacacatat ggactgtgag caccaagtcc agccctgaat | 9840 | ||
| ctgtgaccac ctgccaagat gcccctaact gggatccacc aatcactgca catggcaggc | 9900 | ||
| agcgaggctt ggaggtgctt cgccacaagg cagccccaat ttgctgggag tttcttggca | 9960 | ||
| cctggtagtg gtgaggagcc ttgggaccct caggattact ccccttaagc atagtgggga | 10020 | ||
| cccttctgca tccccagcag gtgccccgct cttcagagcc tctctctctg aggtttaccc | 10080 | ||
| agacccctgc accaatgaga ccatgctgaa gcctcagaga gagagatgga gctttgacca | 10140 | ||
| ggagccgctc ttccttgagg gccagggcag ggaaagcagg aggcagcacc aggagtggga | 10200 | ||
| acaccagtgt ctaagcccct gatgagaaca gggtggtctc tcccatatgc ccataccagg | 10260 | ||
| cctgtgaaca gaatcctcct tctgcagtga caatgtctga gaggacgaca tgtttcccag | 10320 | ||
| cctaacgtgc agccatgccc atctacccac tgcctactgc aggacagcac caacccagga | 10380 | ||
| gctgggaagc tgggagaaga catggaatac ccatggcttc tcaccttcct ccagtccagt | 10440 | ||
| gggcaccatt tatgcctagg acacccacct gccggcccca ggctcttaag agttaggtca | 10500 | ||
| cctaggtgcc tctgggaggc cgaggcagga gaattgcttg aacccgggag gcagaggtta | 10560 | ||
| cagtgagccg agatcacacc actgcactcc agcctgggtg acagaatgag actctgtctc | 10620 | ||
| aaaaaaaaag agaaagatag catcagtggc taccaagggc taggggcagg ggaaggtgga | 10680 | ||
| gagttaatga ttaatagtat gaagtttcta tgtgagatga tgaaaatgtt ctggaaaaaa | 10740 | ||
| aaatatagtg gtgaggatgt agaatattgt gaatataatt aacggcattt aattgtacac | 10800 | ||
| ttaacatgat taatgtggca tattttatct tatgtatttg actacatcca agaaacactg | 10860 | ||
| ggagagggaa agcccaccat gtaaaataca cccaccctaa tcagatagtc ctcattgtac | 10920 | ||
| ccaggtacag gcccctcatg acctgcacag gaataactaa ggatttaagg acatgaggct | 10980 | ||
| tcccagccaa ctgcaggtgc acaacataaa tgtatctgca aacagactga gagtaaagct | 11040 | ||
| gggggcacaa acctcagcac tgccaggaca cacacccttc tcgtggattc tgactttatc | 11100 | ||
| tgacccggcc cactgtccag atcttgttgt gggattggga caagggaggt cataaagcct | 11160 | ||
| gtccccaggg cactctgtgt gagcacacga gacctcccca cccccccacc gttaggtctc | 11220 | ||
| cacacataga tctgaccatt aggcattgtg aggaggactc tagcgcgggc tcagggatca | 11280 | ||
| caccagagaa tcaggtacag agaggaagac ggggctcgag gagctgatgg atgacacaga | 11340 | ||
| gcagggttcc tgcagtccac aggtccagct caccctggtg taggtgcccc atccccctga | 11400 | ||
| tccaggcatc cctgacacag ctccctcccg gagcctcctc ccaggtgaca catcagggtc | 11460 | ||
| cctcactcaa gctgtccaga gagggcagca ccttggacag cgcccacccc acttcactct | 11520 | ||
| tcctccctca cagggctcag ggctcagggc tcaagtctca gaacaaatgg cagaggccag | 11580 | ||
| tgagcccaga gatggtgaca gggcaatgat ccaggggcag ctgcctgaaa cgggagcagg | 11640 | ||
| tgaagccaca gatgggagaa gatggttcag gaagaaaaat ccaggaatgg gcaggagagg | 11700 | ||
| agaggaggac acaggctctg tggggctgca gcccaggatg ggactaagtg tgaagacatc | 11760 | ||
| tcagcaggtg aggccaggtc ccatgaacag agaagcagct cccacctccc ctgatgcacg | 11820 | ||
| gacacacaga gtgtgtggtg ctgtgccccc agagtcgggc tctcctgttc tggtccccag | 11880 | ||
| ggagtgagaa gtgaggttga cttgtccctg ctcctctctg ctaccccaac attcaccttc | 11940 | ||
| tcctcatgcc cctctctctc aaatatgatt tggatctatg tccccgccca aatctcatgt | 12000 | ||
| caaattgtaa accccaatgt tggaggtggg gccttgtgag aagtgattgg ataatgcggg | 12060 | ||
| tggattttct gctttgatgc tgtttctgtg atagagatct cacatgatct ggttgtttaa | 12120 | ||
| aagtgtgtag cacctctccc ctctctctct ctctctctta ctcatgctct gccatgtaag | 12180 | ||
| acgttcctgt ttccccttca ccgtccagaa tgattgtaag ttttctgagg cctccccagg | 12240 | ||
| agcagaagcc actatgcttc ctgtacaact gcagaatgat gagcgaatta aacctctttt | 12300 | ||
| ctttataaat tacccagtct caggtatttc tttatagcaa tgcgaggaca gactaataca | 12360 | ||
| atcttctact cccagatccc cgcacacgct tagccccaga catcactgcc cctgggagca | 12420 | ||
| tgcacagcgc agcctcctgc cgacaaaagc aaagtcacaa aaggtgacaa aaatctgcat | 12480 | ||
| ttggggacat ctgattgtga aagagggagg acagtacact tgtagccaca gagactgggg | 12540 | ||
| ctcaccgagc tgaaacctgg tagcactttg gcataacatg tgcatgaccc gtgttcaatg | 12600 | ||
| tctagagatc agtgttgagt aaaacagcct ggtctggggc cgctgctgtc cccacttccc | 12660 | ||
| tcctgtccac cagagggcgg cagagttcct cccaccctgg agcctcccca ggggctgctg | 12720 | ||
| acctccctca gccgggccca cagcccagca gggtccaccc tcacccgggt cacctcggcc | 12780 | ||
| cacgtcctcc tcgccctccg agctcctcac acggactctg tcagctcctc cctgcagcct | 12840 | ||
| atcggccgcc cacctgaggc ttgtcggccg cccacttgag gcctgtcggc tgccctctgc | 12900 | ||
| aggcagctcc tgtcccctac accccctcct tccccgggct cagctgaaag ggcgtctccc | 12960 | ||
| agggcagctc cctgtgatct ccaggacagc tcagtctctc acaggctccg acgcccccta | 13020 | ||
| tgctgtcacc tcacagccct gtcattacca ttaactcctc agtcccatga agttcactga | 13080 | ||
| gcgcctgtct cccggttaca ggaaaactct gtgacaggga ccacgtctgt cctgctctct | 13140 | ||
| gtggaatccc agggcccagc ccagtgcctg acacggaaca gatgctccat aaatactggt | 13200 | ||
| taaatgtgtg ggagatctct aaaaagaagc atatcacctc cgtgtggccc ccagcagtca | 13260 | ||
| gagtctgttc catgtggaca caggggcact ggcaccagca tgggaggagg ccagcaagtg | 13320 | ||
| cccgcggctg ccccaggaat gaggcctcaa cccccagagc ttcagaaggg aggacagagg | 13380 | ||
| cctgcaggga atagatcctc cggcctgacc ctgcagccta atccagagtt cagggtcagc | 13440 | ||
| tcacaccacg tcgaccctgg tcagcatccc tagggcagtt ccagacaagg ccggaggtct | 13500 | ||
| cctcttgccc tccagggggt gacattgcac acagacatca ctcaggaaac ggattcccct | 13560 | ||
| ggacaggaac ctggctttgc taaggaagtg gaggtggagc ctggtttcca tcccttgctc | 13620 | ||
| caacagaccc ttctgatctc tcccacatac ctgctctgtt cctttctggg tcctatgagg | 13680 | ||
| accctgttct gccaggggtc cctgtgcaac tccagactcc ctcctggtac caccatgggg | 13740 | ||
| aaggtggggt gatcacagga cagtcagcct cgcagagaca gagaccaccc aggactgtca | 13800 | ||
| gggagaacat ggacaggccc tgagccgcag ctcagccaac agacacggag agggagggtc | 13860 | ||
| cccctggagc cttccccaag gacagcagag cccagagtca cccacctccc tccaccacag | 13920 | ||
| tcctctcttt ccaggacaca caagacacct ccccctccac atgcaggatc tggggactcc | 13980 | ||
| tgagacctct gggcctgggt ctccatccct gggtcagtgg cggggttggt ggtactggag | 14040 | ||
| acagagggct ggtccctccc cagccaccac ccagtgagcc tttttctagc ccccagagcc | 14100 | ||
| acctctgtca ccttcctgtt gggcatcatc ccaccttccc agagccctgg agagcatggg | 14160 | ||
| gagacccggg accctgctgg gtttctctgt cacaaaggaa aataatcccc ctggtgtgac | 14220 | ||
| agacccaagg acagaacaca gcagaggtca gcactgggga agacaggttg tcctcccagg | 14280 | ||
| ggatgggggt ccatccacct tgccgaaaag atttgtctga ggaactgaaa atagaaggga | 14340 | ||
| aaaaagagga gggacaaaag aggcagaaat gagaggggag gggacagagg acacctgaat | 14400 | ||
| aaagaccaca cccatgaccc acgtgatgct gagaagtact cctgccctag gaagagactc | 14460 | ||
| transcription start site | |||
| agggcagagg gaggaaggac agcagaccag acagtcacag cagccttgac aaaacgttcc | 14520 | ||
| tggaactcaa gctcttctcc acagaggagg acagagcaga cagcagagac catggagtct | 14580 | ||
| ccctcggccc ctccccacag atggtgcatc ccctggcaga ggctcctgct cacaggtgaa | 14640 | ||
| gggaggacaa cctgggagag ggtgggagga gggagctggg gtctcctggg taggacaggg | 14700 | ||
| ctgtgagacg gacagagggc tcctgttgga gcctgaatag ggaagaggac atcagagagg | 14760 | ||
| gacaggagtc acaccagaaa aatcaaattg aactggaatt ggaaaggggc aggaaaacct | 14820 | ||
| caagagttct attttcctag ttaattgtca ctggccacta cgtttttaaa aatcataata | 14880 | ||
| actgcatcag atgacacttt aaataaaaac ataaccaggg catgaaacac tgtcctcatc | 14940 | ||
| cgcctaccgc ggacattgga aaataagccc caggctgtgg agggccctgg gaaccctcat | 15000 | ||
| gaactcatcc acaggaatct gcagcctgtc ccaggcactg gggtgcaacc aagatc | 15056 | ||
| Mucin-TRE | |||
| cgagcggccc ctcagcttcg gcgcccagcc ccgcaaggct cccggtgacc actagagggc 60 | SEQ ID NO:15 | ||
| gggaggagct cctggccagt ggtggagagt ggcaaggaag gaccctaggg ttcatcggag | |||
| 120 | |||
| cccaggttta ctcccttaag tggaaatttc ttcccccact cctccttggc tttctccaag | |||
| 180 | |||
| gagggaaccc aggctgctgg aaagtccggc tggggcgggg actgtgggtt caggggagaa | |||
| 240 | |||
| cggggtgtgg aacgggacag ggagcggtta gaagggtggg gctattccgg gaagtggtgg | |||
| 300 | |||
| ggggagggag cccaaaacta gcacctagtc cactcattat ccagccctct tatttctcgg | |||
| 360 | |||
| ccgctctgct tcagtggacc cggggagggc ggggaagtgg agtgggagac ctaggggtgg | |||
| 420 | |||
| gcttcccgac cttgctgtac aggacctcga cctagctggc tttgttcccc atccccacgt | |||
| 480 | |||
| tagttgttgc cctgaggcta aaactagagc ccaggggccc caagttccag actgcccctc | |||
| 540 | |||
| ccccctcccc cggagccagg gagtggttgg tgaaaggggg aggccagctg gagaacaaac | |||
| 600 | |||
| gggtagtcag ggggttgagc gattagagcc cttgtaccct acccaggaat ggttggggag | |||
| 660 | |||
| gaggaggaag aggtaggagg taggggaggg ggcggggttt tgtcacctgt cacctgctcg | |||
| 720 | |||
| ctgtgcctag ggcgggcggg cggggagtgg ggggaccggt ataaagcggt aggcgcctgt | |||
| 780 | |||
| gcccgctcca cctctcaagc agccagcgcc tgcctgaatc tgttctgccc cctccccacc | |||
| 840 | |||
| catttcacca ccaccatg | |||
| 858 | |||
| αFP-TRE | |||
| gaattcttag aaatatgggg gtaggggtgg tggtggtaat tctgttttca ccccataggt 60 | SEQ ID NO:16 | ||
| gagataagca ttgggttaaa tgtgctttca cacacacatc acatttcata agaattaagg | |||
| 120 | |||
| aacagactat gggctggagg actttgagga tgtctgtctc ataacacttg ggttgtatct | |||
| 180 | |||
| gttctatggg gcttgtttta agcttggcaa cttgcaacag ggttcactga ctttctcccc | |||
| 240 | |||
| aagcccaagg tactgtcctc ttttcatatc tgttttgggg cctctggggc ttgaatatct | |||
| 300 | |||
| gagaaaatat aaacatttca ataatgttct gtggtgagat gagtatgaga gatgtgtcat | |||
| 360 | |||
| tcatttgtat caatgaatga atgaggacaa ttagtgtata aatccttagt acaacaatct | |||
| 420 | |||
| gagggtaggg gtggtactat tcaatttcta tttataaaga tacttatttc tatttattta | |||
| 480 | |||
| tgcttgtgac aaatgttttg ttcgggacca caggaatcac aaagatgagt ctttgaattt | |||
| 540 | |||
| aagaagttaa tggtccagga ataattacat agcttacaaa tgactatgat ataccatcaa | |||
| 600 | |||
| acaagaggtt ccatgagaaa ataatctgaa aggtttaata agttgtcaaa ggtgagaggg | |||
| 660 | |||
| ctcttctcta gctagagact aatcagaaat acattcaggg ataattattt gaatagacct | |||
| 720 | |||
| taagggttgg gtacattttg ttcaagcatt gatggagaag gagagtgaat atttgaaaac | |||
| 780 | |||
| attttcaact aaccaaccac ccaatccaac aaacaaaaaa tgaaaagaat ctcagaaaca | |||
| 840 | |||
| gtgagataag agaaggaatt ttctcacaac ccacacgtat agctcaactg ctctgaagaa | |||
| 900 | |||
| gtatatatct aatatttaac actaacatca tgctaataat gataataatt actgtcattt | |||
| 960 | |||
| tttaatgtct ataagtacca ggcatttaga agatattatt ccatttatat atcaaaataa | |||
| 1020 | |||
| acttgagggg atagatcatt ttcatgatat atgagaaaaa ttaaaaacag attgaattat | |||
| 1080 | |||
| ttgcctgtca tacagctaat aattgaccat aagacaatta gatttaaatt agttttgaat | |||
| 1140 | |||
| ctttctaata ccaaagttca gtttactgtt ccatgttgct tctgagtggc ttcacagact | |||
| 1200 | |||
| tatgaaaaag taaacggaat cagaattaca tcaatgcaaa agcattgctg tgaactctgt | |||
| 1260 | |||
| acttaggact aaactttgag caataacaca catagattga ggattgtttg ctgttagcat | |||
| 1320 | |||
| acaaactctg gttcaaagct cctctttatt gcttgtcttg gaaaatttgc tgttcttcat | |||
| 1380 | |||
| ggtttctctt ttcactgcta tctatttttc tcaaccactc acatggctac aataactgtc | |||
| 1440 | |||
| tgcaagctta tgattcccaa atatctatct ctagcctcaa tcttgttcca gaagataaaa | |||
| 1500 | |||
| agtagtattc aaatgcacat caacgtctcc acttggaggg cttaaagacg tttcaacata | |||
| 1560 | |||
| caaaccgggg agttttgcct ggaatgtttc ctaaaatgtg tcctgtagca catagggtcc | |||
| 1620 | |||
| tcttgttcct taaaatctaa ttacttttag cccagtgctc atcccaccta tggggagatg | |||
| 1680 | |||
| agagtgaaaa gggagcctga ttaataatta cactaagtca ataggcatag agccaggact | |||
| 1740 | |||
| gtttgggtaa actggtcact ttatcttaaa ctaaatatat ccaaaactga acatgtactt | |||
| 1800 | |||
| agttactaag tctttgactt tatctcattc ataccactca gctttatcca ggccacttat | |||
| 1860 | |||
| ttgacagtat tattgcgaaa acttcctaac tggtctcctt atcatagtct tatccccttt | |||
| 1920 | |||
| tgaaacaaaa gagacagttt caaaatacaa atatgatttt tattagctcc cttttgttgt | |||
| 1980 | |||
| ctataatagt cccagaagga gttataaact ccatttaaaa agtctttgag atgtggccct | |||
| 2040 | |||
| tgccaacttt gccaggaatt cccaatatct agtattttct actattaaac tttgtgcctc | |||
| 2100 | |||
| ttcaaaactg cattttctct cattccctaa gtgtgcattg ttttccctta ccggttggtt | |||
| 2160 | |||
| tttccaccac cttttacatt ttcctggaac actataccct ccctcttcat ttggcccacc | |||
| 2220 | |||
| tctaattttc tttcagatct ccatgaagat gttacttcct ccaggaagcc ttatctgacc | |||
| 2280 | |||
| cctccaaaga tgtcatgagt tcctcttttc attctactaa tcacagcatc catcacacca | |||
| 2340 | |||
| tgttgtgatt actgatacta ttgtctgttt ctctgattag gcagtaagct caacaagagc | |||
| 2400 | |||
| tacatggtgc ctgtctcttg ttgctgatta ttcccatcca aaaacagtgc ctggaatgca | |||
| 2460 | |||
| gacttaacat tttattgaat gaataaataa aaccccatct atcgagtgct actttgtgca | |||
| 2520 | |||
| agacccggtt ctgaggcatt tatatttatt gatttattta attctcattt aaccatgaag | |||
| 2580 | |||
| gaggtactat cactatcctt attttatagt tgataaagat aaagcccaga gaaatgaatt | |||
| 2640 | |||
| aactcaccca aagtcatgta gctaagtgac agggcaaaaa ttcaaaccag ttccccaact | |||
| 2700 | |||
| ttacgtgatt aatactgtgc tatactgcct ctctgatcat atggcatgga atgcagacat | |||
| 2760 | |||
| ctgctccgta aggcagaata tggaaggaga ttggaggatg acacaaaacc agcataatat | |||
| 2820 | |||
| cagaggaaaa gtccaaacag gacctgaact gatagaaaag ttgttactcc tggtgtagtc | |||
| 2880 | |||
| gcatcgacat cttgatgaac tggtggctga cacaacatac attggcttga tgtgtacata | |||
| 2940 | |||
| ttatttgtag ttgtgtgtgt atttttatat atatatttgt aatattgaaa tagtcataat | |||
| 3000 | |||
| ttactaaagg cctaccattt gccaggcatt tttacatttg tcccctctaa tcttttgatg | |||
| 3060 | |||
| agatgatcag attggattac ttggccttga agatgatata tctacatcta tatctatatc | |||
| 3120 | |||
| tatatctata tctatatcta tatctatatc tatatctata tatgtatatc agaaaagctg | |||
| 3180 | |||
| aaatatgttt tgtaaagtta taaagatttc agactttata gaatctggga tttgccaaat | |||
| 3240 | |||
| gtaacccctt tctctacatt aaacccatgt tggaacaaat acatttatta ttcattcatc | |||
| 3300 | |||
| aaatgttgct gagtcctggc tatgaaccag acactgtgaa agcctttggg atattttgcc | |||
| 3360 | |||
| catgcttggg caagcttata tagtttgctt cataaaactc tatttcagtt cttcataact | |||
| 3420 | |||
| aatacttcat gactattgct tttcaggtat tccttcataa caaatacttt ggctttcata | |||
| 3480 | |||
| tatttgagta aagtccccct tgaggaagag tagaagaact gcactttgta aatactatcc | |||
| 3540 | |||
| tggaatccaa acggatagac aaggatggtg ctacctcttt ctggagagta cgtgagcaag | |||
| 3600 | |||
| gcctgttttg ttaacatgtt ccttaggaga caaaacttag gagagacacg catagcagaa | |||
| 3660 | |||
| aatggacaaa aactaacaaa tgaatgggaa ttgtacttga ttagcattga agaccttgtt | |||
| 3720 | |||
| tatactatga taaatgtttg tatttgctgg aagtgctact gacggtaaac cctttttgtt | |||
| 3780 | |||
| taaatgtgtg ccctagtagc ttgcagtatg atctattttt taagtactgt acttagctta | |||
| 3840 | |||
| tttaaaaatt ttatgtttaa aattgcatag tgctctttca ttgaagaagt tttgagagag | |||
| 3900 | |||
| agatagaatt aaattcactt atcttaccat ctagagaaac ccaatgttaa aactttgttg | |||
| 3960 | |||
| tccattattt ctgtctttta ttcaacattt tttttagagg gtgggaggaa tacagaggag | |||
| 4020 | |||
| gtacaatgat acacaaatga gagcactctc catgtattgt tttgtcctgt ttttcagtta | |||
| 4080 | |||
| acaatatatt atgagcatat ttccatttca ttaaatattc ttccacaaag ttattttgat | |||
| 4140 | |||
| ggctgtatat caccctactt tatgaatgta ccatattaat ttatttcctg gtgtgggtta | |||
| 4200 | |||
| tttgatttta taatcttacc tttagaataa tgaaacacct gtgaagcttt agaaaatact | |||
| 4260 | |||
| ggtgcctggg tctcaactcc acagattctg atttaactgg tctgggttac agactaggca | |||
| 4320 | |||
| ttgggaattc aaaaagttcc cccagtgatt ctaatgtgta gccaagatcg ggaacccttg | |||
| 4380 | |||
| tagacaggga tgataggagg tgagccactc ttagcatcca tcatttagta ttaacatcat | |||
| 4440 | |||
| catcttgagt tgctaagtga atgatgcacc tgacccactt tataaagaca catgtgcaaa | |||
| 4500 | |||
| taaaattatt ataggacttg gtttattagg gcttgtgctc taagttttct atgttaagcc | |||
| 4560 | |||
| atacatcgca tactaaatac tttaaaatgt accttattga catacatatt aagtgaaaag | |||
| 4620 | |||
| tgtttctgag ctaaacaatg acagcataat tatcaagcaa tgataatttg aaatgaattt | |||
| 4680 | |||
| attattctgc aacttaggga caagtcatct ctctgaattt tttgtacttt gagagtattt | |||
| 4740 | |||
| gttatatttg caagatgaag agtctgaatt ggtcagacaa tgtcttgtgt gcctggcata | |||
| 4800 | |||
| tgataggcat ttaatagttt taaagaatta atgtatttag atgaattgca taccaaatct | |||
| 4860 | |||
| gctgtctttt ctttatggct tcattaactt aatttgagag aaattaatta ttctgcaact | |||
| 4920 | |||
| tagggacaag tcatgtcttt gaatattctg tagtttgagg agaatatttg ttatatttgc | |||
| 4980 | |||
| aaaataaaat aagtttgcaa gttttttttt tctgccccaa agagctctgt gtccttgaac | |||
| 5040 | |||
| ataaaataca aataaccgct atgctgttaa ttattggcaa atgtcccatt ttcaacctaa | |||
| 5100 | |||
| ggaaatacca taaagtaaca gatataccaa caaaaggtta ctagttaaca ggcattgcct | |||
| 5160 | |||
| gaaaagagta taaaagaatt tcagcatgat tttccatatt gtgcttccac cactgccaat | |||
| 5220 | |||
| aaca | |||
| 5224 | |||
